Anti-myostatin antibodies and methods of use
Patent Information
- Application Number
- TW111107921
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-06-17
- Filing Date
- 2017-06-16
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2037-06-15
AI Technical Summary
Current treatments for muscle-wasting diseases and conditions, such as muscular dystrophy and sarcopenia, are limited, and existing anti-myostatin antibodies primarily target mature myostatin rather than latent myostatin, lacking specificity and efficacy in inhibiting muscle atrophy.
Development of anti-myostatin antibodies that specifically bind to latent myostatin, inhibiting its activation and release, and polypeptides with variant Fc regions that enhance FcγRIIb binding for improved immunosuppressive properties.
The antibodies effectively increase muscle mass and strength by inhibiting myostatin activity, while the variant Fc regions provide enhanced therapeutic efficacy and reduced side effects by selectively targeting FcγRIIb, minimizing autoimmune responses and improving treatment safety.
Smart Images

Figure TWG2TB001919923_001 
Figure TWG2TB001919923_002 
Figure TWG2TB001919923_003
Abstract
Description
Technical field
[0001] The present invention relates to anti-myostatin antibodies and methods of use thereof. The invention also relates to polypeptides comprising variant Fc regions and methods of use thereof.
Prior Technology
[0002] Myostatin, also known as growth differentiation factor 8 (GDF8), is a secreted protein and a member of the transforming growth factor beta (TGF-beta) superfamily of proteins. Members of this superfamily have properties of growth regulation and morphological change (please refer, for example, to Non-Patent Document 1, Non-Patent Document 2, and Patent Document 1). Myostatin is primarily expressed in developing and adult skeletal muscle and acts as a negative regulator of muscle growth. Systemic overexpression of myostatin in adult mice leads to muscle atrophy (see, for example, Non-Patent Document 3), whereas conversely, myostatin knockout (knockout) mice develop skeletal muscle hypertrophy and hyperplasia characteristic, resulting in two to three times more muscle mass than their wild-type littermates (see, for example, Non-Patent Document 4).
[0003] Like other members of the TGF-β family, myostatin is synthesized as a large precursor protein that contains an N-terminal propeptide domain and a C-terminal domain that is considered an active molecule (see, For example, Non-Patent Document 5 and Patent Document 2). The two molecules of the myostatin precursor are covalently linked by a single disulfide bond present in the C-terminal growth factor domain. Active mature myostatin (a disulfide-bonded homodimer composed of a C-terminal growth factor domain) is released from the myostatin precursor through multiple steps of proteolytic processing. In the first step of the myostatin activation pathway, the peptide bond between the N-terminal pro-peptide domain and the C-terminal growth factor domain, Arg266-Asp267, is blocked in both chains of the homodimeric precursor Cleavage by furin-type proprotein convertase. However, the three peptides produced (two propeptides and one mature myostatin) (i.e., disulfide-bonded homodimers composed of growth factor domains)) remain associated, forming non-covalent bonds The inactive complex is called "latent myostatin". Mature myostatin can then be released from latent myostatin by cleavage of the pro-peptide. Members of the bone morphogenic protein 1 (BMP1) family of metalloproteases cleave a single peptide bond within the pro-peptide, Arg98-Asp99, with concomitant release of mature, active myostatin, a homodimer (see, for example, Non-Patent Document 6). In addition, latent myostatin can be activated in vitro by treating the dissociated complex with acid or heat (see, for example, Non-Patent Document 7).
[0004] Myostatin exerts its effects through a family of transmembrane serine / threonine kinase heterotetrameric receptors, whose activation enhances receptor transphosphorylation, resulting in stimulation of serine / threonine kinase activity. The myostatin pathway has been shown to involve the binding of active myostatin dimers to the high-affinity activin receptor type IIB (ActRIIB), which in turn recruits and activates the low-affinity receptor-like activin kinase 4 ( ALK4) / activin-like kinase 5 (ALK5) transphosphorylation. It has also been shown that the proteins Smad 2 and Smad 3 are then activated and form a complex with Smad 4, which then translocate to the nucleus for activation of transcription of target genes. ActRIIB has been shown to mediate the effects of myostatin in vivo, as expression of a dominant negative form of ActRIIB in mice mimics myostatin gene knockout (see, e.g., non-patent Document 8).
[0005] Many diseases and conditions are associated with muscle wasting (eg, loss of muscle tissue or impaired function), such as muscular dystrophy (MD; including Duchenne muscular dystrophy), amyotrophic lateral sclerosis (ALS), muscular dystrophy, organ wasting disease, frailty, congestive obstructive pulmonary disease (COPD), sarcopenia, and cachexia caused by cancer or other diseases, as well as kidney disease, heart failure or disease, and Liver Disease. An increase in muscle mass and / or muscle strength would benefit patients, however, there are currently limited treatments available for these diseases. Therefore, due to its role as a negative regulator of skeletal muscle growth, myostatin is ideal for therapeutic or preventive intervention, or for monitoring the progress of such diseases or conditions. Target. In particular, agents that inhibit the activity of myostatin may be therapeutically beneficial.
[0006] Inhibition of myostatin expression leads to muscle hypertrophy and hyperplasia (Non-Patent Document 4). Myostatin negatively regulates muscle regeneration after injury, and the absence of myostatin in myostatin-null mice leads to accelerated muscle regeneration (see, for example, Non-Patent Document 9). Anti-myostatin (GDF8) antibodies have been described in, for example, Patent Document 3, Patent Document 4, Patent Document 5, Patent Document 6 and Patent Document 7, and Patent Document 8, Patent Document 9 and Patent Document 10 have been shown in Binds and inhibits myostatin activity in vitro and in vivo, including myostatin activity associated with the negative regulation of skeletal muscle mass. In the skeletal muscle of wild-type mice (please refer to, for example, non-patent literature 10) and in the mdx mouse of muscular dystrophy model (please refer, for example, non-patent literature 11, non-patent literature 12), myostatin -Neutralizing antibodies increase body weight, skeletal muscle mass and muscle size and strength. However, these prior art antibodies are all specific for mature myostatin rather than latent myostatin, and the strategy for inhibiting the activity of myostatin is to utilize the binding and neutralizing mature myostatin Antibodies to the protein.
[0007] Antibodies have attracted attention as drugs because they are highly stable in blood and have few side effects (see, for example, Non-Patent Document 13 and Non-Patent Document 14). Almost all therapeutic antibodies currently on the market are antibodies of the human IgG1 subclass. One of the known functions of antibodies of the IgG subclass is antibody-dependent cell-mediated cytotoxicity (hereinafter expressed as ADCC activity) (see, for example, Non-Patent Document 15). For an antibody to exhibit ADCC activity, the Fc region of the antibody must bind to Fcγ receptors (hereinafter denoted FcγR), which are antibodies that appear on the surface of effector cells, such as killer cells, natural killer cells, and activated macrophages Binding receptors.
[0008] In humans, FcγRIa (CD64A), FcγRIIa (CD32A), FcγRIIb (CD32B), FcγRIIIa (CD16A) and FcγRIIIb (CD16B) isoforms have been reported as FcγR protein families, and their respective isoforms (allotype) has also been reported (see, for example, Non-Patent Document 16). FcγRIa, FcγRIIa, and FcγRIIIa are called activating FcγRs because of their immunoreactive function, while FcγRIIb is called an inhibitory FcγR because of their immunosuppressive function (see, for example, Non-Patent Document 17).
[0009] In the binding between the Fc region and the FcγR, many amino acid residues in the antibody hinge region and the CH2 domain, and the sugar chain attached to the Asn at position 297 (EU numbering) of the CH2 domain has been shown to be important (see, eg, Non-Patent Document 18, Non-Patent Document 19, and Non-Patent Document 20). So far, many variants having FcγR-binding properties, mainly antibodies with mutations introduced at these positions, have been studied; and Fc region variants having higher binding activity to activated FcγRs have been obtained (see, for example, patent Document 11, Patent Document 12, Patent Document 13 and Patent Document 14).
[0010] When an activated FcγR is cross-linked with an immune complex, it phosphorylates an immunoreceptor tyrosine-activating motif (immunoreceptor tyrosine- based activating motif, ITAM), activates the signal converter SYK and triggers an inflammatory immune response by initiating the activation signaling cascade (please refer to, for example, Non-Patent Document 21).
[0011] FcγRIIb is the only FcγR expressed on B cells (see, for example, Non-Patent Document 22). The interaction between antibody Fc region and FcγRIIb has been reported to inhibit the primary immune response of B cells (please refer to, for example, Non-Patent Document 23). In addition, it has been reported that when FcγRIIb on B cells and the B cell receptor (BCR) are cross-linked by immune complexes in blood, the activation of B cells and the production of antibodies by B cells are inhibited (see, e.g., Non- Patent Document 24). In this immunosuppressive signal transmission mediated by BCR and FcγRIIb, the immunoreceptor tyrosine inhibition motif (ITIM) contained in the intracellular domain of FcγRIIb is necessary (see, for example, non-patent literature 25 and non-patent literature 26). When ITIM is signaled to be phosphorylated, the SH2-containing inositol polyphosphate 5-phosphatase (SHIP) is recruited, the transmission of other activated FcγR signaling cascades is inhibited and the inflammatory immune response is suppressed (see, For example, Non-Patent Document 27). Furthermore, aggregation of FcγRIIb alone has been reported to transiently inhibit calcium influx resulting from BCR cross-linking and B-cell influx in a BCR-independent manner without inducing apoptosis of IgM-producing B cells. Proliferation (see, for example, Non-Patent Document 28).
[0012] FcyRIIb is also expressed on dendritic cells, macrophages, activated neutrophils, mast cells and basophils. FcγRIIb inhibits the functions of activated FcγRs, such as phagocytosis and release of inflammatory cytokines in these cells, and suppresses inflammatory immune responses (see, for example, Non-Patent Document 17).
[0013] To date, the importance of the immunosuppressive function of FcyRIIb has been elucidated by studies using FcyRIIb knockout mice. It has been reported that in FcγRIIb knockout mice, humoral immunity is not properly regulated (see, e.g., Non-Patent Document 29), and sensitivity to collagen-induced arthritis (CIA) is increased (see, e.g., Non-Patent Document 29). Patent Document 30), lupus-like symptoms appear, and symptoms similar to pulmonary hemorrhage nephritic syndrome (Goodpasture's syndrome-like) appear (see, for example, Non-Patent Document 31).
[0014] Furthermore, insufficient control of FcyRIIb has been reported to be associated with autoimmunity in humans. For example, the relationship between gene polymorphism in the transmodal region and the promoter region of FcγRIIb and the frequency of occurrence of systemic lupus erythematosus (SLE) (see, for example, Non-Patent Document 32, Non-Patent Document 33, Non-Patent Document 33, Non-Patent Document 33, Patent Document 34, Non-Patent Document 35, and Non-Patent Document 36), the decreased expression of FcγRIIb on B cells of SLE patients has been reported (see, for example, Non-Patent Document 37 and Non-Patent Document 38).
[0015] From the above-mentioned mouse models and clinical findings, FcγRIIb is considered to play a role in controlling autoimmune diseases and inflammatory diseases through a specific association with B cells, and it is a potential therapeutic agent for controlling autoimmune diseases and inflammatory diseases. target molecule.
[0016] IgG1, mainly as a commercially available therapeutic antibody, is known not only to bind to FcγRIIb but also to strongly activate FcγR (see, for example, Non-Patent Document 39). By utilizing Fc regions with enhanced FcyRIIb binding or improved FcyRIIb binding selectivity compared to activated FcyRs, it is possible to develop therapeutic antibodies with stronger immunosuppressive properties compared to IgG1. For example, it has been suggested that B cell activation can be inhibited using an antibody having a variant region that binds to BCR and Fc with enhanced FcγRIIb binding ability (see, for example, Non-Patent Document 40). It has been reported that crosslinking FcγRIIb on B cells and IgE bound to the B cell receptor inhibits B cell differentiation into plasma cells, resulting in inhibition of IgE production; and in human PBMC-transplanted mice, human IgG and IgM concentrations are maintained while human IgE concentrations are reduced (see, for example, Non-Patent Document 41). In addition to IgE, it has been reported that when FcγRIIB and CD79b, which is a component molecule of the B cell receptor complex, are cross-linked by antibodies, B cell proliferation in vitro is inhibited, and arthritis in collagen-induced arthritis models Symptoms were alleviated (see, for example, Non-Patent Document 42).
[0017] In addition to B cells, it has been reported to cross-link FcεRI and FcγRIIb on mast cells using molecules in which the Fc portion of IgG with enhanced FcγRIIb binding is fused to the Fc portion of IgE, which binds to IgE The receptor, FcεRI, causes phosphorylation of FcγRIIb, thereby inhibiting FcεRI-dependent calcium influx. This suggests that inhibition of degranulation via FcγRIIb stimulation is possible by enhancing FcγRIIb binding force (see, for example, Non-Patent Document 43).
[0018] Accordingly, antibodies to Fc with improved FcγRIIb binding activity show potential as therapeutic agents for inflammatory diseases such as autoimmune diseases.
[0019] In addition, it has been reported that the activation of macrophages and dendritic cells through Toll-like receptor 4 (Toll-like receptor 4) due to LPS stimulation is inhibited in the presence of antibody-antigen immune complexes. Inhibition, and this effect is also shown as the effect of the immune complex through FcγRIIb (please refer to, for example, Non-Patent Document 44 and Non-Patent Document 45). Thus, the use of antibodies with enhanced FcγRIIb binding is expected to result in increased inhibition of TLR-mediated activation signaling; thus, such antibodies have shown potential as therapeutic agents for inflammatory diseases such as autoimmune diseases .
[0020] Furthermore, mutants with enhanced FcyRIIb binding have been shown to have potential as therapeutic agents for cancer, as well as for inflammatory diseases such as autoimmune diseases. So far, FcγRIIb has been found to play an important role in the catalytic activity of agonist antibodies directed against the TNF receptor superfamily. In particular, it has been shown that interaction with FcγRIIb is required for the catalytic activity of antibodies against CD40, DR4, DR5, CD30, and CD137 included in the TNF receptor family (see, for example, Non-Patent Document 46, Non-Patent Document 46, Non-Patent Document 46, Patent Document 47, Non-Patent Document 48, Non-Patent Document 49, Non-Patent Document 50, Non-Patent Document 51, and Non-Patent Document 52). Non-Patent Document 46 shows that the use of antibodies with enhanced FcγRIIb binding ability increases the anti-tumor effect of anti-CD40 antibodies. Therefore, antibodies with enhanced FcγRIIb-binding ability are expected to have the effect of increasing the catalytic activity of agonist antibodies including antibodies against the anti-TNF receptor superfamily.
[0021] Furthermore, it has been shown that cell proliferation is inhibited when an antibody recognizing Kit, a type of receptor tyrosine kinase (RTK), is used to cross-link FcyRIIb and Kit on cells expressing Kit. It has been reported that a similar effect occurs even when such Kit is continuously activated and has tumorigenic mutations (see, for example, Non-Patent Document 53). Thus, the use of antibodies with enhanced FcyRIIb binding is expected to increase the inhibitory effect of cells expressing RTKs with constitutively activating mutations.
[0022] Fc antibodies having improved FcγRIIb-binding activity have been reported (see, for example, Non-Patent Document 40). In this document, the FcγRIIb binding activity was improved by adding alterations such as S267E / L328F, G236D / S267E and S239D / S267E to the antibody Fc region. Among them, the antibody introduced with the S267E / L328F mutation most strongly binds to FcγRIIb, and maintains the same degree of binding to FcγRIa and H-type FcγRIIa. Its residue at position 131 of FcγRIIa is His, which is similar to that of naturally occurring IgG1 same. However, another report showed that this modification increased the binding to R-type FcγRIIa hundreds of times to the same extent as FcγRIIb binding, where R-type FcγRIIa has an Arg residue at position 131 of FcγRIIa, which represents, compared to R-type FcγRIIa, The binding selectivity of FcγRIIb has not been improved (see, for example, Patent Document 15).
[0023] Only the effect of enhancing FcγRIIa binding but not FcγRIIb binding is considered to have an effect on cells expressing FcγRIIa but not FcγRIIb (such as platelets) (see, for example, Non-Patent Document 17). For example, it is known that a patient group administered with bevacizumab, which is an antibody against VEGF, has a higher risk of having thromboembolism (see, for example, Non-Patent Document 54). Furthermore, similar thromboembolism has been observed in clinical development tests of antibodies against CD40 ligands, and clinical tests have been discontinued (see, for example, non-patent document 55). In examples of these antibodies, subsequent studies using animal models and the like have shown that the administered antibodies aggregate platelets through FcγRIIa bound to platelets and form thrombus (see, for example, Non-Patent Document 56 and Non-Patent Document 57). In systemic lupus erythematosus, an autoimmune disease, platelets are activated through an FcγRIIa-dependent mechanism, and it has been reported that platelet activation correlates with the severity of symptoms (see, for example, Non-Patent Document 58). Administering antibodies with enhanced FcγRIIa binding to such patients who are already at high risk of developing thromboembolism will increase the risk of developing thromboembolism and is therefore quite dangerous.
[0024] Furthermore, antibodies with enhanced FcγRIIa binding have been reported to enhance macrophage-mediated antibody-dependent cellular phagocytosis (ADCP) (see, eg, Non-Patent Document 59). When the antigen bound by the antibody is phagocytized by macrophages, the antibody itself is considered to be phagocytosed at the same time. When an antibody is administered as a drug, it is thought that peptide fragments from the administered antibody are likely to be also presented as antigens, thus increasing the risk of the development of antibodies against the therapeutic antibody (anti-therapeutic antibodies). More specifically, enhancing FcyRIIa binding would increase the risk of antibody development against therapeutic antibodies, and this would significantly reduce their value as drugs. In addition, FcγRIIb on dendritic cells has been shown to contribute to the inhibition of dendritic cell activation by immune complexes formed between antigen and antibody, or to inhibit antigen-presenting cells to T cells by activating Fcγ receptors. Peripheral tolerance (see, for example, Non-Patent Document 60). Since FcγRIIa is also expressed on dendritic cells, when Fc with enhanced selective binding to FcγRIIb is used as a drug, due to the enhanced selective binding to FcγRIIb, the antigen is not easily presented by dendritic cells, and the generation of anti-drug antibodies The risk can be relatively reduced. Such antibodies may also be useful in this regard.
[0025] More specifically, when the binding of FcγRIIa is enhanced, it leads to an increased risk of thrombosis through platelet aggregation, and an increased risk of anti-therapeutic antibody production due to increased immunogenicity, which as a drug The value will be significantly lower.
[0026] From this point of view, the aforementioned Fc variants with enhanced FcγRIIb binding exhibit significantly enhanced R-type FcγRIIa binding compared to naturally occurring IgGl. Therefore, its value as a drug for patients with R-type FcyRIIa is significantly reduced. H-type and R-type FcγRIIa are observed at approximately the same frequency in Caucasians and African-Americans (see, for example, Non-Patent Document 61 and Non-Patent Document 62). Therefore, when this Fc variant is used as a treatment for an autoimmune disease, the number of patients who can safely use it and enjoy its effect as a drug will be limited.
[0027] In addition, it has been reported that dendritic cells are mature in dendritic cells lacking FcyRIIb, or in dendritic cells in which the interaction between FcyRIIb and the Fc portion of an antibody is inhibited by an anti-FcyRIIb antibody (see , for example, Non-Patent Document 63 and Non-Patent Document 64). This report shows that FcγRIIb actively inhibits dendritic cell maturation in a steady state in the absence of inflammation and activation. In addition to FcγRIIb, FcγRIIa is also expressed on the surface of dendritic cells; thus, maturation of dendritic cells may thus be promoted even with enhanced binding to inhibitory FcγRIIb and even to activating FcγRs such as FcγRIIa . More specifically, not only improving the FcγRIIb-binding activity but also improving the ratio of the FcγRIIb-binding activity to the FcγRIIa-binding activity is considered to be important in providing an antibody immunosuppressive effect.
[0028] Therefore, when considering the production of drugs utilizing the immunosuppressive effect mediated by FcγRIIb binding, Fc variants must not only have enhanced FcγRIIb-binding activity but also have heterotypic binding to H and R-type FcγRIIa, which Maintained to the same extent or attenuated to a lower extent compared to naturally occurring IgG1.
[0029] At the same time, it has been reported that an example of introducing amino acid changes into the Fc region to increase the binding selectivity of FcγRIIb (please refer to, for example, Non-Patent Document 65). However, as reported in this document, all variants said to have improved FcyRIIb selectivity showed reduced FcyRIIb binding compared to naturally occurring IgGl. Therefore, these variants are considered to be actually less likely to induce FcγRIIb-mediated immunosuppression than IgG1.
[0030] Furthermore, since FcγRIIb plays an important role in the aforementioned activating antibodies, enhancing their binding activity is expected to enhance activating activity. However, when the binding of FcγRIIa is also enhanced, unintended effects (such as ADCC activity and ADCP activity) will appear, and this may cause negative effects. Also from the above viewpoint, an activity capable of selectively enhancing FcγRIIb binding is preferable.
[0031] From these results, it can be seen that when FcγRIIb is used to manufacture therapeutic antibodies for the treatment of autoimmune diseases and cancers, compared with naturally occurring IgG, the binding activity to the FcγRIIa isotype is maintained or decreased, and the binding to FcγRIIb Enhancement is important. However, FcγRIIb shares 93% sequence identity with FcγRIIa, one of the activating FcγRs, in the extracellular region, and they are structurally very similar. FcγRIIa has isotypes, H-type and R-type, and its amino acid at position 131 is His (H-type) or Arg (R-type), but their interactions with antibodies are different (please refer to, for example, non-patent literature 66). Therefore, making Fc region variants with enhanced selective FcyRIIb binding compared to each isotype of FcyRIIa may be a difficult task, which involves distinguishing highly homologous sequences between FcyRIIa and FcyRIIb. Despite these difficulties, a number of Fc region variants with selective binding activity for FcγRIIb over FcγRIIa have been identified to date by performing comprehensive amino acid modification analysis in the Fc region (see, e.g., Patent Document 16, Patent Document 17, Patent Document 18, Patent Document 19, and Patent Document 20).
[0032] At present, there have been reports of Fc region variants related to human FcγRs that have binding selectivity for FcγRIIb, but there are no reports of Fc region variants related to monkey FcγRs that have binding selectivity for FcγRIIb. Because of the absence of this Fc variant, the effect of Fc variants on selective binding to FcyRIIb has not been thoroughly studied in monkeys.
[0033] In addition to the above, it has been reported that by modifying the charge of amino acid residues that may be exposed on the surface of the antibody to increase or decrease the isoelectric point (pI) of the antibody, it is possible to adjust the activity of the antibody in the blood. A half-life is possible (see, for example, Patent Document 21 and Patent Document 22). It shows that it is possible to prolong the plasma half-life of an antibody by lowering the pi of the antibody, and vice versa.
[0034] In addition, it has been reported that the pI of an antibody can be increased by modifying the charge of specified amino acid residues, especially in its CH3 domain, thereby promoting antigen incorporation into cells (see, For example, Patent Document 23). It has also been reported that modifying the charge of amino acid residues in the antibody constant region (mainly the CH1 domain) to reduce the pI can prolong the half-life of the antibody in plasma (see, for example, Patent Document 24). [Citation list] [Patent literature] [Patent Document 1] U.S. Patent No. 5,827,733 [Patent Document 2] WO 1994 / 021681 [Patent Document 3] U.S. Patent No. 6,096,506 [Patent Document 4] U.S. Patent No. 7,261,893 [Patent Document 5] U.S. Patent No. 7,320,789 [Patent Document 5] Document 6] US Patent No. 7,807,159 [Patent Document 7] US Patent No. 7,888,486 [Patent Document 8] WO 2005 / 094446 [Patent Document 9] WO 2007 / 047112 [Patent Document 10] WO 2010 / 070094 [Patent Document 11] WO 2000 / 042072 [Patent Document 12] WO 2006 / 019447 [Patent Document 13] WO 2004 / 099249 [Patent Document 14] WO 2004 / 029207 [Patent Document 15] US Patent Application No. US2009 / 0136485 [Patent Document 16] WO 2012 / 115241 [Patent Document 17] WO 2013 / 047752 [Patent Document 18] WO 2013 / 125667 [Patent Document 19] WO 2014 / 030728 [Patent Document 20] WO 2014 / 163101 [Patent Document 21] WO 2007 / 114319 [Patent Document 22] WO 2009 / 041643 [Patent Document 23] WO 2014 / 145159 [Patent Document 24] WO 2012 / 016227 [Non-Patent Document] [Non-Patent Document 1] Kingsley et al., Genes Dev.8(2):133-146 (1994) [Non-Patent Document 2] Hoodles et al., Curr. Top. Microbiol. Immunol. 228: 235-272 (1998) [Non-Patent Document 3] Zimmers et al., Science296(5572):1486-1488 (2002) [Non-Patent Document 4] McPherron et al., Nature387(6628):83-90 (1997) [Non-Patent Document 5 ] McPherron and Lee, Proc. Natl. Acad. Sci. USA94(23): 12457-12461 (1997) [Non-Patent Document 6] Szláma et al., FEBS J280(16): 3822-3839 (2013) [Non-Patent Document 7] Lee, PloS One3(2):e1628 (2008) [Non-Patent Document 8] Lee, Proc. Natl. Acad. Sci. USA98(16):9306-9311 (2001) [Non-Patent Document 9] McCroskery et al. , J Cell Sci. 118(15):3531-3541 (2005) [Non-Patent Document 10] Whittemore et al., Biochem. Biophys. Res. Commun. 300(4): 965-971 (2003) [Non-Patent Document 11 ] Bogdanovich et al., Nature420(6914):418-421 (2002) [Non-Patent Document 12] Wagner., Ann. Neurol.52(6):832-836 (2002) [Non-Patent Document 13] Reichert et al., Nat. Biotechnol.23:1073-1078 (2005) [Non-Patent Document 14] Pavlou et al., Eur. J. Pharm. Biopharm. 59:389-396 (2005) [Non-Patent Document 15] Clark et al., Chem. Immunol. 65:88-110 (1997) [Non-Patent Document 16] Jefferis et al., Immunol. Lett.82:57-65 (2002) [Non-Patent Document 17] Smith et al., Nat. Rev. Immunol.10: 328-343 (2010) [Non-Patent Document 18] Radaev et al., J. Biol. Chem. 276:16478-16483 (2001) [Non-Patent Document 19] Greenwood et al., Eur. J. Immunol.23:1098- 1104 (1993) [Non-Patent Document 20] Morgan et al., Immunology86:319-324 (1995) [Non-Patent Document 21] Nimmerjahn et al., Nat. Rev. Immunol.8:34-47 (2008) [Non-Patent Document 22] Amigorena et al., Eur. J. Immunol.19:1379-1385 (1989) [Non-Patent Document 23] Sinclair, J. Exp. Med.129:1183-1201 (1969) [Non-Patent Document 24] Heyman, Immunol. Lett.88:157-161 (2003) [Non-patent literature 25] Amigorena et al., Science256:1808-1812 (1992) [Non-patent literature 26] Muta et al., Nature368:70-73 (1994) [Non-patent literature 25] Patent Document 27] Ravetch, Science290:84-89 (2000) [Non-Patent Document 28] Fournier et al., J. Immunol.181:5350-5359 (2008) [Non-Patent Document 29] J. Immunol.163:618- 622 (1999) [Non-Patent Document 30] Yuasa et al., J. Exp. Med.189:187-194 (1999) [Non-Patent Document 31] Nakamura et al., J. Exp. Med.191:899-906 ( 2000) [Non-Patent Document 32] Blank, Hum. Genet.117:220-227 (2005) [Non-Patent Document 33] Olferiev et al., J. Biol. Chem.282:1738-1746 (2007) [Non-Patent Document 34] Chen et al., Arthritis Rheum. 54:3908-3917 (2006) [Non-Patent Document 35] Floto et al., Nat. Med.11:1056-1058 (2005) [Non-Patent Document 36] Li et al., J . Immunol.176:5321-5328 (2006) [Non-Patent Document 37] Mackay et al., J. Exp. Med.203:2157-2164 (2006) [Non-Patent Document 38] Yang et al., J. Immunol.178 :3272-3280 (2007) [Non-Patent Document 39] Bruhns et al., Blood113:3716-3725 (2009) [Non-Patent Document 40] Chu et al., Mol. Immunol.45:3926-3933 (2008) [Non-Patent Document Document 41] Chu et al., J. Allergy Clin. Immunol.129:1102-1115 (2012) [Non-Patent Document 42] Veri et al., Arthritis Rheum.62:1933-1943 (2010) [Non-Patent Document 43] Cemerski et al., Immunol. Lett. 143:34-43 (2012) [Non-Patent Document 44] Wenink et al., J. Immunol.183:4509-4520 (2009) [Non-Patent Document 45] Zhang et al., J. Immunol .182:554-562 (2009) [Non-patent literature 46] Ravetch, Science333:1030-1034 (2011) [Non-patent literature 47] Wilson et al., Cancer Cell19:101-113 (2011) [Non-patent literature 48] Kohrt et al., J. Clin. Invest.122:1066-1075 (2012) [Non-Patent Document 49] Xu et al., J. Immunol.171:562-568 (2003) [Non-Patent Document 50] Zhang et al., Blood108:705-710 (2006) [Non-Patent Document 51] Chuntharapai et al., J. Immunol.166:4891-4898 (2001) [Non-Patent Document 52] Ravetch et al., Proc. Natl. Acad. Sci. USA109: 10966-10971 (2012) [Non-Patent Document 53] Malbec et al., Immunol. Lett.143:28-33 (2012) [Non-Patent Document 54] Scappaticci et al., J. Natl. Cancer. Inst.99:1232- 1239 (2007) [Non-Patent Document 55] Arthritis Rheum. 48:719-727 (2003) [Non-Patent Document 56] Meyer et al., J. Thromb. Haemost.7:171-181 (2008) [Non-Patent Document 57 ] Robles-Carrillo et al., J. Immunol.185:1577-1583 (2010) [Non-Patent Document 58] Duffau et al., Sci. Transl. Med.2:47ra63 (2010) [Non-Patent Document 59] Richards et al. , Mol. Cancer Ther.7:2517-2527 (2008) [Non-Patent Document 60] Desai et al., J. Immunol. 178:6217-6226 (2007) [Non-Patent Document 61] Salmon et al., J. Clin. Invest.97:1348-1354 (1996) [Non-Patent Document 62] Manger et al., Arthritis Rheum.41:1181-1189 (1998) [Non-Patent Document 63] Boruchov et al., J. Clin. Invest.115:2914 -2923 (2005) [Non-Patent Document 64] Dhodapkar et al., Proc. Natl. Acad. Sci. USA102:2910-2915 (2005) [Non-Patent Document 65] Armour et al., Mol. (2003) [Non-Patent Document 66] Warmerdam et al., J. Exp. Med. 172:19-25 (1990)
Content of invention
[0037] The object of the present invention is to provide anti-myostatin antibodies, polypeptides containing variant Fc regions and methods of use thereof.
[0038] The present invention provides anti-myostatin antibodies and methods of using the same. The present invention also provides proteins comprising a variant Fc region and methods of use thereof.
[0039] In some embodiments, the isolated anti-myostatin antibodies of the invention bind to latent myostatin. In yet other embodiments, the antibody binds to an epitope in a fragment consisting of amino acids 21-100 of the promyostatin peptide (SEQ ID NO: 78). In some embodiments, the isolated anti-myostatin antibodies of the invention inhibit the activation of myostatin. In yet other embodiments, the antibody blocks the release of mature myostatin from latent myostatin. In still other embodiments, the antibody blocks the proteolytic release of mature myostatin. In still other embodiments, the antibody blocks the spontaneous release of mature myostatin. In yet other embodiments, the antibody does not bind to mature myostatin. In yet other embodiments, the antibodies bind to the same epitope as the antibodies described in Table 13. In yet other embodiments, the antibody binds to the same epitope as an antibody comprising the VH and VL pair described in Table 13. In yet other embodiments, the antibody binds to the same epitope as the antibody described in Table 2a. In yet other embodiments, the antibody binds to the same epitope as an antibody comprising the VH and VL pair described in Table 2a. In yet other embodiments, the antibody binds to the same epitope as the antibody described in Table 11a. In yet other embodiments, the antibody binds to the same epitope as an antibody comprising the VH and VL pair described in Table 11a. In yet other embodiments, the antibody binds to the same epitope as the antibody described in Table 2a, 11a or 13. In yet other embodiments, the antibody binds to the same epitope as an antibody comprising the VH and VL pair described in Table 2a, 11a or 13.
[0040] In some embodiments, the isolated anti-myostatin antibodies of the invention bind to latent myostatin with a higher affinity at neutral pH than at acidic pH. In some embodiments, the anti-myostatin antibody binds to latent myostatin with a higher affinity at pH 7.4 than at pH 5.8. In some embodiments, the isolated anti-myostatin antibody of the present invention binds to the peptide derived from promyostatin (SEQ ID NO: 78) with a higher affinity at pH 7.4 than at pH 5.8. A polypeptide fragment composed of amino acids 21-100. In some embodiments, the antibody binds to the myostatin epitope with a higher affinity at neutral pH than at acidic pH, which binds to the myostatin epitope described in Table 13. the same. In some additional embodiments, the anti-myostatin antibody binds with a higher affinity to an epitope at pH 7.4 than at pH 5.8 to the epitope to which the antibodies described in Table 13 bind. base is the same. In yet other embodiments, the antibody binds with higher affinity to an epitope that binds to an antigen comprising the VH and VL pair described in Table 13 at pH 7.4 than at pH 5.8. The bases are the same. In some embodiments, the antibody binds to the myostatin epitope with higher affinity at neutral pH than at acidic pH, which binds to the myostatin epitope described in Table 2a. the same. In some embodiments, the antibody binds with a higher affinity to a myostatin epitope at pH 7.4 than at pH 5.8, which binds to a myostatin epitope as described in Table 2a. base is the same. In yet other embodiments, the antibody binds with higher affinity to an epitope that binds to an antigen comprising the VH and VL pair described in Table 2a at pH 7.4 than at pH 5.8. The bases are the same. In some additional embodiments, the anti-myostatin antibody binds with a higher affinity to the epitope at neutral pH than at acidic pH to the epitope to which the antibody described in Table 11a binds the same. In yet other embodiments, the antibody binds to a myostatin epitope with a higher affinity at pH 7.4 than at pH 5.8, which binds to the myostatin antigen described in Table 11a. The bases are the same. In yet other embodiments, the antibody binds with higher affinity to an epitope that binds to an antigen comprising the VH and VL pair described in Table 11a at pH 7.4 than at pH 5.8. The bases are the same. In some additional embodiments, the anti-myostatin antibody binds with a higher affinity to an epitope that binds to the antibody described in Table 2a, 11a, or 13 at neutral pH than at acidic pH The epitopes are the same. In still other embodiments, the antibody binds with a higher affinity to the myostatin epitope at pH 7.4 than at pH 5.8, which binds to the antibody described in Table 2a, 11a, or 13 The myostatin epitope is the same. In yet other embodiments, the antibody binds with a higher affinity to an epitope at pH 7.4 than at pH 5.8 with an antibody comprising the VH and VL pair described in Table 2a, 11a or 13 The epitopes bound are the same.
[0041] In some embodiments, the isolated anti-myostatin antibodies of the invention compete with the antibodies provided herein for binding to latent myostatin. In some embodiments, the isolated anti-myostatin antibodies of the invention compete with the antibodies described in Table 13 for binding to latent myostatin. In some embodiments, the isolated anti-myostatin antibodies of the invention compete with antibodies comprising the VH and VL pairs described in Table 13 for binding to latent myostatin. In some embodiments, the antibody competes for latent myostatin binding with the antibody described in Table 2a. In some embodiments, an isolated anti-myostatin antibody of the invention competes for latent myostatin binding with an antibody comprising the VH and VL pair described in Table 2a. In some embodiments, the antibody competes for latent myostatin binding with the antibody described in Table 11a. In some embodiments, an isolated anti-myostatin antibody of the invention competes for latent myostatin binding with an antibody comprising the VH and VL pair described in Table 11a. In some additional embodiments, the anti-myostatin antibody competes with the antibody described in Table 2a, 11a or 13 for binding to latent myostatin. In some additional embodiments, the anti-myostatin antibody competes for latent myostatin binding with an antibody comprising the VH and VL pair described in Table 2a, 11a or 13. In yet other embodiments, the anti-myostatin antibody binds to latent myostatin with a higher affinity at neutral pH than at acidic pH. In yet other embodiments, the anti-myostatin antibody binds to latent myostatin with a higher affinity at pH 7.4 than at pH 5.8. In yet other embodiments, the anti-myostatin antibody binds to an amino acid derived from the promyostatin peptide (SEQ ID NO: 78) with a higher affinity at pH 7.4 than at pH 5.8 21-100 polypeptide fragments. Methods for assessing the ability of an antibody to compete with a reference antibody for binding to latent myostatin are described herein and are known in the art.
[0042] In some embodiments, the isolated anti-myostatin antibody of the invention is a monoclonal antibody. In some embodiments, the isolated anti-myostatin antibodies of the invention are human, humanized or chimeric antibodies. In some embodiments, an isolated anti-myostatin antibody of the invention is an antibody fragment that binds to myostatin. In some embodiments, an isolated anti-myostatin antibody of the invention is an antibody fragment that binds to latent myostatin. In some embodiments, the isolated anti-myostatin antibody of the present invention is an antibody fragment that binds to a polypeptide fragment consisting of amino acids 21-100 of the promyostatin peptide (SEQ ID NO: 78). In some embodiments, the isolated anti-myostatin antibodies of the invention are full length IgG antibodies.
[0043] In some embodiments, the anti-myostatin antibody of the present invention includes: (a) (i) HVR-H3, comprising the amino acid sequence GVPAX1SX2GGDX3, wherein X1 is Y or H, X2 is T or H, X3 is L or K (SEQ ID NO: 128); (ii) HVR-L3, comprising the amino acid sequence AGGYGGGX1YA, wherein X1 is L or R (SEQ ID NO: 131); and (iii) HVR-H2, comprising the amino acid sequence The amino acid sequence IISX1AGX2X3YX4X5X6WAKX7, wherein X1 is Y or H, X2 is S or K, X3 is T, M or K, X4 is Y or K, X5 is A, M or E, X6 is S or E, X7 is G or K (SEQ ID NO: 127); (b) (i) HVR-H1, comprising the amino acid sequence X1X2DIS, wherein X1 is S or H, and X2 is Y, T, D or E (SEQ ID NO: 126); (ii) HVR-H2, comprising the amino acid sequence IISX1AGX2X3YX4X5X6WAKX7, wherein X1 is Y or H, X2 is S or K, X3 is T, M or K, X4 is Y or K, X5 is A, M or E, X6 is S or E, X7 is G or K (SEQ ID NO: 127); and (iii) HVR-H3, comprising the amino acid sequence GVPAX1SX2GGDX3, wherein X1 is Y or H, X2 is T or H, X3 is L or K (SEQ ID NO: 128); (c) (i) HVR-H1, comprising the amino acid sequence X1X2DIS, wherein X1 is S or H, and X2 is Y, T, D or E (SEQ ID NO: 126); (ii) HVR-H2, comprising the amino acid sequence IISX1AGX2X3YX4X5X6WAKX7, wherein X1 is Y or H, X2 is S or K, X3 is T, M or K, X4 is Y or K, X5 is A, M or E, X6 is S or E, X7 is G or K (SEQ ID: 127); (iii) HVR-H3, including the amino acid sequence GVPAX1SX2GGDX3, wherein X1 is Y or H, X2 is T or H, and X3 is L or K (SEQ ID NO: 128); (iv) HVR-L1, including the amino acid sequence X1X2SQX3VX4X5X6NWLS, wherein X1 is Q or T, X2 is S or T, X3 is S or E, X4 is Y or F, X5 is D Or H, X6 is N, D, A or E (SEQ ID NO: 129); (v) HVR-L2, including the amino acid sequence WAX1TLAX2, wherein X1 is S or E, X2 is S, Y, F or W (SEQ ID NO: 130); and (vi) HVR-L3, comprising the amino acid sequence AGGYGGGX1YA, wherein X1 is L or R (SEQ ID NO: 131); (d) (i) HVR-L1, comprising the amino acid sequence Acid sequence X1X2SQX3VX4X5X6NWLS, wherein X1 is Q or T, X2 is S or T, X3 is S or E, X4 is Y or F, X5 is D or H, X6 is N, D, A or E (SEQ ID NO: 129 ); (ii) HVR-L2, comprising the amino acid sequence WAX1TLAX2, wherein X1 is S or E, X2 is S, Y, F or W (SEQ ID NO: 130); and (iii) HVR-L3, comprising amine The amino acid sequence is AGGYGGGX1YA, wherein X1 is L or R (SEQ ID NO: 131). In some embodiments, the antibody of (b) further includes the heavy chain variable domain framework FR1, including the amino acid sequence of any of SEQ ID NOs: 132-134; FR2, including any of the SEQ ID NOs: 135-136 1; FR3, including the amino acid sequence of SEQ ID NO: 137; and FR4, including the amino acid sequence of SEQ ID NO: 138. In some embodiments, the antibody of (d) further includes the light chain variable domain framework FR1, including the amino acid sequence of SEQ ID NO: 139; FR2, including the amino acid sequence of any of SEQ ID NO: 140-141 sequence; FR3, including the amino acid sequence of any one of SEQ ID NO: 142-143; and FR4, including the amino acid sequence of SEQ ID NO: 144.
[0044] In some embodiments, the isolated anti-myostatin antibody of the present invention comprises: (a) HVR-H3, comprising the amino acid sequence GVPAX1SX2GGDX3, wherein X1 is Y or H, X2 is T or H, and X3 is L or K (SEQ ID NO: 128); (b) HVR-L3, comprising the amino acid sequence AGGYGGGX1YA, wherein X1 is L or R (SEQ ID NO: 131); and (c) HVR-H2, comprising the amino acid sequence Acid sequence IISX1AGX2X3YX4X5X6WAKX7, wherein X1 is Y or H, X2 is S or K, X3 is T, M or K, X4 is Y or K, X5 is A, M or E, X6 is S or E, X7 is G or K (Serial Identification Number: 127).
[0045] In some embodiments, the isolated anti-myostatin antibody of the present invention comprises: (a) HVR-H1, comprising the amino acid sequence X1X2DIS, wherein X1 is S or H, X2 is Y, T, D or E (SEQ ID NO: 126); (b) HVR-H2, including the amino acid sequence IISX1AGX2X3YX4X5X6WAKX7, wherein X1 is Y or H, X2 is S or K, X3 is T, M or K, X4 is Y or K, X5 is A, M or E, X6 is S or E, X7 is G or K (SEQ ID NO: 127); and (c) HVR-H3, including the amino acid sequence GVPAX1SX2GGDX3, wherein X1 is Y or H, X2 is T or H, and X3 is L or K (SEQ ID: 128). In some other embodiments, the antibody comprises the heavy chain variable domain framework FR1, including the amino acid sequence of any of the sequence identification numbers: 132-134; FR2, including the amino acid sequence of any of the sequence identification numbers: 135-136 FR3, including the amino acid sequence of SEQ ID NO: 137; and FR4, including the amino acid sequence of SEQ ID NO: 138. In yet other embodiments, the antibody additionally comprises: (a) HVR-L1, comprising the amino acid sequence X1X2SQX3VX4X5X6NWLS, wherein X1 is Q or T, X2 is S or T, X3 is S or E, X4 is Y or F , X5 is D or H, X6 is N, D, A or E (SEQ ID NO: 129); (b) HVR-L2, including the amino acid sequence WAX1TLAX2, wherein X1 is S or E, X2 is S, Y , F or W (SEQ ID NO: 130); and (c) HVR-L3, comprising the amino acid sequence AGGYGGGX1YA, wherein X1 is L or R (SEQ ID NO: 131).
[0046] In some embodiments, the isolated anti-myostatin antibody of the present invention comprises: (a) HVR-L1, comprising the amino acid sequence X1X2SQX3VX4X5X6NWLS, wherein X1 is Q or T, X2 is S or T, X3 is S or E, X4 is Y or F, X5 is D or H, X6 is N, D, A or E (SEQ ID NO: 129); (b) HVR-L2, including the amino acid sequence WAX1TLAX2, wherein X1 is S or E, X2 is S, Y, F or W (SEQ ID NO: 130); and (c) HVR-L3, comprising the amino acid sequence AGGYGGGX1YA, wherein X1 is L or R (SEQ ID NO: 131). In some other embodiments, the antibody further comprises: light chain variable domain framework FR1, including the amino acid sequence of SEQ ID NO: 139; FR2, including the amino acid sequence of any one of SEQ ID NO: 140-141; FR3 includes the amino acid sequence of any one of SEQ ID NO: 142-143; and FR4 includes the amino acid sequence of SEQ ID NO: 144.
[0047] In some embodiments, the isolated anti-myostatin antibody of the present invention includes: heavy chain variable domain framework FR1, including the sequence identification number: any amino acid sequence in 132-134; FR2, including the sequence Identification number: any amino acid sequence of 135-136; FR3, including the amino acid sequence of SEQ ID NO: 137; and FR4, including the amino acid sequence of SEQ ID NO: 138. In some embodiments, the isolated anti-myostatin antibody of the present invention comprises a light chain variable domain framework FR1 comprising the amino acid sequence of SEQ ID NO: 139; FR2 comprising any of SEQ ID NO: 140-141 FR3, including the amino acid sequence of any one of SEQ ID NO: 142-143; and FR4, including the amino acid sequence of SEQ ID NO: 144.
[0048] In some embodiments, the isolated anti-myostatin antibody of the present invention includes: (a) VH sequence, which is related to any of the sequence identification numbers: 13, 16-30, 32-34 and 86-95 The amino acid sequence has at least 95% sequence identity; (b) the VL sequence has at least 95% sequence identity with any of the amino acid sequences of SEQ ID NO: 15, 31, 35-38 and 96-99 identity; or (c) the VH sequence as described in (a) and the VL sequence as described in (b). In yet other embodiments, the antibody comprises a VH sequence of any one of SEQ ID NOs: 13, 16-30, 32-34, and 86-95. In still other embodiments, the antibody comprises the VL sequence of any one of SEQ ID NOs: 15, 31, 35-38, and 96-99. In some embodiments, the antibody comprises a VH sequence of any one of SEQ ID NOs: 13, 16-30, 32-34, and 86-95. In yet other embodiments, the antibody comprises the VH sequence of any of SEQ ID NOs: 13, 16-30, 32-34, and 86-95; and any of the SEQ ID NOs: 15, 31, 35-38, and 96-99 Either of the VL sequences.
[0049] The invention also provides an isolated nucleic acid encoding an anti-myostatin antibody of the invention. The invention also provides host cells comprising a nucleic acid of the invention. The present invention also provides a method for producing an antibody, comprising culturing the host cell of the present invention such that the antibody is produced.
[0050] In some aspects, the present invention provides a method of producing an anti-myostatin antibody, comprising: (a) cultivating the host cell of the present invention such that the antibody is produced; or (b) immunizing the animal against the polypeptide, wherein The aforementioned polypeptide includes a region corresponding to the amino acids at positions 21-100 of the promyostatin peptide (SEQ ID NO: 78).
[0051] The present invention further provides a method for producing an anti-myostatin antibody. In some embodiments, the method comprises immunizing the animal with a polypeptide comprising a region corresponding to amino acids at positions 21-100 of the promyostatin peptide (SEQ ID NO: 78).
[0052] The present invention also provides a pharmaceutical formulation comprising the anti-myostatin antibody of the present invention and a pharmaceutically acceptable carrier.
[0053] The anti-myostatin antibody of the present invention can be used as a medicament. In some embodiments, antibodies are used in the manufacture of a medicament for: (a) treating muscle wasting disease; (b) increasing muscle tissue mass; (c) increasing muscle tissue strength; or (d) reducing body fat accumulation. In some embodiments, the anti-myostatin antibodies of the invention can be used to treat muscle wasting diseases. The anti-myostatin antibodies of the invention can be used to increase muscle tissue mass. The anti-myostatin antibodies of the invention can be used to increase the strength of muscle tissue. The anti-myostatin antibodies of the invention can be used to reduce body fat accumulation.
[0054] In some embodiments, the anti-myostatin antibodies provided herein have the ability to (a) treat a muscle wasting disease; (b) increase the mass of muscle tissue; (c) increase the strength of muscle tissue; or (d) reduce The accumulated use of body fat.
[0055] The anti-myostatin antibodies of the invention can be used in the manufacture of medicaments. In some embodiments, antibodies are used in the manufacture of: (a) treating muscle wasting disease; (b) increasing muscle tissue mass; (c) increasing muscle tissue strength; or (d) reducing the accumulation of body fat potion. In some embodiments, the agent is used to treat muscle wasting diseases. In some embodiments, the agent is used to increase muscle tissue mass. In some embodiments, the agent is used to increase the strength of muscle tissue. In some embodiments, the agent is used to reduce body fat accumulation.
[0056] The present invention also provides methods of treating an individual with a muscle wasting disease. In some embodiments, the method comprises administering to the individual an effective amount of an anti-myostatin antibody of the invention. The present invention also provides methods of increasing the mass of muscle tissue in an individual. In some embodiments, the method comprises administering to the individual an effective amount of an anti-myostatin antibody of the invention to increase muscle tissue mass. The present invention also provides methods of increasing the strength of musculature in an individual. In some embodiments, the method comprises administering to the individual an effective amount of an anti-myostatin antibody of the invention to increase muscle tissue strength. The invention also provides methods of reducing the accumulation of body fat in an individual. In some embodiments, the method comprises administering to the individual an effective amount of an anti-myostatin antibody of the invention to reduce body fat accumulation. Specifically provided: [1] A use of an antibody that binds to latent myostatin in the treatment of muscle wasting diseases, wherein the antibody inhibits the activation of myostatin; [2] An antibody that binds to latent myostatin Use for increasing muscle tissue mass, wherein the antibody inhibits myostatin activation; [3] A use of an antibody that binds to latent myostatin for increasing muscle tissue strength, wherein the antibody inhibits myostatin activation; [4] A use of an antibody that binds to latent myostatin in reducing body fat accumulation, wherein the antibody inhibits the activation of myostatin; [5] An antibody that binds to latent myostatin is used in the preparation of therapeutic muscle [6] Use of an antibody that binds to latent myostatin in the preparation of a drug for increasing muscle tissue mass, wherein the antibody inhibits the activation of myostatin activation of myostatin; [7] a use of an antibody that binds to latent myostatin in the preparation of a drug for increasing muscle tissue strength, wherein the antibody inhibits the activation of myostatin; [8] an antibody that binds to latent myostatin Use of an antibody against myostatin in the preparation of a medicament for reducing fat accumulation, wherein the antibody inhibits the activation of myostatin; [9] A method of treating an individual with a muscle wasting disease, comprising administering to the individual an effective amount of a latent an antibody that binds to myostatin, wherein the antibody inhibits activation of myostatin;
[10] a method of increasing muscle tissue mass in an individual, comprising administering to the individual an effective amount of an antibody that binds to latent myostatin, wherein the an antibody that inhibits myostatin activation;
[11] a method of increasing muscle tissue strength in an individual comprising administering to the individual an effective amount of an antibody that binds latent myostatin, wherein the antibody inhibits myostatin activation; [ 12] A method of reducing body fat accumulation in an individual, comprising administering to the individual an effective amount of an antibody that binds to latent myostatin, wherein the antibody inhibits activation of myostatin;
[13] such as [1] to [12 ], wherein the antibody blocks the release of mature myostatin from latent myostatin;
[14] the antibody for use, use or method as described in
[13] method, wherein the antibody blocks the proteolytic release of mature myostatin;
[15] the antibody, use or method for use as described in
[13] , wherein the antibody blocks the spontaneous release of mature myostatin;
[16] such as The antibody, use or method for use according to any one of [1] to
[15] , wherein the antibody does not bind to mature myostatin;
[17] as any one of [1] to
[16] The antibody, use or method used, wherein the antibody binds to an epitope, and the epitope is composed of amino acids at positions 21-100 of the promyostatin peptide (SEQ ID: 78)
[18] The antibody, use or method for use as described in any one of [1] to
[17] , wherein the antibody binds to the same antigen as the antibodies described in Tables 2a, 11a and 13 Determinant;
[19] The antibody, use or method for use as described in any one of [1] to
[18] , wherein the antibody binds to latent myostatin, and at neutral pH than at acidic pH
[20] The antibody, use or method as described in any one of [1] to
[19] , wherein the antibody is a monoclonal antibody;
[21] As in [1] ] to
[20] , wherein the antibody is a human, humanized or chimeric antibody;
[22] as in any one of [1] to
[21] The antibody for use, use or method described in Item 1, wherein the antibody is an antibody fragment that binds to myostatin;
[23] The antibody for use, use or method described in any one of [1] to
[22] method, wherein the antibody comprises (a) HVR-H3 comprising the amino acid sequence GVPAX1SX2GGDX3, wherein X1 is Y or H, X2 is T or H, and X3 is L or K (SEQ ID NO: 128); (b) HVR -L3, comprising the amino acid sequence AGGYGGGX1YA, wherein X1 is L or R (SEQ ID NO: 131); and (c) HVR-H2, comprising the amino acid sequence IISX1AGX2X3YX4X5X6WAKX7, wherein X1 is Y or H, and X2 is S or K, X3 is T, M or K, X4 is Y or K, X5 is A, M or E, X6 is S or E, X7 is G or K (SEQ ID: 127);
[24] such as [1] The antibody, use or method for use according to any one of
[22] , wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence X1X2DIS, wherein X1 is S or H, and X2 is Y, T , D or E (SEQ ID NO: 126); (b) HVR-H2, comprising the amino acid sequence IISX1AGX2X3YX4X5X6WAKX7, wherein X1 is Y or H, X2 is S or K, X3 is T, M or K, and X4 is Y or K, X5 is A, M or E, X6 is S or E, X7 is G or K (SEQ ID NO: 127); and (c) HVR-H3, comprising the amino acid sequence GVPAX1SX2GGDX3, wherein X1 is Y or H, X2 is T or H, X3 is L or K (SEQ ID NO: 128);
[25] The antibody, use or method as described in
[24] , wherein the antibody further comprises (a) HVR-L1 , comprising the amino acid sequence X1X2SQX3VX4X5X6NWLS, wherein X1 is Q or T, X2 is S or T, X3 is S or E, X4 is Y or F, X5 is D or H, X6 is N, D, A or E (sequence Identification number: 129); (b) HVR-L2, comprising the amino acid sequence WAX1TLAX2, wherein X1 is S or E, X2 is S, Y, F or W (sequence identification number: 130); and (c) HVR- L3, comprising the amino acid sequence AGGYGGGX1YA, wherein X1 is L or R (SEQ ID NO: 131);
[26] the antibody, use or method used as described in any one of [1] to
[22] , Wherein the antibody comprises (a) HVR-L1, comprising the amino acid sequence X1X2SQX3VX4X5X6NWLS, wherein X1 is Q or T, X2 is S or T, X3 is S or E, X4 is Y or F, X5 is D or H, X6 is N, D, A or E (SEQ ID: 129); (b) HVR-L2, comprising the amino acid sequence WAX1TLAX2, wherein X1 is S or E, and X2 is S, Y, F or W (SEQ ID No. : 130); and (c) HVR-L3, comprising the amino acid sequence AGGYGGGX1YA, wherein X1 is L or R (SEQ ID NO: 131);
[27] the antibody, use or method used as described in
[24] , wherein the antibody further comprises the heavy chain variable domain framework FR1, which comprises the amino acid sequence of any of the sequence identification numbers: 132-134; FR2, which comprises the amino acid sequence of any of the sequence identification numbers: 135-136 sequence; FR3, which includes the amino acid sequence of SEQ ID NO: 137; and FR4, which includes the amino acid sequence of SEQ ID NO: 138.
[28] The antibody, use or method for use as described in
[26] , wherein the antibody further comprises the light chain variable domain framework FR1, which comprises the amino acid sequence of SEQ ID NO: 139; FR2, which comprises the sequence identification No.: the amino acid sequence of any one of 140-141; FR3, which comprises the amino acid sequence of any one of the sequence identification numbers: 142-143; and FR4, which comprises the amino acid sequence of the sequence identification number: 144.
[29] The antibody for use, use or method according to any one of [1] to
[22] , wherein the antibody comprises (a) a VH sequence whose sequence identification numbers are: 13, 16-30, 32 Any of the amino acid sequences of -34 and 86-95 have at least 95% sequence identity; (b) VL sequence for any of SEQ ID NO: 15, 31, 35-38 and 96-99 The amino acid sequence has at least 95% sequence identity; or (c) the VH sequence as (a), and the VL sequence as (b);
[30] the antibody used, the use or The method, wherein the antibody comprises a VH sequence, which is the amino acid sequence of any one of SEQ ID NO: 13, 16-30, 32-34, and 86-95;
[31] the antibody used as described in
[29] , use or method, wherein the antibody comprises a VL sequence, which is the amino acid sequence of any one of SEQ ID NO: 15, 31, 35-38 and 96-99;
[32] an antibody for the treatment of muscular wasting diseases purposes, the antibody comprises a VH sequence, which is the amino acid sequence of any one of the sequence identification numbers: 13, 16-30, 32-34 and 86-95, and a VL sequence, which is the sequence identification number: 15, 31, The amino acid sequence of any one of 35-38 and 96-99;
[33] The use of an antibody for increasing the mass of muscle tissue, the antibody contains a VH sequence, which is the sequence identification number: 13, 16-30, 32- The amino acid sequence of any one of 34 and 86-95, and the VL sequence, which is the amino acid sequence of any one of SEQ ID NO: 15, 31, 35-38 and 96-99;
[34] an antibody For the purpose of increasing muscle tissue strength, the antibody comprises a VH sequence, which is the amino acid sequence of any one of SEQ ID NO: 13, 16-30, 32-34 and 86-95, and a VL sequence, which is the sequence identification number No.: the amino acid sequence of any one of 15, 31, 35-38, and 96-99;
[35] A use of an antibody for reducing body fat accumulation, the antibody contains a VH sequence, and its sequence identification number is: 13, The amino acid sequence of any of 16-30, 32-34 and 86-95, and the VL sequence, which is the amino acid sequence of any of 15, 31, 35-38 and 96-99; And
[36] the antibody for use, use or method according to any one of [1] to
[35] , wherein the antibody is a full-length IgG antibody.
[0057] The present invention provides polypeptides comprising variant Fc regions and methods of making and using the same.
[0058] In one embodiment, the invention provides Fc[gamma]RIIB-binding polypeptides comprising a variant Fc region and methods of use thereof. In some embodiments, the variant Fc region with enhanced FcγRIIB binding activity of the present invention includes at least one amino acid alteration in the parent Fc region. In yet other embodiments, the ratio of [KD value of parental Fc region to monkey FcγRIIb] / [KD value of variant Fc region to monkey FcγRIIb] is 2 or greater. In yet other embodiments, the ratio of [KD value of parental Fc region to monkey FcγRIIIa] / [KD value of variant Fc region to monkey FcγRIIIa] is 0.5 or less. In still other embodiments, the ratio of [KD value of parental Fc region to human FcγRIIb] / [KD value of variant Fc region to human FcγRIIb] is 2 or greater. In yet other embodiments, the ratio of [KD value of parental Fc region to human FcγRIIIa] / [KD value of variant Fc region to human FcγRIIIa] is 0.5 or less. In yet other embodiments, the ratio of [KD value of parental Fc region to human FcγRIIa (type H)] / [KD value of variant Fc region to human FcγRIIa (type H)] is 5.0 or less. In yet other embodiments, the ratio of [KD value of parental Fc region to human FcγRIIa (type R)] / [KD value of variant Fc region to human FcγRIIa (type R)] is 5.0 or less. In another embodiment, the KD value of the variant Fc region for monkey FcγRIIb is 1.0×10 −6 M or less. In another embodiment, the KD value of the variant Fc region for monkey FcγRIIIa is 5.0×10 −7 M or greater. In another example, the variant Fc region has a KD value of 2.0×10 −6 M or less for human FcγRIIb. In another embodiment, the variant Fc region has a KD value of 1.0×10 −6 M or greater for human FcγRIIIa. In another embodiment, the KD value of the mutated Fc region for human FcγRIIa (type H) is 1.0×10 −7 M or greater. In another embodiment, the variant Fc region has a KD value of 2.0×10 −7 M or greater for human FcγRIIa (R type).
[0059] In some embodiments, the variant Fc region of the invention having enhanced FcγRIIb binding activity comprises at least one amino acid modification selected from at least one of: 231, 232, 233, 234, 235, 236 , 237, 238, 239, 264, 266, 267, 268, 271, 295, 298, 325, 326, 327, 328, 330, 331, 332, 334 and 396 (according to EU numbering) .
[0060] In yet other embodiments, the variant Fc region having enhanced FcγRIIb binding activity comprises at least two amino acid modifications comprising: (a) an amino acid modification at position 236; and (b) at least an amino acid modification at least one selected from: (i) positions 231, 232, 233, 234, 235, 237, 238, 239, 264, 266, 267, 268, 271, 295, 298, 325, 326, 327, 328, 330, 331, 332, 334 and 396; (ii) positions 231, 232, 235, 239, 268, 295, 298, 326, 330 and 396; or (iii) positions 268, 295, 326 and the location of the group formed by 330 (according to the EU number).
[0061] In yet other embodiments, the variant Fc region having enhanced FcγRIIb binding activity comprises at least two amino acid modifications comprising: (a) an amino acid modification at position 236; and (b) at least An amino acid modification at least one selected from: 231, 232, 233, 234, 235, 237, 238, 239, 264, 266, 267, 268, 271, 295, 298, 325, 326, 327, The position of the group consisting of 328, 330, 331, 332, 334 and 396 (according to EU numbering).
[0062] In yet other embodiments, the variant Fc region having enhanced FcγRIIb binding activity comprises at least two amino acid modifications, including: (a) an amino acid modification at position 236; and (b) at least An amino acid modification at at least one position selected from the group consisting of: 231, 232, 235, 239, 268, 295, 298, 326, 330, and 396 (according to EU numbering).
[0063] In yet other embodiments, the variant Fc region having enhanced FcγRIIb binding activity comprises at least two amino acid modifications comprising: (a) an amino acid modification at position 236; and (b) at least An amino acid modification at at least one position selected from the group consisting of: 268, 295, 326 and 330 (according to EU numbering).
[0064] In some embodiments, the variant Fc region of the present invention having enhanced FcγRIIb binding activity comprises at least one amino acid selected from: (a) Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr at position 231; (b) Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, Tyr at position 232; (c) Asp at position 233; (d) Trp, Tyr at position 234; (e) Trp at position 235; (f) Ala, Asp, Glu, His, Ile, Leu, Met, Asn, Gln, Ser, Thr, Val at position 236; (g) Asp, Tyr at position 237; (h) Glu, Ile, Met, Gln, Tyr at position 238 (i) Ile, Leu, Asn, Pro, Val at position 239; (j) Ile at position 264; (k) Phe at position 266; (l) Ala, His, Leu at position 267; (m) Asp, Glu at position 268; (n) Asp, Glu, Gly at position 271; (o) Leu at position 295; (p) Leu at position 298; (q) Glu, Phe, Ile, Leu at position 325; (r) Thr at position 326; (s) Ile, Asn at position 327; (t) Thr at position 328; (u) Lys, Arg at position 330; (v) Glu at position 331; (w) Asp at position 332; x) Asp, Ile, Met, Val, Tyr at position 334; and (y) Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val , Trp, Tyr at position 396 (according to the EU numbering) group.
[0065] In yet other embodiments, the variant Fc region with enhanced FcγRIIb binding activity comprises at least one amino acid selected from: (a) Gly, Thr at position 231; (b) Asp at position 232 (c) Trp at position 235; (d) Asn, Thr at position 236; (e) Val at position 239; (f) Asp, Glu at position 268; (g) Leu at position 295; The group consisting of (i) Thr at position 326; (j) Lys, Arg at position 330; and (k) Lys, Met at position 396 (according to EU numbering).
[0066] In another embodiment, the invention provides polypeptides comprising variant Fc regions with increased isoelectric points (pi) and methods of use thereof. In some embodiments, the polypeptide of the variant Fc region comprising an increased pi comprises at least two amino acid modifications to the parental Fc region. In yet other embodiments, each amino acid modification increases the isoelectric point (pi) of the variant Fc region compared to the isoelectric point (pi) of the parental Fc region. In yet other embodiments, amino acids may be exposed on the surface of the variant Fc region. In yet other embodiments, the polypeptide comprises a variant Fc region and an antigen binding domain. In yet other embodiments, the antigen binding activity of the antigen binding domain is altered according to ion concentration conditions. In yet other embodiments, the variant Fc region of the invention having increased pi comprises at least two amino acid modifications selected from at least two of: 285, 311, 312, 315, 318, 333, 335 , 337, 341, 342, 343, 384, 385, 388, 390, 399, 400, 401, 402, 413, 420, 422 and 431 The position of the group (according to the EU number). In yet other embodiments, the variant Fc region with increased pi includes Arg or Lys at each selected position.
[0067] In some embodiments, the variant Fc regions of the invention comprise amino acid modifications as described in Tables 14-30.
[0068] In some embodiments, the polypeptide comprises a variant Fc region of the invention. In yet other embodiments, the parental Fc region is derived from human IgGl. In yet other embodiments, the polypeptide is an antibody. In yet other embodiments, the polypeptide is an Fc fusion protein.
[0069] The present invention provides a polypeptide comprising the amino acid sequence of any one of SEQ ID NO: 229-381.
[0070] The invention also provides an isolated nucleic acid encoding a polypeptide comprising a variant Fc region of the invention. The invention also provides host cells comprising a nucleic acid of the invention. The present invention also provides a method of producing a polypeptide comprising a variant Fc region comprising culturing a host cell of the present invention such that the polypeptide is produced.
[0071] The present invention further provides a pharmaceutical formulation comprising the polypeptide comprising the variant Fc region of the present invention and a pharmaceutically acceptable carrier.
Implementation
[0073] The techniques or steps described or cited herein are generally conventional methods well known and commonly used by those skilled in the art, such as, for example, as Sambrook et al., Molecular Cloning: A Laboratory Manual 3d edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Current Protocols in Molecular Biology (eds. F.M. Ausubel et al. (2003)); the series Methods in Enzymology (Academic Press, Inc.): PCR 2: A Practical Approach (M.J. MacPherson , B.D. Hames and G.R. Taylor, ed. (1995)), Harlow and Lane, ed. (1988) Antibodies, A Laboratory Manual, and Animal Cell Culture (R.I. Freshney, ed. (1987)); Oligonucleotide Synthesis (M.J. Gait, ed., 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (ed. J.E. Cellis, 1998) Academic Press; Animal Cell Culture (R.I. Freshney), edited, 1987); Introduction to Cell and Tissue Culture (J. P. Mather and P.E. Roberts, 1998 ) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (eds. A. Doyle, J.B. Griffiths and D.G. Newell, 1993-8) J. Wiley and Sons; Handbook of Experimental Immunology (eds. D.M. Weir and C.C. Blackwell); Gene Transfer Vectors for Mammalian Cells (eds. J.M. Miller and M.P. Calos, 1987); PCR: The Polymerase Chain Reaction, (eds. Mullis et al., 1994); Current Protocols in Immunology (eds. J.E. Coligan et al., 1991); Short Protocols in Molecular Biology (Wiley et al., eds., 1991); and Sons, 1999); Immunobiology (C.A. Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: A Practical Approach (ed. D. Catty., IRL Press, 1988-1989); Monoclonal Antibodies: A Practical Approach (edited by P. Shepherd and C. Dean, Oxford University Press, 2000); Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and J. D. Capra, eds., Harwood Academic Publishers, 1995); and the widely used method described in Cancer: Principles and Practice of Oncology (V.T. DeVita et al., eds., J.B. Lippincott Company, 1993). Ⅰ. Definition
[0074] Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, N.Y. 1994) and March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 4th ed., John Wiley & Sons (New York, N.Y. 1992) provides those skilled in the art with general guidance for many of the terms used in this application. Documents cited herein, including patent applications and publications, are hereby incorporated by reference in their entirety.
[0075] For purposes of interpreting this specification, the following definitions will be used, and whenever appropriate, terms used in the singular may also include the plural and vice versa. It should be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. In the event that any definition set forth below conflicts with any document incorporated herein by reference, the definition set forth below shall control.
[0076] An "acceptor human framework" for the purposes herein is one comprising a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework as defined below framework of the amino acid sequence. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may comprise amino acid sequence changes. In some embodiments, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 1 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to a VL human immunoglobulin framework sequence or a human consensus framework sequence.
[0077] "Affinity" refers to the aggregate strength of non-covalent interactions between a single binding site of a molecule (eg, an antibody) and its binding partner (eg, an antigen). As used herein, unless otherwise indicated, "binding affinity" refers to intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (eg, antibody and antigen). The affinity of a molecule X to its partner Y can generally be expressed by a dissociation constant (Kd). Affinity can be measured by methods known in the art, including those described herein. Specific instructions and illustrative examples for measuring binding affinity are described below.
[0078] An "affinity matured" antibody is one that has one or more alterations in one or more hypervariable regions (HVRs) compared to a parent antibody that does not possess such alterations , such changes result in an improvement in the affinity of the antibody for the antigen.
[0079] The terms "anti-myostatin antibody" and "antibody that binds to myostatin" refer to an antibody that is capable of binding myostatin with sufficient affinity such that the antibody can be used as a diagnostic in targeting myostatin and / or therapeutic agents. In one embodiment, the extent to which an anti-myostatin antibody binds to an unrelated non-myostatin protein is less than about 10% of the binding of the antibody to myostatin, as measured, for example, by radioimmunoassay (RIA). In specific embodiments, the antibody that binds to myostatin has ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10-8 M or less, For example, a dissociation constant (Kd) from 10-8M to 10-13M, such as from 10-9M to 10-13M). In specific embodiments, the anti-myostatin antibody binds to an epitope of myostatin that is conserved with myostatin from a different species.
[0080] The term "antibody" is used herein in the broadest sense and encompasses a variety of antibody structures including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments , so long as they exhibit the desired antigen-binding activity.
[0081] "Antibody fragment" refers to a molecule other than an intact antibody that includes a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single chain antibody molecules (e.g., scFv); Formation of multispecific antibodies.
[0082] "Antibody that binds to the same epitope" as a reference antibody refers to an antibody that blocks the binding of the reference antibody to its antigen in a competition assay, and / or conversely, the reference antibody that is used in a competition assay Blocks the binding of an antibody to its antigen. An exemplary competitive analysis is provided herein.
[0083] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chains is from a particular source or species and the remainder of the heavy and / or light chains is from a different source or species.
[0084] The "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these classes can be further divided into subgroups (isotypes), for example, IgGl, IgG2, IgG3, IgG4, IgA1 and IgA2. The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively.
[0085] The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents cellular function and / or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioisotopes (e.g., radioisotopes of At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212, and Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan ), mitomycin C, chlorambucil, daunorubicin, or other intercalating agents); growth inhibitors; enzymes and fragments thereof, such as nucleolytic enzymes; antibiotics; toxins, such as bacteria , small molecule toxins or enzyme-active toxins derived from fungi, plants or animals, including fragments and / or variants thereof; and various antitumor or anticancer agents disclosed below.
[0086] "Effector functions" refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: Clq binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis ; negative regulation of cell surface receptors (eg, B cell receptors); and B cell activation.
[0087] An "effective amount" of an agent, such as a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time required, to achieve the desired therapeutic or prophylactic result.
[0088] The term "epitope" includes any determinant capable of being bound by an antibody. An epitope is the region of an antigen that is bound by an antibody targeting that antigen, and contains specific amino acids that directly contact the antibody. Epitope Epitopes may comprise chemically active surface clusters of molecules such as amino acids, sugar branches, phosphate groups, or sulfonyl groups, and may have specific three-dimensional structural properties, and / or specific charge properties. In general, antibodies specific for a particular target antigen will preferentially recognize epitopes on the target antigen in a complex mixture of proteins and / or macromolecules.
[0089] "Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. In some embodiments, the FcR is a native human FcR. In some embodiments, the FcR is a receptor that binds to an IgG antibody (a gamma receptor) and includes receptors of the FcyRI, FcyRII, and FcyRIII subclasses, including allelic variants and alternatively spliced forms of these receptors ( alternatively spliced form). FcyRII receptors include FcyRIIA ("activating receptor") and FcyRIIB ("inhibiting receptor"), which have similar amino acid sequences and differ mainly in their cytoplasmic domains. The activating receptor FcyRIIA contains an immunoreceptor tyrosine activation motif (ITAM) in its cytoplasmic domain. The inhibitory receptor FcyRIIB contains an immunoreceptor tyrosine inhibition motif (ITIM) in its cytoplasmic domain (see, eg, Daëron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs have been reviewed, for example, in Ravetch and Kinet, Annu. Rev. Immunol. 9:457-92 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those identified in the future, are encompassed herein by the term "FcR".
[0090] The term "Fc receptor" or "FcR" also includes the neonatal receptor, FcRn, which is responsible for the transfer of the mother's IgG to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)) and the constant regulation of immunoglobulins. Methods for measuring binding to FcRn are known (see, e.g., Ghetie and Ward, Immunol. Today 18(12):592-598 (1997); Ghetie et al., Nature Biotechnology 15(7):637-640 (1997) ; Hinton et al., J. Biol. Chem.279(8):6213-6216 (2004); WO 2004 / 92219 (Hinton et al.). Binding to human FcRn in vivo and identification of polypeptides binding to human FcRn with high affinity Plasma half-life can be analyzed, for example, in transgenic mice or human cell lines transfected to express human FcRn, or in primates administered polypeptides with variant Fc regions. WO 2000 / 42072 (Presta) Antibody variants with improved or reduced binding to FcRs are described. See also, eg, Shields et al., J. Biol. Chem. 9(2):6591-6604 (2001).
[0091] The term "Fc region" is used herein to define the C-terminal region of an immunoglobulin heavy chain, which comprises at least a portion of the constant region. The term encompasses both native sequence Fc regions and variant Fc regions. In one embodiment, the human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxy-terminus of the heavy chain. However, the C-terminal lysine (Lys447) or glycine-lysine (Gly446-Lys447) of the Fc region may or may not be present. Unless otherwise stated herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
[0092] The term "Fc region-comprising antibody" refers to an antibody that includes an Fc region. The C-terminal lysine (residue 477, according to the EU numbering system) or the C-terminal glycine-lysine (residues 446-447) of the Fc region may be removed, for example, during antibody purification or by encoding during the recombination engineering of nucleic acids. Therefore, the composition comprising the antibody having an Fc region of the present invention may include an antibody with G446-K447, an antibody with G446 and no K447, an antibody with all G446-K447 removed, or a mixture of the above three antibodies.
[0093] "Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3 and FR4. Thus, HVR and FR sequences generally appear in a VH (or VL) in the following order: FR1-H1(LI)-FR2-H2(L2)-FR3-H3(L3)-FR4.
[0094] The terms "full-length antibody", "intact antibody" and "whole antibody" are used interchangeably herein to refer to a protein having a structure substantially similar to that of a native antibody or comprising an Fc region as defined herein. heavy chain antibodies.
[0095] A "functional Fc region" possesses the "effector functions" of a native sequence Fc region. Exemplary "effector functions" include Clq binding; CDC; Fc receptor binding; ADCC; phagocytosis; Such effector functions typically require an Fc region for binding to a binding domain (eg, an antibody variable domain) and can be assessed using a variety of disclosed assays, eg, as defined herein.
[0096] The terms "host cell", "host cell line" and "host cell culture" are used interchangeably to refer to a cell into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the originally transformed cell and progeny derived therefrom, regardless of passage number. The nucleic acid content of the progeny may not be identical to that of the parental cells, but may contain mutations. Contemplated herein are mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell.
[0097] A "human antibody" is one having an amino acid sequence corresponding to an antibody produced by a human or human cell or derived from a non-human source encoded by a human antibody library or other human antibody sequence. This definition of a human antibody specifically excludes humanized antibodies that include non-human antigen-binding residues.
[0098] A "human consensus framework" is a framework representing the most frequently occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. In general, the selection of human immunoglobulin VL or VH sequences is derived from the subtype of variable domain sequences. Typically, the subtype of the sequence is that of Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols. 1-3. In one example, for VL, the subtype is subtype kappa I as in Kabat et al., supra. In one example, for VH, the subtype is subtype III as in Kabat et al., supra.
[0099] A "humanized" antibody refers to a chimeric antibody that includes amino acid residues from non-human HVRs as well as amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and usually two, variable domains, wherein all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and All or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally comprises at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody (eg, a non-human antibody) refers to an antibody that has been humanized.
[0100] The term "hypervariable region" or "HVR" as used herein refers to antibody variable domains that are hypervariable in sequence ("complementarity determining regions" or "CDRs"), and / or form structurally defined loops ("highly variable domains"). variation loop"), and / or each region comprising antigen contact residues ("antigen contacts"). In general, antibodies include six HVRs: three in the VH (H1, H2, H3) and three in the VL (L1, L2, L3). Exemplary HVRs herein include: (a) occurrences at amino acid residues 26-32(L1), 50-52(L2), 91-96(L3), 26-32(H1), 53-55(H2 ) and the hypervariable loop of 96-101(H3) (Chothia, J. Mol. Biol. 196:901-917 (1987)); (b) occurs at amino acid residues 24-34(L1), 50- 56(L2), 89-97(L3), 31-35b(H1), 50-65(H2) and 95-102(H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service , NIH, Bethesda, MD (1991)); (c) occurs at amino acid residues 27c-36(L1), 46-55(L2), 89-96(L3), 30-35b(H1) , 47-58(H2) and 93-101(H3) (MacCallum et al., J. Mol. Biol. 262:732-745 (1996)); and (d) (a), (b) and / or a combination of (c), comprising HVR amino acid residues 46-56(L2), 47-56(L2), 48-56(L2), 49-56(L2), 26-35(H1), 26-35b(H1), 49-65(H2), 93-102(H3) and 94-102(H3).
[0101] Unless otherwise stated, HVR residues and other residues in variable domains (eg, FR residues) herein are numbered according to Kabat et al., supra.
[0102] An "immunoconjugate" is an antibody conjugated to one or more heterogeneous molecules, including but not limited to cytotoxic agents.
[0103] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (such as cattle, sheep, cats, dogs, and horses), primates (such as humans and non-human primates such as monkeys), rabbits, and rodents (such as mice and rats) ). In certain embodiments, the individual or subject is a human.
[0104] An "isolated" antibody is one that has been separated from components of its natural environment. In some embodiments, antibodies are purified to greater than 95% or 99% purity by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reverse Phase HPLC) method for determination. For a review of methods for assessing antibody purity see, eg, Flatman et al., J. Chromatogr. B848:79-87 (2007).
[0105] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from components of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that normally contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location other than its natural chromosomal location.
[0106] "Isolated nucleic acid encoding an anti-myostatin antibody" refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), contained in a single vector or in separate vectors. , and such nucleic acid molecules present at one or more locations in the host cell.
[0107] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., individual antibodies comprising the same population and / or binding to the same epitope, except for example: Except for antibodies that contain naturally occurring mutations or possible variants that arise during the production of monoclonal antibodies (such variants usually exist in small amounts). Unlike the production of polyclonal antibodies, which usually contain different antibodies directed against different determinants (epitopes), monoclonal antibodies are prepared in which each monoclonal antibody is directed against a single epitope on the antigen. Thus, the modifier "monoclonal" refers to the characteristics of antibodies obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring any particular method to produce the antibodies. For example, monoclonal antibodies to be used in accordance with the present invention can be prepared by a variety of techniques including, but not limited to, fusion tumor technology, recombinant DNA methods, phage display methods, and the use of all or part of the human immunoglobulin loci ( loci), such methods and other exemplary methods for producing monoclonal antibodies are described herein.
[0108] "Naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (eg, a cytotoxic moiety) or a radiolabel. Naked antibodies may be present in pharmaceutical formulations.
[0109] "Native antibody" refers to a naturally occurring immunoglobulin molecule of varying structure. For example, native IgG antibodies are heterotetrameric glycoproteins of approximately 150,000 daltons consisting of two identical light chains and two identical heavy chains disulfide-bonded. From N to C-terminus, each heavy chain has a variable region (VH), also called variable heavy domain or heavy chain variable domain, followed by three constant domains (CH1, CH2 and CH3). Similarly, from N to C-terminus, each light chain has a variable region (VL), also known as a variable light domain or light chain variable domain, followed by a constant light (CL) domain. Depending on the amino acid sequence of its constant domains, the light chains of antibodies can be assigned to one of two types, called kappa and lambda.
[0110] A "native sequence Fc region" includes an amino acid sequence identical to that of an Fc region found in nature. Natural sequence human Fc regions include natural sequence human IgG1 Fc regions (non-A and A allotypes); natural sequence human IgG2 Fc regions; natural sequence human IgG3 Fc regions; and natural sequence human IgG4 Fc regions, as well as naturally occurring variants thereof.
[0111] The term "package insert" is used to refer to instructions usually included in commercial packages of therapeutic products, which contain information on indications, usage, dosage, administration, concomitant therapies, contraindications and / or WARNINGS REGARDING THE USE OF THIS THERAPY PRODUCT.
[0112] "Percent (%) amino acid sequence identity" relative to a reference polypeptide sequence is defined as after aligning the sequences and introducing gaps (gap) if necessary to achieve the maximum percent sequence identity, without any Where conservative substitutions are considered part of the sequence identity, the percentage of amino acid residues in a candidate sequence that are identical to amino acid residues in a reference polypeptide sequence. Alignment for the purpose of determining percent amino acid sequence identity can be achieved in various ways within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, Megalign (DNASTAR ) software or GENETYX (registered trademark) (Genetyx Co., Ltd.). Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. The ALIGN-2 sequence comparison computer program was written by Genentech, Inc., and the source code has been submitted with the user documentation to the US Copyright Office, Washington D.C., 20559, where it is registered under US Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available at Genentech, Inc., South San Francisco, California, or can be compiled from source code. ALIGN-2 programs should be compiled for use on UNIX operating systems, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
[0113] In the case of using ALIGN-2 for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A to, and or relative to, a given amino acid sequence B ( Alternatively it can be expressed as a given amino acid sequence A having or comprising a specific % amino acid sequence identity over, and or relative to a given amino acid sequence B) calculated as: 100 times the fraction X / Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in the alignment of A and B of the program, and where Y is the amino acid in B total number of residues. It will be understood that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A over B will not equal the % amino acid sequence identity of B over A sex. Unless expressly stated otherwise, all % amino acid sequence identity values used herein were obtained using the ALIGN-2 computer program as described in the preceding paragraph.
[0114] The term "pharmaceutical formulation" refers to a preparation which is in such a form as to allow the biological activity of the active ingredients contained therein to be effective and which does not contain additional ingredients which are unacceptably toxic to the subject to whom the formulation is to be administered .
[0115] "Pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation other than the active ingredient, which is nontoxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers or preservatives.
[0116] The term "myostatin" as used herein may refer to any natural myostatin from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). Unless otherwise stated, the term "myostatin" refers to a human having the amino acid sequence shown in SEQ ID NO: 1 and comprising the terminal propeptide domain of human myostatin shown in SEQ ID NO: 75 or 78 myostatin protein. The term encompasses "full length", unprocessed myostatin as well as any form of myostatin that results from intracellular processing. The term also encompasses naturally occurring variants of myostatin, eg, splice variants or allelic variants. The amino acid sequence of an exemplary human myostatin is shown in SEQ ID NO: 1 (promyostatin). The amino acid sequence of the C-terminal growth factor domain of an exemplary human myostatin is shown in SEQ ID NO: 2. The amino acid sequence of an exemplary N-terminal propeptide domain of human myostatin is shown in SEQ ID NO: 75 or 78. Active mature myostatin is a disulfide-bonded homodimer composed of two C-terminal growth factor domains. Inactive latent myostatin is a non-covalently linked complex of two propeptides and mature myostatin. As disclosed herein, the antibodies of the invention bind to inactive latent myostatin, but not to mature active myostatin homodimers. In some embodiments, the antibody of the present invention binds to an epitope within a fragment consisting of amino acids 21-100 of promyostatin peptide (SEQ ID NO: 78), but does not bind to mature active muscle Binding of statin homodimers. The amino acid sequences of exemplary rhesus monkey and murine (murine) myostatin (promyostatin) are shown in SEQ ID NO: 3 and 5, respectively. The amino acid sequences of the C-terminal growth factor domains of exemplary rhesus monkey and mouse myostatin are shown in SEQ ID NO: 4 and 6, respectively. The amino acid sequences of the N-terminal pro-peptide domains of exemplary rhesus monkey and murine myostatin are shown in SEQ ID NO: 76 or 79, and 77 or 80, respectively. GDF-11 (BMP-11) is a molecule closely related to myostatin, and they are all members of the TGF-β superfamily. Similar to myostatin, GDF11 is first synthesized as a precursor peptide, which is then cleaved into N-terminal prodomain and C-terminal mature GDF11. The amino acid sequence of human GDF11 (precursor) is shown in SEQ ID NO: 81. The amino acid sequence of the mature human GDF11 at the C-terminus is shown in SEQ ID NO: 82. The amino acid sequence of the N-terminal prodomain of human GDF11 is shown in SEQ ID NO: 83 or 84. The amino acid sequences of SEQ ID NO: 1, 3, 5, 78, 79, 80, 81, and 84 contain a message sequence that corresponds to their amino acids 1-24, and the message sequence is displaced during processing in the cell remove.
[0117] "Treatment" (and grammatical variants thereof) as used herein refers to clinical intervention that attempts to alter the natural course of the disease in the individual being treated, and may be performed prophylactically or during the course of clinical pathology. The desired therapeutic effects include, but are not limited to, preventing the occurrence or recurrence of the disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, ameliorating or palliating the disease state, and slowing down or improving prognosis. In some embodiments, the antibodies of the invention are used to delay the development of a disease or slow the progression of a disease.
[0118] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. The variable domains (VH and VL, respectively) of the heavy and light chains of natural antibodies usually have a similar structure, and each domain includes four conserved framework regions (FR) and three hypervariable regions (HVR) (see , eg Kindt et al., Kuby Immunology, 6thed., W.H. Freeman and Co., p. 91 (2007)). A single VH or VL domain may be sufficient to confer antigen binding specificity. In addition, antibodies that bind to a particular antigen can be isolated using the VH or VL domains from antibodies that bind that antigen to screen complementary VL or VH domain libraries, respectively. See, eg, Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).
[0119] A "variant Fc region" includes an amino acid sequence that differs from a native sequence Fc region due to at least one amino acid modification (modification), preferably one or more amino acid substitutions. Preferably, the variant Fc region has at least one amino acid substitution, for example, about 1 to 10 amino acid substitutions, preferably about 1 to 5 amino acid substitutions, compared to the native sequence Fc region or the Fc region of the parent polypeptide The acid substitution is in the native sequence Fc region or the Fc region of the parent polypeptide. The variant Fc region herein will preferably have at least about 80% homology, and most preferably at least about 90% homology, more preferably at least about 95% homology to the native sequence Fc region and / or the Fc region of the parental polypeptide. % homology.
[0120] The term "vector" as used herein refers to a nucleic acid molecule capable of multiplying another nucleic acid to which it has been linked. The term encompasses a vector that is an autonomously replicating nucleic acid structure, as well as a vector that is incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vehicles are referred to herein as "expression vehicles." II. COMPOSITION AND METHODS
[0121] In one aspect, the invention is based, in part, on anti-myostatin antibodies and uses thereof. In specific embodiments, antibodies that bind to myostatin are provided. The antibodies of the invention are useful, for example, in the diagnosis and treatment of muscle wasting diseases.
[0122] In one aspect, the invention is based, in part, on polypeptides comprising variant Fc regions and uses thereof. In one embodiment, polypeptides comprising a variant Fc region with enhanced FcγRIIb binding activity are provided. In another embodiment, polypeptides comprising a variant Fc region with increased pi are provided. In some specific embodiments, the polypeptides of the invention are antibodies. Polypeptides of the invention comprising variant Fc regions are useful, for example, in the diagnosis and treatment of diseases. A. Exemplary anti-myostatin antibodies and polypeptides comprising variant Fc regions
[0123] In one aspect, the invention provides an isolated antibody that binds to myostatin. In some specific embodiments, the anti-myostatin antibodies of the invention bind to latent myostatin. In yet other embodiments, an anti-myostatin antibody of the invention binds to a native myostatin peptide (human: SEQ ID NO: 75 or 78; rhesus monkey: SEQ ID NO: 76 or 79; mouse: SEQ ID NO: 76 or 79; mouse: SEQ ID NO: 75 or 78; : 77 or 80). In yet other embodiments, the antibody binds to an epitope within the fragment consisting of amino acids 21-100 of the myostatin native peptide (SEQ ID NO: 78). Native peptide is included as one of the components in latent myostatin, as described above. In some specific embodiments, the anti-myostatin antibodies of the invention inhibit the activation of myostatin. In some specific embodiments, the anti-myostatin antibody blocks the release of mature myostatin from latent myostatin. It has been reported that mature myostatin is released from latent myostatin by proteolytic and non-proteolytic steps. The anti-myostatin antibodies of the invention can block the proteolytic and / or non-proteolytic release of mature myostatin from latent myostatin. In some specific embodiments, the anti-myostatin antibody blocks the proteolytic cleavage of latent myostatin. In some specific embodiments, the anti-myostatin antibody blocks protease access to latent myostatin (in particular access to the proteolytic cleavage site of latent myostatin (Arg98-Asp99)). In yet other embodiments, the protease may be a metalloprotease of the BMP1 / TLD family, such as BMP1, TED, tolloid-like protein-1 (tolloid-like protein-1, TLL-1) or tolloid-like protein-2 (TLL-2). In another embodiment, the anti-myostatin antibody blocks the non-proteolytic release of mature myostatin from latent myostatin. As used herein, non-proteolytic release represents the spontaneous release of mature myostatin from latent myostatin, which is not accompanied by proteolytic cleavage of latent myostatin. Non-proteolytic release comprises, for example, releasing mature myostatin by incubating latent myostatin, eg, at 37°C in the absence of a protease that cleaves latent myostatin. In some specific embodiments, the anti-myostatin antibodies of the invention do not bind to mature myostatin. In some embodiments, the anti-myostatin antibody binds to the same epitope as the antibody described in Table 2a. In some embodiments, the anti-myostatin antibody competes with the antibodies described in Table 2a for binding to latent myostatin. In some additional embodiments, the anti-myostatin antibody competes for latent myostatin binding with an antibody comprising the VH and VL pair described in Table 2a. In some embodiments, the anti-myostatin antibody competes with the antibody described in Table 2a for binding to a fragment consisting of amino acids 21-100 of the native myostatin peptide (SEQ ID NO: 78). In yet other embodiments, the anti-myostatin antibody binds to the same epitope as the antibody described in Table 11a or 13. In some embodiments, the anti-myostatin antibody competes with the antibody described in Table 11a or 13 for binding to latent myostatin. In some embodiments, the anti-myostatin antibody competes with the antibody described in Table 11a or 13 for binding to a fragment consisting of amino acids 21-100 of native myostatin peptide (SEQ ID NO: 78). In some embodiments, an anti-myostatin antibody of the invention binds to latent myostatin and inhibits myostatin activation. In yet other embodiments, the antibody: (a) blocks the release of mature myostatin from latent myostatin; (b) blocks the proteolytic release of mature myostatin; (c) blocks the release of mature myostatin or (d) not bound to mature myostatin; or bound to an epitope within a fragment consisting of amino acids 21-100 of myostatin native peptide (SEQ ID NO: 78) . In still other embodiments, the antibody competes for latent myostatin binding with an antibody comprising the VH and VL pair described in Table 2a, 11a or 13, or with an antibody comprising the VH and VL pair described in Table 2a, 11a or 13 Antibodies bind to the same epitope. In yet other embodiments, the antibody binds to latent myostatin with a higher affinity at neutral pH (eg, pH 7.4) than at acidic pH (eg, pH 5.8). In yet other embodiments, the antibody is (a) a monoclonal antibody; (b) a human, humanized, or chimeric antibody; (c) a full-length IgG antibody; or (d) binds latent myostatin or myostatin Antibody fragments of native peptides.
[0124] In another embodiment, the anti-myostatin antibodies of the invention do not bind to GDF11. In some specific embodiments, the anti-myostatin antibodies of the invention do not inhibit the activation of GDF11. In some specific embodiments, the anti-myostatin antibody does not block the release of mature GDF11 from latent GDF11. The anti-myostatin antibodies of the invention did not block the proteolytic and non-proteolytic release of mature GDF11 from latent GDF11. In some specific embodiments, the anti-myostatin antibody does not block proteolytic cleavage of latent GDF11. In some specific embodiments, the anti-myostatin antibody does not block protease access to latent GDF11 (in particular access to the proteolytic cleavage site of latent GDF11). In yet other embodiments, the protease may be a metalloprotease of the BMP1 / TLD family, like BMP1, TED, tolloid-like protein 1 (TLL-1 ) or tolloid-like protein 2 (TLL-2). As used herein, non-proteolytic release represents the spontaneous release of mature GDF11 from latent GDF11, which is not accompanied by proteolytic cleavage of latent GDF11. Non-proteolytic release comprises, for example, releasing mature GDF11 by incubating latent GDF11, eg, at 37°C in the absence of a protease that cleaves latent GDF11. Most of the currently known anti-myostatin antibodies are not specific for myostatin. These antibodies have high affinity for other members of the TGF-beta superfamily like GDF11 and neutralize their biological activity. GDF11 plays an important role during embryogenesis and is responsible for the homologous transformation of the axial skeleton. Homozygous GDF11 knockout mice are perinatal lethal, mice with one copy of the wild-type GDF11 gene are viable but have skeletal defects. Since GDF11 plays an important role during embryogenesis, antagonists that inhibit GDF11 pose a theoretical safety risk that could cause toxicity in treated patients or reproductive toxicity in, for example, women of reproductive age. Therefore, specific inhibition of myostatin activity is needed in the treatment of myostatin-related disorders where it is desired to increase muscle mass, size, strength, etc., and is particularly needed in women of reproductive age .
[0125] In another aspect, the invention provides anti-myostatin antibodies that exhibit pH-dependent binding properties. As used herein, the phrase "pH-dependent" means that the antibody exhibits "decreased binding to myostatin at acidic pH compared to neutral pH" (both terms are interchangeable for the purposes of this disclosure. use instead). For example, an antibody "having pH-dependent binding properties" includes an antibody that binds to myostatin with a higher affinity at neutral pH than at acidic pH. In particular embodiments, an antibody of the invention exhibits a pH of at least 2, 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 at neutral pH as compared to at acidic pH. , 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more fold affinity to myostatin. In some embodiments, the antibody binds to myostatin (eg, latent myostatin or the propeptide myostatin) with a higher affinity at pH 7.4 than at pH 5.8. In still other embodiments, the antibodies of the present invention have a ratio of at least 2, 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, Binds to myostatin with 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more fold affinity.
[0126] When the antigen is a soluble protein, binding of the antibody to the antigen can result in a prolongation of the half-life of the antigen in plasma (i.e., reduced clearance of the antigen from plasma), since the antibody can have a longer lifetime in plasma than the antigen itself. half-life, and can be used as a carrier for antigens. This results from the recycling of antigen-antibody complexes by FcRn through the endosomal pathway in cells (Roopenian, Nat. Rev. Immunol. 7(9): 715-725 (2007)). However, an antibody with pH-dependent binding properties, which binds to its antigen in the neutral extracellular environment and releases the antigen into the acidic endosomal compartment as it enters the cell, is pH-dependent. Antibodies with binding properties are expected to have superior performance in terms of antigen neutralization and clearance, which is related to its corresponding binding in a pH-dependent manner (Igawa et al., Nature Biotechnol. 28(11):1203-1207 ( 2010); Devanaboyina et al., mAbs5(6):851-859 (2013); WO 2009 / 125825).
[0127] The "affinity" of an antibody for myostatin is, for the purposes of this disclosure, expressed in terms of the KD of the antibody. The KD of an antibody refers to the equilibrium dissociation constant for the antibody-antigen interaction. The greater the KD value of an antigen binding to its antigen, the weaker its binding affinity for that particular antigen. Thus, as used herein, "higher affinity at neutral pH compared to acidic pH" (or the equivalent expression "pH-dependent binding") means that the antibody binds to myostatin at acidic pH with a KD greater than Antibody binds to the KD of myostatin at neutral pH. For example, in the context of the present invention, an antibody is considered to bind to myostatin at neutral pH if its KD for binding to myostatin at acidic pH is at least twice greater than the KD for binding to myostatin at neutral pH. At acidic pH, binds to myostatin with higher affinity. Accordingly, the invention encompasses that the KD for binding to myostatin at acidic pH is at least 2, 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more times the antibody. In another embodiment, the antibody may have a KD value of 10-7M, 10-8M, 10-9M, 10-10M, 10-11M, 10-12M or less at neutral pH. In another embodiment, the KD value of the antibody at acidic pH may be 10-9M, 10-8M, 10-7M, 10-6M or greater.
[0128] In yet other embodiments, if the antibody binds to myostatin (e.g., latent myostatin or pro-peptide myostatin) with a KD at pH 5.8 that is at least greater than the antibody binds to myostatin at pH 7.4 Twice the KD of myostatin, the antibody was seen to bind to myostatin with higher affinity at neutral pH compared to acidic pH. In some embodiments, provided antibodies have a KD that binds to myostatin at pH 5.8 that is at least 3, 5, 10, 15, 20, 25, 30, 35 times greater than the KD of the antibody that binds to myostatin at pH 7.4 , 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more times. In another embodiment, the KD value of the antibody at pH 7.4 may be 10-7M, 10-8M, 10-9M, 10-10M, 10-11M, 10-12M or less. In another embodiment, the KD value of the antibody at pH 5.8 may be 10-9M, 10-8M, 10-7M, 10-6M or greater.
[0129] The binding properties of an antibody for a particular antigen can also be expressed by the kd of the antibody. The kd of an antibody refers to the dissociation rate constant of the antibody for a specific antigen, expressed in the reciprocal of seconds (ie sec-1). An increased kd value indicates that the antibody binds weaker to its antigen. The invention thus encompasses antibodies that bind myostatin at acidic pH with a higher kd value than at neutral pH. The present invention comprises binding to myostatin at an acidic pH with a kd at least 2, 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 greater than the kd for binding to myostatin at a neutral pH , 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more times the antibody. In another embodiment, the kd value of the antibody may be 10-21 / s, 10-31 / s, 10-41 / s, 10-51 / s, 10-61 / s or less at neutral pH. In another embodiment, the kd value of the antibody may be 10-31 / s, 10-21 / s, 10-11 / s or greater at acidic pH. The invention also encompasses antibodies that bind to myostatin (eg, latent myostatin or the pro-peptide myostatin) with a greater kd value at pH 5.8 than at pH 7.4. The present invention comprises that the kd binding to myostatin at pH 5.8 is at least 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more times the antibody. In another embodiment, the kd value of the antibody at pH 7.4 may be 10-21 / s, 10-31 / s, 10-41 / s, 10-51 / s, 10-61 / s or less. In another embodiment, the antibody may have a kd value of 10-31 / s, 10-21 / s, 10-11 / s or greater at pH 5.8.
[0130] In a particular example, "decreased binding to myostatin at acidic pH compared to at neutral pH" is expressed in terms of the KD value of antibody binding to myostatin at acidic pH compared to antibody binding at neutral pH to the ratio of the KD value of myostatin (or vice versa). For example, for the purposes of the present invention, an antibody may be considered "reduced binding to myostatin at acidic pH compared to neutral pH" if the antibody has an acidic / neutral KD ratio of 2 or greater . In some specific embodiments, the pH5.8 / pH7.4 KD ratio of the anti-myostatin antibodies of the present invention may be 2 or greater. In some specific exemplary embodiments, the acidic / neutral KD ratio of the antibody of the present invention may be 2, 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more. In another embodiment, the antibody may have a KD value of 10-7M, 10-8M, 10-9M, 10-10M, 10-11M, 10-12M or less at neutral pH. In another embodiment, the KD value of the antibody at acidic pH may be 10-9M, 10-8M, 10-7M, 10-6M or greater. In a further example, if the antibody has a pH5.8 / pH7.4 KD ratio of 2 or greater, the antibody can be considered "more reactive with myostatin (e.g., latent) at acidic pH than at neutral pH." decreased binding of myostatin). In some specific exemplary embodiments, the pH5.8 / pH7.4 KD ratio of the antibody can be 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more. In another embodiment, the KD value of the antibody at pH 7.4 may be 10-7M, 10-8M, 10-9M, 10-10M, 10-11M, 10-12M or less. In another embodiment, the KD value of the antibody at pH 5.8 may be 10-9M, 10-8M, 10-7M, 10-6M or greater.
[0131] In a particular example, "the binding to myostatin at acidic pH is reduced compared to at neutral pH" is defined as the ratio of the kd value of antibody binding to myostatin at neutral pH at neutral pH to expressed as the ratio of the kd value of myostatin (or vice versa). For example, for the purposes of the present invention, an antibody may be considered "reduced binding to myostatin at acidic pH compared to neutral pH" if the antibody has an acidic / neutral kd ratio of 2 or greater . In some specific exemplary embodiments, antibodies of the invention may have a pH5.8 / pH7.4 kd ratio of 2 or greater. In some specific exemplary embodiments, the acidic / neutral kd ratio of the antibody of the present invention may be 2, 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more. In another embodiment, the antibody may have a kd value of 10-21 / s, 10-31 / s, 10-41 / s, 10-51 / s, 10-61 / s or less at neutral pH. In another embodiment, the kd value of the antibody at acidic pH may be 10-31 / s, 10-21 / s, 10-11 / s or greater. In some specific exemplary embodiments, the antibody may have a pH5.8 / pH7.4 kd ratio of 2, 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more. In another embodiment, the kd value of the antibody at pH 7.4 may be 10-21 / s, 10-31 / s, 10-41 / s, 10-51 / s, 10-61 / s or less. In another embodiment, the antibody may have a kd value of 10-31 / s, 10-21 / s, 10-11 / s or greater at pH 5.8.
[0132] As used herein, the term "acidic pH" refers to a pH of 4.0 to 6.5. The term "acidic pH" includes 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, Any pH value of 6.2, 6.3, 6.4 and 6.5. In certain aspects, the "acidic pH" is 5.8.
[0133] As used herein, the term "neutral pH" refers to a pH of 6.7 to about 10.0. The term "neutral pH" includes 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8 , 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9 and 10.0 any of the pH value. In certain aspects, "neutral pH" is 7.4.
[0134] KD and kd values, as indicated herein, can be determined using surface plasmon resonance based biosensors to characterize antibody-antigen interactions (see, eg, Example 7 herein). KD value and kd value can be measured at 25°C or 37°C.
[0135] In some specific embodiments, an anti-myostatin antibody of the invention binds myostatin from more than one species. In yet other embodiments, the anti-myostatin antibodies bind myostatin from humans and non-humans. In yet other embodiments, the anti-myostatin antibody binds to myostatin from humans, mice, and monkeys (rheses, macaques, marmosets, chimpanzees, or baboons).
[0136] In some specific embodiments, an anti-myostatin antibody of the invention binds latent myostatin from more than one species. In yet other embodiments, the anti-myostatin antibodies bind latent myostatin from humans and non-humans. In yet other embodiments, the anti-myostatin antibodies bind latent myostatin from humans, mice and monkeys.
[0137] In some specific embodiments, the anti-myostatin antibodies of the invention bind to the propeptide myostatin from more than one species. In yet other embodiments, the anti-myostatin antibody binds to the propeptide myostatin from humans and non-humans. In yet other embodiments, the anti-myostatin antibody binds to the propeptide myostatin from humans, mice and monkeys.
[0138] In yet another aspect, the invention provides anti-myostatin antibodies that form an immune complex (i.e., an antigen-antibody complex) with myostatin. In some specific embodiments, two or more anti-myostatin Antibodies to myostatin bind to two or more myostatin molecules to form an immune complex. This is possible because myostatin exists as a homodimer containing two myostatin molecules, and an antibody has two Antigen-binding site. Anti-myostatin antibodies can bind to the same epitope on the myostatin molecule, or they can bind to a different epitope on the myostatin molecule, much like a bispecific antibody. In general, when When two or more antibodies form immune complexes with two or more antigens, the resulting immune complexes can strongly bind to Fc receptors present on the cell surface because the Fc region of the antibodies in the complexes affinity (avidity) effect and can then be taken up in the cell with high efficiency.Therefore, the above-mentioned anti- Antibodies to myostatin can lead to rapid clearance of myostatin from plasma in vivo through strong binding to Fc receptors due to affinity effects.
[0139] In addition, antibodies with pH-dependent binding properties are considered to have superior performance in antigen neutralization and clearance, which is related to its corresponding binding in a pH-dependent manner (Igawa et al., Nature Biotech. 28(11):1203-1207 (2010); Devanaboyina et al., mAbs5(6):851-859 (2013); WO 2009 / 125825). Therefore, antibodies having both of the above properties, i.e., antibodies having pH-dependent binding properties and forming immune complexes comprising two or more antibodies and two or more antigens, are expected to have even more superior properties to Highly accelerates the elimination of antigens from plasma (WO 2013 / 081143).
[0140] In another aspect, the invention provides an anti-myostatin antibody comprising at least one, two, three, four, five or six hypervariable regions (HVRs) selected from (a) HVR-H1 comprising the amino acid sequence of any of the sequence identification numbers: 55-57, 114-115, and 126; (b) comprising any of the amino acid sequences of the sequence identification numbers: 58-60, 116-120, and 127 HVR-H2 of the acid sequence; (c) HVR-H3 including the amino acid sequence of any of the sequence identification numbers: 61-64, 121, 128; (d) including the sequence identification numbers: 65-69, 122-124 HVR-L1 of any amino acid sequence in , 129; (e) HVR-L2 including the amino acid sequence of any of the sequence identification numbers: 70-72, 125, 130; and (f) including sequence identification No.: HVR-L3 of any amino acid sequence in 73-74, 131.
[0141] In another aspect, the invention provides an anti-myostatin antibody comprising at least one, two, three, four, five or six HVRs selected from (a) comprising the sequence identification number: HVR-H1 of any amino acid sequence in 55-57; (b) HVR-H2 including the amino acid sequence of any of the sequence identification numbers: 58-60; (c) including the sequence identification number: 61- HVR-H3 of any amino acid sequence in 64; (d) HVR-L1 including the amino acid sequence of any of the sequence identification numbers: 65-69; (e) including the sequence identification numbers: 70-72 HVR-L2 of any amino acid sequence; and (f) HVR-L3 comprising any amino acid sequence of SEQ ID NO: 73-74.
[0142] In another aspect, the invention provides an anti-myostatin antibody comprising at least one, two, three, four, five or six hypervariable regions (HVR) selected from (a) HVR-H1 including the amino acid sequence of any of the sequence identification numbers: 114-115; (b) HVR-H2 including the amino acid sequence of any of the sequence identification numbers: 116-120; (c) including the sequence Identification number: HVR-H3 of the amino acid sequence of 121; (d) HVR-L1 including the amino acid sequence of any one of the sequence identification numbers: 122-124; (e) including the amino acid sequence of the sequence identification number: 125 HVR-L2 of the acid sequence; and (f) HVR-L3 comprising the amino acid sequence of any one of SEQ ID NO: 73-74.
[0143] In another aspect, the invention provides an anti-myostatin antibody comprising at least one, two, three, four, five or six HVRs selected from (a) comprising the sequence identification number: HVR-H1 with an amino acid sequence of 114; (b) HVR-H2 including an amino acid sequence with a sequence identification number of 58; (c) HVR-H3 with an amino acid sequence with a sequence identification number of 63; ( d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 122; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 71; and (f) comprising the amino acid sequence of SEQ ID NO: 74 acid sequence of HVR-L3. In another aspect, the invention provides an anti-myostatin antibody comprising at least one, two, three, four, five or six HVRs selected from (a) an amine comprising SEQ ID NO: 114 (b) HVR-H2 including the amino acid sequence of SEQ ID NO: 58; (c) HVR-H3 including the amino acid sequence of SEQ ID NO: 63; (d) including SEQ ID NO: HVR-L1 of the amino acid sequence of 123; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 71; and (f) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 74 HVR-L3.
[0144] In one aspect, the invention provides an anti-myostatin antibody comprising at least one, two, three, four, five or six HVRs selected from (a) comprising SEQ ID NO: 126 (b) HVR-H2 including the amino acid sequence of sequence identification number: 127; (c) HVR-H3 including the amino acid sequence of sequence identification number: 128; (d ) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 129; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 130; and (f) comprising the amino acid of SEQ ID NO: 131 Sequence of HVR-L3.
[0145] In one aspect, the invention provides an antibody comprising at least one, at least two or all three of the amino groups selected from (a) including any of the sequence identification numbers: 55-57, 114-115, 126 HVR-H1 of the acid sequence; (b) HVR-H2 including the amino acid sequence of any one of the sequence identification numbers: 58-60, 116-120, and 127; and (c) including the sequence identification numbers: 61-64, The VH HVR sequence of HVR-H3 of any one of the amino acid sequences of 121 and 128. In one embodiment, the antibody comprises HVR-H3, which comprises the amino acid sequence of any one of SEQ ID NO: 61-64, 121, 128. In another embodiment, the antibody includes: HVR-H3, which includes the amino acid sequence of any one of the sequence identification numbers: 61-64, 121, 128, and HVR-L3, which includes the sequence identification numbers: 73-74 The amino acid sequence of any one of 131 and 131. In yet another embodiment, the antibody includes: HVR-H3, which includes the amino acid sequence of any one of the sequence identification numbers: 61-64, 121, and 128, HVR-L3, which includes the sequence identification numbers: 73-74, The amino acid sequence of any one of 131, and HVR-H2, which includes the amino acid sequence of any one of SEQ ID NOs: 58-60, 116-120, and 127. In yet another embodiment, the antibody comprises (a) HVR-H1 comprising any of the amino acid sequences of Sequence Identification Numbers: 55-57, 114-115, and 126; (b) comprising Sequence Identification Numbers: 58-60 , 116-120, 127 in any one of the amino acid sequence of HVR-H2; and (c) sequence identification numbers: 61-64, 121, 128 of any one of the amino acid sequence HVR-H3.
[0146] In one aspect, the invention provides an antibody comprising at least one, at least two or all three HVR- H1; (b) HVR-H2 comprising the amino acid sequence of any of the sequence identification numbers: 58-60; and (c) HVR-H3 comprising the amino acid sequence of any of the sequence identification numbers: 61-64 The VH HVR sequence. In one embodiment, the antibody comprises HVR-H3, which comprises the amino acid sequence of any one of SEQ ID NO: 61-64. In another embodiment, the antibody includes: HVR-H3, which includes the amino acid sequence of any of SEQ ID NOs: 61-64, and HVR-L3, which includes any of the SEQ ID NOs: 73-74 amino acid sequence. In yet another embodiment, the antibody includes: HVR-H3, which includes the amino acid sequence of any of SEQ ID NO: 61-64, HVR-L3, which includes the amine of any of SEQ ID NO: 73-74 amino acid sequence, and HVR-H2, which includes the amino acid sequence of any one of SEQ ID NO: 58-60. In yet another embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of any of SEQ ID NO: 55-57; (b) comprising any of the amino acid sequence of SEQ ID NO: 58-60 HVR-H2 of the acid sequence; and (c) HVR-H3 comprising the amino acid sequence of any one of SEQ ID NO: 61-64.
[0147] In one aspect, the invention provides an antibody comprising at least one, at least two or all three HVR- H1; (b) HVR-H2 comprising the amino acid sequence of any one of SEQ ID NO: 116-120; and (c) the VH HVR sequence of HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121. In one embodiment, the antibody comprises HVR-H3, which comprises the amino acid sequence of SEQ ID NO: 121. In another embodiment, the antibody includes: HVR-H3, which includes the amino acid sequence of SEQ ID NO: 121, and HVR-L3, which includes the amino acid sequence of any one of SEQ ID NO: 73-74. In yet another embodiment, the antibody comprises: HVR-H3, which includes the amino acid sequence of SEQ ID NO: 121, HVR-L3, which includes the amino acid sequence of any one of SEQ ID NO: 73-74, and HVR-H2, which includes the amino acid sequence of any one of SEQ ID NO: 116-120. In yet another embodiment, the antibody comprises (a) HVR-H1 comprising any of the amino acid sequences of SEQ ID NO: 114-115; (b) comprising any of the amine groups of SEQ ID NO: 116-120 and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121. In another aspect, the invention provides an antibody comprising at least one, at least two or all three HVR-H1 selected from (a) comprising the amino acid sequence of SEQ ID NO: 114; (b) comprising the sequence Identification number: HVR-H2 of the amino acid sequence of 58; and (c) the VH HVR sequence of HVR-H3 comprising the amino acid sequence of SEQ ID NO: 63. In one embodiment, the antibody comprises HVR-H3, which comprises the amino acid sequence of SEQ ID NO: 63. In another embodiment, the antibody includes: HVR-H3, which includes the amino acid sequence of SEQ ID NO: 63, and HVR-L3, which includes the amino acid sequence of SEQ ID NO: 74. In yet another embodiment, the antibody comprises: HVR-H3, which includes the amino acid sequence of SEQ ID NO: 63, HVR-L3, which includes the amino acid sequence of SEQ ID NO: 74, and HVR-H2, which Including the amino acid sequence of SEQ ID NO: 58. In yet another embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 114; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 58; and (c ) comprising HVR-H3 of the amino acid sequence of SEQ ID NO: 63.
[0148] In another aspect, the invention provides an antibody comprising at least one, at least two or all three HVR-H1 selected from (a) the amino acid sequence comprising SEQ ID NO: 126; (b ) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 127; and (c) the VH HVR sequence of HVR-H3 comprising the amino acid sequence of SEQ ID NO: 128. In one embodiment, the antibody comprises HVR-H3, which comprises the amino acid sequence of SEQ ID NO: 128. In another embodiment, the antibody includes: HVR-H3, which includes the amino acid sequence of SEQ ID NO: 128, and HVR-L3, which includes the amino acid sequence of SEQ ID NO: 131. In yet another embodiment, the antibody comprises: HVR-H3, which includes the amino acid sequence of SEQ ID NO: 128, HVR-L3, which includes the amino acid sequence of SEQ ID NO: 131, and HVR-H2, which Including the amino acid sequence of SEQ ID NO: 127. In yet another embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 126; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 127; and (c ) comprising HVR-H3 of the amino acid sequence of SEQ ID NO: 128.
[0149] In another aspect, the present invention provides an antibody comprising at least one, at least two or all three selected from (a) comprising sequence identification numbers: any of 65-69, 122-124, 129 (b) HVR-L1 comprising the amino acid sequence of any of the sequence identification numbers: 70-72, 125, and 130: and (c) comprising the sequence identification numbers: 73-74 The VL HVR sequence of HVR-L3 of the amino acid sequence of any one of 131 and 131. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of any of the sequence identification numbers: 65-69, 122-124, and 129; (b) comprising the sequence identification numbers: 70-72, HVR-L2 of any one of the amino acid sequences of 125 and 130; and (c) HVR-L3 comprising any of the amino acid sequences of SEQ ID NO: 73-74 and 131.
[0150] In another aspect, the present invention provides an antibody comprising at least one, at least two or all three of the amino acid sequences selected from (a) comprising any of the sequence identification numbers: 65-69 HVR-L1; (b) HVR-L2 comprising the amino acid sequence of any of the sequence identification numbers: 70-72: and (c) HVR comprising the amino acid sequence of any of the sequence identification numbers: 73-74 - VL HVR sequence of L3. In one embodiment, the antibody comprises (a) HVR-L1 comprising any of the amino acid sequences of SEQ ID NO: 65-69; (b) comprising any of the amino acids of SEQ ID NO: 70-72 and (c) HVR-L3 comprising the amino acid sequence of any one of SEQ ID NO: 73-74.
[0151] In another aspect, the present invention provides an antibody comprising at least one, at least two or all three of the amino acid sequences selected from (a) comprising any of the sequence identification numbers: 122-124 HVR-L1; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 125: and (c) VL HVR of HVR-L3 comprising the amino acid sequence of any of SEQ ID NO: 73-74 sequence. In one embodiment, the antibody comprises (a) HVR-L1 comprising any amino acid sequence of SEQ ID NO: 122-124; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 125 and (c) HVR-L3 comprising the amino acid sequence of any one of SEQ ID NO: 73-74. In another aspect, the present invention provides an antibody comprising at least one, at least two or all three HVR-L1 selected from (a) the amino acid sequence comprising SEQ ID NO: 122; (b) comprising SEQ ID NO: HVR-L2 of the amino acid sequence of 71: and (c) VL HVR sequence of HVR-L3 comprising the amino acid sequence of SEQ ID NO: 74. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 122; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 71; and (c) HVR-L3 comprising the amino acid sequence of any one of SEQ ID NO: 74. In another aspect, the present invention provides an antibody comprising at least one, at least two or all three HVR-L1 selected from (a) the amino acid sequence comprising SEQ ID NO: 123; (b) comprising SEQ ID NO: HVR-L2 of the amino acid sequence of 71: and (c) VL HVR sequence of HVR-L3 comprising the amino acid sequence of SEQ ID NO: 74. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 123; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 71; and (c) HVR-L3 comprising the amino acid sequence of any one of SEQ ID NO: 74.
[0152] In another aspect, the present invention provides an antibody comprising at least one, at least two or all three HVR-L1 selected from (a) the amino acid sequence comprising SEQ ID NO: 129; ( b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 130: and (c) the VL HVR sequence of HVR-L3 comprising the amino acid sequence of SEQ ID NO: 131. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 129; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 130; and (c) HVR-L3 comprising the amino acid sequence of any one of SEQ ID NO: 131.
[0153] In another aspect, the antibody of the invention comprises (a) a VH domain comprising at least one, at least two or all three selected from (i) comprising the sequence identification numbers: 55-57, 114, 115 , HVR-H1 of any amino acid sequence in 126, (ii) HVR-H2 including the amino acid sequence of any of the sequence identification numbers: 58-60, 116-120, and 127, and (iii) including SEQ ID NO: the VH HVR sequence of HVR-H3 of any amino acid sequence in 61-64, 121, 128; and (b) a VL domain comprising at least one, at least two or all three selected from (i) HVR-L1 comprising any amino acid sequence in sequence identification number: 65-69, 122-124, 129, (ii) comprising any amine in sequence identification number: 70-72, 125, 130 The amino acid sequence of HVR-L2, and (iii) the VL HVR sequence of HVR-L3 comprising the amino acid sequence of any one of SEQ ID NO: 73-74, 131.
[0154] In another aspect, the antibody of the invention comprises (a) a VH domain comprising at least one, at least two or all three selected from (i) comprising any of SEQ ID NO: 55-57 HVR-H1 of the amino acid sequence, (ii) HVR-H2 comprising the amino acid sequence of any of the sequence identification numbers: 58-60, and (iii) comprising any of the amines of the sequence identification numbers: 61-64 The VH HVR sequence of the HVR-H3 amino acid sequence; and (b) the VL domain, which includes at least one, at least two or all three of the amines selected from (i) including any one of SEQ ID NO: 65-69 HVR-L1 of the amino acid sequence, (ii) HVR-L2 comprising the amino acid sequence of any of the sequence identification numbers: 70-72, and (iii) comprising any of the amine groups of the sequence identification numbers: 73-74 VL HVR sequence of HVR-L3 acid sequence.
[0155] In another aspect, the antibody of the invention comprises (a) a VH domain comprising at least one, at least two or all three selected from (i) comprising any of SEQ ID NO: 114-115 HVR-H1 of the amino acid sequence, (ii) HVR-H2 including the amino acid sequence of any one of the sequence identification numbers: 116-120, and (iii) HVR including the amino acid sequence of the sequence identification number: 121 - the VH HVR sequence of H3; and (b) the VL domain, which includes at least one, at least two or all three of the HVRs selected from (i) any amino acid sequence comprising SEQ ID NO: 122-124 -L1, (ii) HVR-L2 including the amino acid sequence of SEQ ID NO: 125, and (iii) the VL HVR sequence of HVR-L3 including the amino acid sequence of any of 73-74 . In another aspect, the antibody of the invention comprises (a) a VH domain comprising at least one, at least two or all three HVR-H1 selected from (i) the amino acid sequence comprising SEQ ID NO: 114 , (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 58, and (iii) the VH HVR sequence of HVR-H3 comprising the amino acid sequence of SEQ ID NO: 63; and (b) the VL domain , which includes at least one, at least two or all three selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 122, (ii) comprising the amino acid sequence of SEQ ID NO: 71 HVR-L2, and (iii) the VL HVR sequence of HVR-L3 comprising the amino acid sequence of SEQ ID NO: 74. In another aspect, the antibody of the invention comprises (a) a VH domain comprising at least one, at least two or all three HVR-H1 selected from (i) the amino acid sequence comprising SEQ ID NO: 114 , (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 58, and (iii) the VH HVR sequence of HVR-H3 comprising the amino acid sequence of SEQ ID NO: 63; and (b) the VL domain , which includes at least one, at least two or all three selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 123, (ii) comprising the amino acid sequence of SEQ ID NO: 71 HVR-L2, and (iii) the VL HVR sequence of HVR-L3 comprising the amino acid sequence of SEQ ID NO: 74.
[0156] In another aspect, the antibody of the invention comprises (a) a VH domain comprising at least one, at least two or all three of the amino acid sequences selected from (i) comprising SEQ ID NO: 126 HVR-H1, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 127, and (iii) the VH HVR sequence of HVR-H3 comprising the amino acid sequence of SEQ ID NO: 128; and (b ) VL domain comprising at least one, at least two or all three selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 129, (ii) comprising the amino acid sequence of SEQ ID NO: 130 The amino acid sequence of HVR-L2, and (iii) the VL HVR sequence of HVR-L3 comprising the amino acid sequence of SEQ ID NO: 131.
[0157] In another aspect, the invention provides an antibody, which includes: (a) HVR-H1 including the amino acid sequence of any one of the sequence identification numbers: 55-57, 114-115, and 126; (b) HVR-H2 including the amino acid sequence of any of the sequence identification numbers: 58-60, 116-120, and 127; (c) including the amino acid sequence of any of the sequence identification numbers: 61-64, 121, and 128 (d) HVR-L1 including any amino acid sequence in sequence identification numbers: 65-69, 122-124, 129; (e) including sequence identification numbers: 70-72, 125, 130 HVR-L2 of any one of the amino acid sequences; and (f) HVR-L3 comprising any of the amino acid sequences of SEQ ID NO: 73-74, 131.
[0158] In another aspect, the invention provides an antibody, which includes: (a) HVR-H1 including the amino acid sequence of any of the sequence identification numbers: 55-57, 114-115; (b) including the sequence Identification number: HVR-H2 of any amino acid sequence in 58-60, 116-120; (c) HVR-H3 including any amino acid sequence in sequence identification number: 61-64, 121; ( d) HVR-L1 including the amino acid sequence of any of the sequence identification numbers: 65-69, 122-124; (e) HVR including the amino acid sequence of any of the sequence identification numbers: 70-72, 125 -L2; and (f) HVR-L3 comprising the amino acid sequence of any one of SEQ ID NO: 73-74.
[0159] In another aspect, the invention provides an antibody comprising: (a) HVR-H1 comprising any amino acid sequence of SEQ ID NO: 114-115; (b) comprising SEQ ID NO: 116 HVR-H2 of any amino acid sequence in -120; (c) HVR-H3 including the amino acid sequence of sequence identification number: 121; (d) including any amine of sequence identification number: 122-124 (e) HVR-L2 including the amino acid sequence of SEQ ID NO: 125; and (f) HVR-L2 including the amino acid sequence of any of SEQ ID NO: 73-74 L3. In another aspect, the invention provides an antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 114; (b) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 58 H2; (c) HVR-H3 including the amino acid sequence of sequence identification number: 63; (d) HVR-L1 including the amino acid sequence of sequence identification number: 122; (e) including the amino acid sequence of sequence identification number: 71 HVR-L2 of the amino acid sequence; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 74. In another aspect, the invention provides an antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 114; (b) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 58 H2; (c) HVR-H3 including the amino acid sequence of sequence identification number: 63; (d) HVR-L1 including the amino acid sequence of sequence identification number: 123; (e) including the amino acid sequence of sequence identification number: 71 HVR-L2 of the amino acid sequence; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 74.
[0160] In another aspect, the invention provides an antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 126; (b) comprising the amino acid sequence of SEQ ID NO: 127 (c) HVR-H3 including the amino acid sequence of sequence identification number: 128; (d) HVR-L1 including the amino acid sequence of sequence identification number: 129; (e) including the sequence identification number HVR-L2 having the amino acid sequence of :130; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 131.
[0161] In some specific embodiments, any one or more amino acids of the anti-myostatin antibody provided above are substituted at the following HVR positions: (a) in HVR-H1 (SEQ ID NO: 55), At positions 1 and 2; (b) in HVR-H2 (SEQ ID NO: 58), at positions 4, 7, 8, 10, 11, 12 and 16; (c) in HVR-H3 (SEQ ID NO: 61 ), at positions 5, 7 and 11; (d) in HVR-L1 (SEQ ID NO: 65), at positions 1, 2, 5, 7, 8 and 9; (e) in HVR-L2 (SEQ ID NO: :70), at positions 3 and 7; and (f) in HVR-L3 (SEQ ID NO: 73), at position 8.
[0162] In some specific embodiments, one or more amino acid substitutions of the anti-myostatin antibody are conservative substitutions, as provided herein. In some specific embodiments, any one or more of the following substitutions can be performed in any combination: (a) in HVR-H1 (SEQ ID NO: 55), S1H; Y2T, D or E; (b) in HVR-H2 (SEQ ID NO: 58), Y4H; S7K; T8M or K; Y10K; A11M or E; S12E; G16K; (c) in HVR-H3 (SEQ ID NO: 61), Y5H; T7H; L11K; (d) In HVR-L1 (sequence identification number: 65), Q1T, S2T; S5E; Y7F; D8H; N9D or A or E; (e) in HVR-L2 (sequence identification number: 70), S3E; S7Y or F or W and (f) in HVR-L3 (SEQ ID NO: 73), L8R.
[0163] All possible combinations of the above substitutions are respectively the sequence identification numbers of the consensus sequences of HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2 and HVR-L3: 126, 127, 128, 129, 130 and 131 covered.
[0164] In any of the above embodiments, the anti-myostatin antibody can be humanized. In one embodiment, the anti-myostatin antibody comprises the HVR of any one of the above embodiments, and further comprises a receptor human framework, for example, a human immunoglobulin framework or a human consensus framework. In another embodiment, the anti-myostatin antibody includes HVR as in any of the above embodiments, and further includes VH or VL, which includes FR sequences. In yet another embodiment, the anti-myostatin antibody comprises the following heavy chain and / or light chain variable domain FR sequences. For the heavy chain variable domain, FR1 includes the amino acid sequence of any of the sequence identification numbers: 132-134, FR2 includes the amino acid sequence of any of the sequence identification numbers: 135-136, and FR3 includes the amino acid sequence of any of the sequence identification numbers: 137 The amino acid sequence of FR4 includes the amino acid sequence of SEQ ID NO: 138. For the light chain variable domain, FR1 includes the amino acid sequence of the sequence identification number: 139, FR2 includes the amino acid sequence of any of the sequence identification numbers: 140-141, and FR3 includes any of the sequence identification numbers: 142-143 The amino acid sequence of FR4 includes the amino acid sequence of SEQ ID NO: 144.
[0165] In one aspect, the invention provides an anti-myostatin antibody comprising at least one, two, three, four, five or six HVRs selected from: (a) comprising a sequence identification number: HVR-H1 of any amino acid sequence in 157-162; (b) HVR-H2 including the amino acid sequence of any of the sequence identification numbers: 163-168; (c) including the sequence identification number: 169- HVR-H3 of any amino acid sequence in 174; (d) HVR-L1 including the amino acid sequence of any of the sequence identification numbers: 175-180; (e) including sequence identification numbers: 181-186 HVR-L2 of any amino acid sequence; and (f) HVR-L3 comprising any amino acid sequence of SEQ ID NO: 187-192.
[0166] In one aspect, the invention provides an antibody comprising at least one, at least two or all three selected from (a) HVR-H1 comprising any amino acid sequence in sequence identification number: 157-162 (b) HVR-H2 comprising the amino acid sequence of any of the sequence identification numbers: 163-168; and (c) comprising the HVR-H3 of the amino acid sequence of any of the sequence identification numbers: 169-174 VH HVR sequence. In one embodiment, the antibody comprises HVR-H3, which comprises the amino acid sequence of any one of SEQ ID NO: 169-174. In another embodiment, the antibody includes: HVR-H3, which includes the amino acid sequence of any one of the sequence identification numbers: 169-174, and HVR-L3, which includes any one of the sequence identification numbers: 187-192 amino acid sequence. In yet another embodiment, the antibody includes: HVR-H3, which includes the amino acid sequence of any of the sequence identification numbers: 169-174, HVR-L3, which includes the amine of any of the sequence identification numbers: 187-192 amino acid sequence, and HVR-H2, which includes the amino acid sequence of any one of SEQ ID NO: 163-168. In yet another embodiment, the antibody comprises (a) HVR-H1 comprising any of the amino acid sequences of SEQ ID NO: 157-162; (b) comprising any of the amine groups of SEQ ID NO: 163-168 HVR-H2 with an acid sequence; and (c) HVR-H3 with any one of the amino acid sequences of SEQ ID NO: 169-174.
[0167] In another aspect, the antibody of the invention comprises at least one, at least two or all three HVR-L1 selected from (a) any amino acid sequence comprising sequence identification numbers: 175-180 (b) HVR-L2 comprising the amino acid sequence of any of the sequence identification numbers: 181-186; and (c) comprising the HVR-L3 of the amino acid sequence of any of the sequence identification numbers: 187-192 VL HVR sequence. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of any of the sequence identification numbers: 175-180; (b) comprising any of the amino acids of the sequence identification numbers: 181-186 and (c) the VL HVR sequence of HVR-L3 comprising the amino acid sequence of any one of SEQ ID NO: 187-192.
[0168] In another aspect, the antibody of the invention comprises (a) a VH domain comprising at least one, at least two or all three selected from (i) comprising any of SEQ ID NO: 157-162 HVR-H1 of the amino acid sequence, (ii) HVR-H2 comprising the amino acid sequence of any of the sequence identification numbers: 163-168, and (iii) comprising the amine of any of the sequence identification numbers: 169-174 The VH HVR sequence of the HVR-H3 amino acid sequence; and (b) the VL domain, which includes at least one, at least two or all three of the amines selected from (i) including any one of SEQ ID NO: 175-180 HVR-L1 of the amino acid sequence, (ii) HVR-L2 comprising the amino acid sequence of any of the sequence identification numbers: 181-186, and (iii) comprising any of the amino acid sequences of the sequence identification numbers: 187-192 VL HVR sequence of HVR-L3 acid sequence.
[0169] In another aspect, the invention provides an antibody comprising (a) HVR-H1 comprising any amino acid sequence in SEQ ID NO: 157-162; (b) comprising SEQ ID NO: 163- HVR-H2 of any amino acid sequence in 168; (c) HVR-H3 including the amino acid sequence of any of the sequence identification numbers: 169-174; (d) including the sequence identification numbers: 175-180 HVR-L1 of any amino acid sequence; (e) HVR-L2 comprising the amino acid sequence of any of the sequence identification numbers: 181-186; and (f) comprising any of the amino acid sequences of the sequence identification numbers: 187-192 An amino acid sequence of HVR-L3.
[0170] In another aspect, the anti-myostatin antibody comprises a heavy chain variable domain (VH) sequence for the amine of any of SEQ ID NOs: 13, 16-30, 32-34, and 86-95 An amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. In some specific embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity relative to the reference sequence, Anti-myostatin antibodies comprising substitutions (eg, conservative substitutions), insertions or deletions, but including that sequence retain the ability to bind to myostatin. In some specific embodiments, a total of 1 to 10 amino acids in any of SEQ ID NOs: 13, 16-30, 32-34 and 86-95 are substituted, inserted and / or deleted. In some specific embodiments, substitutions, insertions or deletions occur in regions outside the HVRs (ie, in FRs). Alternatively, the anti-myostatin antibody comprises the VH sequence of any one of SEQ ID NO: 13, 16-30, 32-34, and 86-95, comprising post-translational modifications of that sequence. In a specific embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR comprising the amino acid sequence of any of SEQ ID NO: 55-57, 114-115, 126- H1, (b) HVR-H2 including the amino acid sequence of any of the sequence identification numbers: 58-60, 116-120, and 127, and (c) including any of the sequence identification numbers: 61-64, 121, and 128 An amino acid sequence of HVR-H3. Post-translational modification includes, but is not limited to, modification of N-terminal glutamic acid or glutamic acid at the heavy chain or light chain to pyroglutamic acid by pyroglutamylation.
[0171] In another aspect, the anti-myostatin antibody comprises a heavy chain variable domain (VH) sequence for any amino acid in SEQ ID NO: 13, 16-30, 32, 33 and 34 Sequences having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. In some specific embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity relative to the reference sequence, Anti-myostatin antibodies comprising substitutions (eg, conservative substitutions), insertions or deletions, but including that sequence retain the ability to bind to myostatin. In some specific embodiments, a total of 1 to 10 amino acids in any of SEQ ID NO: 13, 16-30, 32, 33 and 34 are substituted, inserted and / or deleted. In some specific embodiments, substitutions, insertions or deletions occur in regions outside the HVRs (ie, in FRs). Optionally, the anti-myostatin antibody comprises the VH sequence of any one of SEQ ID NO: 13, 16-30, 32, 33 and 34, comprising post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of any of SEQ ID NO: 55-57, (b) comprising SEQ ID NO: HVR-H2 of any amino acid sequence in 58-60, and (c) HVR-H3 including the amino acid sequence of any of SEQ ID NO: 61-64. Post-translational modifications include, but are not limited to, modification of N-terminal glutamic acid or glutamic acid at the heavy or light chain to pyroglutamic acid by pyroglutination.
[0172] In another aspect, the anti-myostatin antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity. In some specific embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity relative to the reference sequence, Anti-myostatin antibodies comprising substitutions (eg, conservative substitutions), insertions or deletions, but including that sequence retain the ability to bind to myostatin. In some specific embodiments, a total of 1 to 10 amino acids in any of SEQ ID NO: 86-95 are substituted, inserted and / or deleted. In some specific embodiments, substitutions, insertions or deletions occur in regions outside the HVRs (ie, in FRs). Alternatively, the anti-myostatin antibody comprises the VH sequence of any one of SEQ ID NO: 86-95 comprising post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of any of SEQ ID NO: 57, 114-115, 126, (b) HVR-H2 comprising the amino acid sequence of any of the sequence identification numbers: 58, 116-120, and 127, and (c) comprising the amino acid sequence of any of the sequence identification numbers: 63, 121, and 128 The HVR-H3. Post-translational modifications include, but are not limited to, modification of N-terminal glutamic acid or glutamic acid at the heavy or light chain to pyroglutamic acid by pyroglutination. In another aspect, the anti-myostatin antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity. In some specific embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity relative to the reference sequence, Anti-myostatin antibodies comprising substitutions (eg, conservative substitutions), insertions or deletions, but including that sequence retain the ability to bind to myostatin. In some specific embodiments, in SEQ ID NO: 86, a total of 1 to 10 amino acids are substituted, inserted and / or deleted. In some specific embodiments, substitutions, insertions or deletions occur in regions outside the HVRs (ie, in FRs). Alternatively, the anti-myostatin antibody comprises a VH sequence of SEQ ID NO: 86 comprising post-translational modifications of that sequence. In a specific embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 114, (b) comprising the amino acid sequence of SEQ ID NO: 58 HVR-H2 of the amino acid sequence of (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 63. Post-translational modifications include, but are not limited to, modification of N-terminal glutamic acid or glutamic acid at the heavy or light chain to pyroglutamic acid by pyroglutination. In another aspect, the anti-myostatin antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity. In some specific embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity relative to the reference sequence, Anti-myostatin antibodies comprising substitutions (eg, conservative substitutions), insertions or deletions, but including that sequence retain the ability to bind to myostatin. In some specific embodiments, in SEQ ID NO: 92, a total of 1 to 10 amino acids are substituted, inserted and / or deleted. In some specific embodiments, substitutions, insertions or deletions occur in regions outside the HVRs (ie, in FRs). Alternatively, the anti-myostatin antibody comprises a VH sequence of SEQ ID NO: 92 comprising post-translational modifications of that sequence. In a specific embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 114, (b) comprising the amino acid sequence of SEQ ID NO: 58 HVR-H2 of the amino acid sequence of (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 63. Post-translational modifications include, but are not limited to, modification of N-terminal glutamic acid or glutamic acid at the heavy or light chain to pyroglutamic acid by pyroglutination.
[0173] In another aspect, an anti-myostatin antibody is provided, wherein the antibody comprises a VL having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. In some specific embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity relative to a reference sequence, Anti-myostatin antibodies comprising substitutions (eg, conservative substitutions), insertions or deletions, but including that sequence retain the ability to bind to myostatin. In some specific embodiments, a total of 1 to 10 amino acids are substituted, inserted and / or deleted in any of SEQ ID NOs: 15, 31, 35-38, and 96-99. In some specific embodiments, substitutions, insertions or deletions occur in regions outside the HVRs (ie, in FRs). Alternatively, the anti-myostatin antibody comprises the VL sequence of any one of SEQ ID NOs: 15, 31, 35-38, and 96-99, comprising post-translational modifications of that sequence. In a particular embodiment, the VL includes one, two or three HVRs selected from: (a) HVRs including any of the amino acid sequences of SEQ ID NO: 65-69, 122-124, 129- L1, (b) HVR-L2 including the amino acid sequence of any of the sequence identification numbers: 70-72, 125, 130, and (c) including the amino acid sequence of any of the sequence identification numbers: 73-74, 131 acid sequence of HVR-L3. Post-translational modifications include, but are not limited to, modification of N-terminal glutamic acid or glutamic acid at the heavy or light chain to pyroglutamic acid by pyroglutination.
[0174] In another aspect, an anti-myostatin antibody is provided, wherein the antibody comprises a VL having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. In some specific embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity relative to a reference sequence, Anti-myostatin antibodies comprising substitutions (eg, conservative substitutions), insertions or deletions, but including that sequence retain the ability to bind to myostatin. In some specific embodiments, a total of 1 to 10 amino acids in any of SEQ ID NO: 15, 31, 35, 36, 37 and 38 are substituted, inserted and / or deleted. In some specific embodiments, substitutions, insertions or deletions occur in regions outside the HVRs (ie, in FRs). Alternatively, the anti-myostatin antibody comprises the VL sequence of any one of SEQ ID NO: 15, 31, 35, 36, 37 and 38, comprising post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from: (a) HVR-L1 comprising the amino acid sequence of any of SEQ ID NO: 65-69, (b) comprising SEQ ID NO: HVR-L2 of any amino acid sequence in 70-72, and (c) HVR-L3 including the amino acid sequence of any of SEQ ID NO: 73-74. Post-translational modifications include, but are not limited to, modification of N-terminal glutamic acid or glutamic acid at the heavy or light chain to pyroglutamic acid by pyroglutination.
[0175] In another aspect, an anti-myostatin antibody is provided, wherein the antibody comprises a VL having at least 90%, 91%, 92% of the amino acid sequence of any of SEQ ID NO: 96-99 , 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity. In some specific embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity relative to a reference sequence, Anti-myostatin antibodies comprising substitutions (eg, conservative substitutions), insertions or deletions, but including that sequence retain the ability to bind to myostatin. In some specific embodiments, a total of 1 to 10 amino acids are substituted, inserted and / or deleted in any of SEQ ID NO: 96-99. In some specific embodiments, substitutions, insertions or deletions occur in regions outside the HVR. Alternatively, the anti-myostatin antibody comprises the VL sequence of any one of SEQ ID NO: 96-99 comprising post-translational modifications of that sequence. In a specific embodiment, VL includes one, two or three HVRs selected from: (a) HVR-L1 including any amino acid sequence of SEQ ID NO: 122-124, 129, (b ) HVR-L2 comprising the amino acid sequence of any one of SEQ ID NO: 71, 125, 130, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 74, 131. Post-translational modifications include, but are not limited to, modification of N-terminal glutamic acid or glutamic acid at the heavy or light chain to pyroglutamic acid by pyroglutination. In another aspect, an anti-myostatin antibody is provided, wherein the antibody comprises a VL having at least 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence of SEQ ID NO: 96 %, 96%, 97%, 98%, 99% or 100% sequence identity. In some specific embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity relative to a reference sequence, Anti-myostatin antibodies comprising substitutions (eg, conservative substitutions), insertions or deletions, but including that sequence retain the ability to bind to myostatin. In some specific embodiments, in SEQ ID NO: 96, a total of 1 to 10 amino acids are substituted, inserted and / or deleted. In some specific embodiments, substitutions, insertions or deletions occur in regions outside the HVR. Alternatively, the anti-myostatin antibody comprises the VL sequence of SEQ ID NO: 96 comprising post-translational modifications of that sequence. In a specific embodiment, the VL comprises one, two or three HVRs selected from: (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 122, (b) comprising the amino acid sequence of SEQ ID NO: 71 HVR-L2 of the amino acid sequence of (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 74. Post-translational modifications include, but are not limited to, modification of N-terminal glutamic acid or glutamic acid at the heavy or light chain to pyroglutamic acid by pyroglutination. In another aspect, an anti-myostatin antibody is provided, wherein the antibody comprises a VL having at least 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence of SEQ ID NO: 97 %, 96%, 97%, 98%, 99% or 100% sequence identity. In some specific embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity relative to a reference sequence, Anti-myostatin antibodies comprising substitutions (eg, conservative substitutions), insertions or deletions, but including that sequence retain the ability to bind to myostatin. In some specific embodiments, in SEQ ID NO: 97, a total of 1 to 10 amino acids are substituted, inserted and / or deleted. In some specific embodiments, substitutions, insertions or deletions occur in regions outside the HVR. Alternatively, the anti-myostatin antibody comprises the VL sequence of SEQ ID NO: 97 comprising post-translational modifications of that sequence. In a specific embodiment, the VL comprises one, two or three HVRs selected from: (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 123, (b) comprising the amino acid sequence of SEQ ID NO: 71 HVR-L2 of the amino acid sequence of (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 74. Post-translational modifications include, but are not limited to, modification of N-terminal glutamic acid or glutamic acid at the heavy or light chain to pyroglutamic acid by pyroglutination.
[0176] In another aspect, an anti-myostatin antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH sequence of any of the sequence identification numbers: 13, 16-30, 32-34 and 86-95 and any of the sequence identification numbers: 15, 31, 35-38 and 96-99 A VL sequence comprising post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH sequence of any of SEQ ID NO: 13, 16-30 and 32-34 and the VL sequence of any of SEQ ID NO: 15, 31 and 35-38, which comprises those Post-translational modification of sequences. In one embodiment, the antibody comprises a VH sequence of SEQ ID NO: 86-95, and a VL sequence of SEQ ID NO: 96-99, respectively, comprising post-translational modifications of those sequences. Post-translational modifications include, but are not limited to, modification of N-terminal glutamic acid or glutamic acid at the heavy or light chain to pyroglutamic acid by pyroglutination.
[0177] In another aspect, an anti-myostatin antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises a VH sequence of SEQ ID NO: 86 and a VL sequence of SEQ ID NO: 96, respectively, comprising post-translational modifications of those sequences. In one embodiment, the antibody comprises a VH sequence of SEQ ID NO: 92 and a VL sequence of SEQ ID NO: 97, respectively, comprising post-translational modifications of those sequences. Post-translational modifications include, but are not limited to, modification of N-terminal glutamic acid or glutamic acid at the heavy or light chain to pyroglutamic acid by pyroglutination.
[0178] In another aspect, an anti-myostatin antibody is provided, wherein the antibody comprises a VH sequence having at least 90%, 91% of any amino acid sequence in SEQ ID NO: 12, 145-150 , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity. In some specific embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity relative to the reference sequence, Anti-myostatin antibodies comprising substitutions (eg, conservative substitutions), insertions or deletions, but including that sequence retain the ability to bind to myostatin. In some specific embodiments, a total of 1 to 10 amino acids in any of SEQ ID NO: 12, 145-150 are substituted, inserted and / or deleted. In some specific embodiments, substitutions, insertions or deletions occur in regions outside the HVRs (ie, in FRs). Optionally, the anti-myostatin antibody comprises the VH sequence of any one of SEQ ID NO: 12, 145-150 comprising post-translational modifications of that sequence. In a specific embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of any of SEQ ID NO: 55, 157-162, (b ) HVR-H2 comprising the amino acid sequence of any of the sequence identification numbers: 58, 163-168, and (c) HVR-H3 comprising the amino acid sequence of any of the sequence identification numbers: 61, 169-174 . Post-translational modifications include, but are not limited to, modification of N-terminal glutamic acid or glutamic acid at the heavy or light chain to pyroglutamic acid by pyroglutination.
[0179] In another aspect, an anti-myostatin antibody is provided, wherein the antibody comprises a light chain variable domain (VL), which has an amino acid sequence of any of SEQ ID NO: 14, 151-156, At least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. In some specific embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity relative to a reference sequence, Anti-myostatin antibodies comprising substitutions (eg, conservative substitutions), insertions or deletions, but including that sequence retain the ability to bind to myostatin. In some specific embodiments, a total of 1 to 10 amino acids in any of SEQ ID NO: 14, 151-156 are substituted, inserted and / or deleted. In some specific embodiments, substitutions, insertions or deletions occur in regions outside the HVRs (ie, in FRs). Optionally, the anti-myostatin antibody comprises the VL sequence of any one of SEQ ID NO: 14, 151-156 comprising post-translational modifications of that sequence. In a particular embodiment, VL comprises one, two or three HVRs selected from: (a) HVR-L1 comprising any of the amino acid sequences of SEQ ID NO: 65, 175-180, (b ) HVR-L2 comprising the amino acid sequence of any of the sequence identification numbers: 70, 181-186, and (c) HVR-L3 comprising the amino acid sequence of any of the sequence identification numbers: 73, 187-192 . Post-translational modifications include, but are not limited to, modification of N-terminal glutamic acid or glutamic acid at the heavy or light chain to pyroglutamic acid by pyroglutination.
[0180] In another aspect, an anti-myostatin antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH sequence of any of SEQ ID NOs: 12, 145-150 and the VL sequence of any of SEQ ID NOs: 14, 151-156, respectively, comprising post-translational modifications of those sequences. Post-translational modifications include, but are not limited to, modification of N-terminal glutamic acid or glutamic acid at the heavy or light chain to pyroglutamic acid by pyroglutination.
[0181] In some specific embodiments, the anti-myostatin antibody of the present invention includes VH in any embodiment as provided above, and includes sequence identification numbers: 7, 9, 11, 193, 195-198, 227 , 228, 229-381 in any amino acid sequence of the heavy chain constant region. In some specific embodiments, the anti-myostatin antibody of the present invention comprises the VL in any of the embodiments provided above, and a light chain constant region comprising the amino acid sequence of any one of SEQ ID NO: 8 and 10 .
[0182] In yet another aspect, the invention provides antibodies that bind to the same epitope as the anti-myostatin antibodies provided herein. In yet another aspect, the invention provides antibodies that bind to the same epitope as the antibodies described in Table 2a. In yet another aspect, the invention provides an antibody that binds to the same epitope as the antibody described in Table 11a or 13. In some specific embodiments, provided antibodies bind to an epitope of a fragment of the promyostatin peptide consisting of amino acids 21-100 of SEQ ID NO: 78. Alternatively, the antibody binds to amino acids 21-80, 41-100, 21-60, 41-80, 61-100, 21-40, 41-60, 61-80 or 81- 100 fragments of myostatin peptide.
[0183] In yet another aspect, the anti-myostatin antibody according to any of the above embodiments is a monoclonal antibody, including chimeric, humanized or human antibodies. In one embodiment, the anti-myostatin antibody is an antibody fragment, eg, Fv, Fab, Fab', scFv, diabody, or F(ab')2 fragment. In another embodiment, the antibody is a full length IgG antibody, eg, a full IgGl or IgG4 antibody or other antibody class or isotype as defined herein.
[0184] In yet another aspect, an anti-myostatin antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in Sections 1-7 below. 1. Antibody Affinity
[0185] In some specific embodiments, the antibodies provided herein have a ≤1 μm, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g. Small, eg, from 10-8M to 10-13M, eg, from 10-9M to 10-13M), dissociation constant (Kd).
[0186] In one embodiment, Kd is measured by a radiolabeled antigen binding assay (RIA). In one embodiment, RIA is performed in Fab format of the antibody of interest and its antigen. Solution binding of Fab to antigen is measured, for example, by equilibrating the Fab with a minimal concentration of (125I)-labeled antigen in the presence of a titration series of unlabeled antigen, followed by capturing the bound antigen on an anti-Fab antibody-coated dish Affinity (see, eg, Chen et al., J. Mol. Biol. 293:865-881 (1999)). To establish assay conditions, MICROTITER® multiwell discs (Thermo Scientific) were coated overnight with 5 μg / ml anti-Fab antibody (Cappel Labs) for capture in 50 mM sodium carbonate (pH 9.6), followed by 2% ( w / v) Bovine serum albumin Blocking was performed at room temperature (about 23°C) for 2 to 5 hours. In non-adsorbent plates (Nunc #269620), mix 100 pM or 26 pM [125I]-antigen with serial dilutions of the Fab of interest (eg, with Presta et al., Cancer Res. 57:4593-4599 (1997) against VEGF Antibodies, Fab-12 assessed in agreement) mixed. The Fab of interest is then cultured overnight; however, culture can be continued for a longer period of time (eg, about 65 hours) to ensure equilibrium is reached. Thereafter, the mixture is transferred to a capture plate for incubation at room temperature (eg, 1 hour). The solution was then removed and the dish was washed 8 times with PBS containing 0.1% polysorbate 20 (TWEEN-20®). When the plate had dried, 150 μl / well of scintillation fluid (MICROSCINT-20™; Packard) was added and the plate was counted for 10 minutes on a TOPCOUNT™ gamma counter (Packard). Concentrations of each Fab giving less than or equal to 20% of maximal binding were selected for use in competitive binding assays.
[0187] According to another embodiment, Kd is measured using BIACORE® surface plasmon resonance assay. For example, assays using the BIACORE®-2000 or BIACORE®-3000 (BIACORE®, Inc., Piscataway, NJ) are performed at about 10 response units (RU) at 25°C on immobilized antigen CM5 chips. In one embodiment, N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) activated carboxymethylated polydextrose biosensor chip (CM5, BIACORE®, Inc.). Antigen was diluted to 5 μg / ml (approximately 0.2 μM) in 10 mM sodium acetate, pH 4.8, before infusing at a flow rate of 5 μl / min to obtain approximately 10 response units (RU) of coupled protein. Following injection of antigen, 1M ethanolamine was injected to block unreacted groups. For kinetic measurements, two-fold serial dilutions of Fab (0.78nM to 500nM) were injected into PBS (PBST )middle. Association rates (kon) and dissociation rates (koff) were calculated by simultaneously fitting association and dissociation sensorgrams using a simple one-to-one Langmuir binding model (BIACORE® Evaluation Software version 3.2). Equilibrium dissociation constants (Kd) were calculated as the ratio koff / kon. See, eg, Chen et al., J. Mol. Biol. 293:865-881 (1999). If the on-rate exceeds 106 M-1 s-1 according to the surface plasmon resonance assay described above, then the on-rate is determined using the fluorescence quenching technique measured at 20 nM of anti-antigen antibody in PBS, pH 7.2, at 25°C Increase or decrease of fluorescence emission intensity (excitation = 295nm; emission = 340nm, 16nm bandpass) (Fab format) in a spectrometer, such as a spectrophotometer equipped with a stop-flow device (Aviv Instruments) Or 8000 series SLM-AMINCOTM spectrophotometer (ThermoSpectronic) with agitated colorimetric tubes to measure the concentration of antigen in the presence of increasing. 2. Antibody fragments
[0188] In some specific embodiments, the antibodies provided herein are antibody fragments. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, and scFv fragments, and other fragments as described below. For a review of specific antibody fragments, see Hudson et al., Nat. Med. 9:129-134 (2003). For a review of specific scFv fragments see, e.g., Pluckthün, The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds. (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93 / 16185; and US Patent Nos. 5,571,894 and 5,587,458. For a discussion of Fab and F(ab')2 fragments comprising salvage receptor binding epitope residues with increased in vivo half-life, see US Patent No. 5,869,046.
[0189] Diabodies (diobodies) are antibody fragments having two antigen-binding sites, which may be bivalent or bispecific, see, for example, EP 404,097; WO 1993 / 01161; Hudson et al., Nat. Med 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).
[0190] A single domain antibody is an antibody fragment that includes all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody. In some specific embodiments, the single domain antibody is a human single domain antibody (Domantis, Inc., Waltham, MA; see, eg, US Patent No. 6,248,516 B1).
[0191] Antibody fragments can be formed by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies, and production by recombinant host cells (eg, E. coli or phage), as described herein. 3. Chimeric and humanized antibodies
[0192] In some specific embodiments, the antibodies provided herein are chimeric antibodies. Specific chimeric antibodies are described, eg, in US Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984)). In one example, a chimeric antibody includes non-human variable regions (eg, variable regions derived from mouse, rat, rodent, rabbit, or a non-human primate such as monkey) and human constant regions. In yet another example, a chimeric antibody is a "class switched" antibody, wherein the class or subclass has been changed from that of the parent antibody. A chimeric antibody comprises an antigen-binding fragment thereof.
[0193] In some specific embodiments, the chimeric antibody is a humanized antibody. Typically, non-human antibodies are humanized to reduce immunogenicity to humans while retaining the specificity and affinity of the parental non-human antibody. Generally, a humanized antibody comprises one or more variable domains in which HVRs, eg, CDRs (or portions thereof) are derived from non-human antibodies and FRs (or portions thereof) are derived from human antibody sequences. A humanized antibody optionally also will comprise at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity. and sex.
[0194] Humanized antibodies and methods of making them are reviewed, e.g., in Almagro, Front. Biosci. 13:1619-1633 (2008), and further described, e.g., in Riechmann et al., Nature 332:323-329 (1988) ; Queen et al., Proc. Nat'l Acad. Sci. USA86:10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321 and 7,087,409; Determining region (SDR) shift); Padlan, Mol. Immunol.28:489-498 (1991) (describing "resurfacing"); Dall'Acqua et al., Methods 36:43-60 (2005) (describing "FR reshuffling" ); and Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer 83:252-260 (2000) (describing a "guided selection" approach to FR shuffling).
[0195] Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using a "best fit" approach (see, e.g., Sims et al., J. Immunol. 151:2296 (1993); from The framework region of the consensus sequence of human antibodies for the light or heavy chain variable regions of a particular subtype (see, e.g., Carter et al., Proc. Natl. Acad. Sci. USA89:4285 (1992); and Presta et al. Human, J. Immunol.151:2623 (1993); Human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci.13:1619-1633 (2008 )); and framework regions derived from screening FR databases (see, e.g., Baca et al., J. Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271: 22611-22618 (1996)). 4. Human Antibodies
[0196] In some specific embodiments, the antibodies provided herein are human antibodies. Human antibodies can be produced using a variety of well-known techniques. Human antibodies are generally described in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5:368-374 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).
[0197] Human Antibodies Human antibodies can be prepared by administering an immunogen to transgenic animals that have been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or part of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly within the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin loci have generally been inactivated. For a review of methods for obtaining human antibodies from transgenic animals, please refer to Lonberg, Nat. Biotech. 23:1117-1125 (2005). Please also refer, for example, to U.S. Patent Nos. 6,075,181 and 6,150,584, which describe XENOMOUSE™ technology; U.S. Patent No. 5,770,429, which describes HuMab® technology; U.S. Patent No. 7,041,870, which describes K-M MOUSE® technology, and U.S. Patent Publication No. US 2007 / 0061900, which describes VelociMouse® technology). The human variable regions of intact antibodies produced by such animals can be further modified, for example, by combining with different human constant regions.
[0198] Human antibodies can also be generated by fusionoma-based methods. Human myeloma and mouse-human fusion myeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., Kozbor, J. Immunol. 133:3001 (1984); Brodeur et al., Monoclonal antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al. Human, J. Immunol. 147:86 (1991). Human antibodies produced by human B cell fusion tumor technology are also described in Li et al., Proc. Natl. Acad. Sci. USA 103:3557-3562 (2006). Other methods include those described, for example, in U.S. Pat. No. 7,189,826 (describing production of monoclonal human IgM antibodies by fusionoma cell lines) and Ni, Xiandai Mianyixue 26(4):265-268 (2006) (describing human-human fusionomas) The method of human fusion tumor technology (Trioma technology) is also described in Vollmers and Brandlein, Histology and Histopathology20 (3): 927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology 27 (3): 185- 191 (2005).
[0199] Human antibodies can also be generated by isolating variable domain sequences of Fv strains selected from human phage display databases. Such variable domain sequences can then be combined with the desired human constant domains. Techniques for selecting human antibodies from antibody databases are described below. 5. Antibodies from databases
[0200] Antibodies of the invention can be isolated by screening combinatorial databases for antibodies having the desired activity. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies with desired binding characteristics. Such methods are reviewed, e.g., in Hoogenboom et al., Methods in Molecular Biology 178:1-37 (2000); edited by O'Brien et al., Human Press, Totowa, NJ, 2001, and further, e.g., in McCafferty et al., Nature 348: 552-554; Clackson et al., Nature 352:624-628 (1991); Marks et al., J. Mol. Biol.222:581-597 (1992); Marks and Bradbury, Methods in Molecular Biology 248:161-175 (Lo , ed., Human Press, Totowa, NJ, 2003); Sidhu et al., J. Mol. Biol.338(2):299-310 (2004); Lee et al., J. Mol. Biol.340(5) :1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA101(34):12467-12472 (2004); and Lee et al., J. Immunol. Methods 284(1-2):119-132 ( 2004) described.
[0201] In a specific phage display method, the repertoires of VH and VL genes are respectively selected by polymerase chain reaction (PCR) and randomly recombined in the phage database, which can then be obtained by such as Winter et al. Human, Ann. Rev. Immunol. 12:433-455 (1994), in which antigen-binding phage were screened. Phage typically present antibody fragments in the form of single-chain Fv (ScFv) fragments or Fab fragments. Libraries from immune sources provide high-affinity antibodies to immunogens without the need to construct fusionomas. Alternatively, natural repertoires can be cloned (e.g., from humans) to provide a single source of antibodies against a broad range of non-self antigens as well as self antigens without any immunization, as Griffiths et al., EMBO J, 12:725-734 (1993). Finally, natural repertoires can also be generated synthetically by transplanting unrearranged V gene segments from stem cells, using PCR primers containing random sequences to encode the hypervariable CDR3 region, and performing in vitro rearrangements, As described by Hoogenboom and Winter, J. Mol. Biol. 227:381-388 (1992). Patent publications describing human antibody phage libraries include, for example: U.S. Patent No. 5,750,373, and U.S. Patent Publication Nos. 0292936 and 2009 / 0002360.
[0202] Antibodies or antibody fragments isolated from human antibody databases are considered human antibodies or human antibody fragments herein. 6. Multispecific Antibodies
[0203] In some specific embodiments, provided antibodies are multispecific antibodies, eg, bispecific antibodies. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In some specific embodiments, one of the binding specificities is for myostatin and the other is for any other antigen. In some specific embodiments, bispecific antibodies can bind to two different epitopes of myostatin. Bispecific antibodies can also be used to localize cytotoxic agents to myostatin-expressing cells. Bispecific antibodies can be produced as full-length antibodies or antibody fragments.
[0204] Techniques for producing multispecific antibodies include, but are not limited to, recombinant co-expression (co-expression) of two immunoglobulin heavy chain-light chain pairs with different specificities (see Milstein and Cuello, Nature 305:537 (1983)), WO 1993 / 08829, and Traunecker et al., EMBO J. 10:3655 (1991)), and "knob-in-hole" engineering (see, eg, US Patent No. 5,731,168). Multi-specific antibodies can also be produced by the following methods: engineering electrostatic guidance for the preparation of antibody Fc-heterodimeric molecules (WO 2009 / 089004A1); cross-linking two or more antibodies or fragments ( See, e.g., U.S. Patent No. 4,676,980, and Brennan et al., Science, 229:81 (1985)); use of leucine zippers to generate bispecific antibodies (see, e.g., Kostelny et al., J. Immunol. 148( 5):1547-1553 (1992)); use of "diabody" technology to generate bispecific antibody fragments (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA90:6444-6448 (1993)) and the use of single-chain Fv (sFv) diabodies (see, for example, Gruber et al., J. Immunol. 152:5368 (1994)); and the preparation of trispecific antibodies, such as, for example, Tutt et al., J. Immunol. 147:60 (1991).
[0205] Also included herein are engineered antibodies having three or more functional antigen-binding sites, including "Octopus antibodies" (see, eg, US 2006 / 0025576A1).
[0206] Antibodies or fragments herein also include "dual acting FAbs" or "DAFs" that include an antigen binding site that binds to myostatin as well as a different antigen (see, eg, US 2008 / 0069820). 7. Antibody variants
[0207] In some specific embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to increase the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of antibodies can be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions, and / or insertions and / or substitutions of residues within the amino acid sequence of the antibody. Any combination of deletions, insertions and substitutions can be made into the final construct provided that the final construct possesses the desired characteristics, eg, antigen binding. a. Substitution, insertion and deletion variants
[0208] In some specific embodiments, antibody variants having one or more amino acid substitutions are provided. Positions of interest for substitution mutagenesis include HVR and FR. Conservative substitutions are shown in Table 1 under the heading "Preferred Substitutions". More substantial changes are provided in Table 1 under the heading "Exemplary Substitutions" and are described further below with reference to amino acid side chain classes. Amino acid substitutions can be introduced into an antibody of interest and the products screened for a desired activity, eg, retained / improved antibody binding, reduced immunogenicity, or improved ADCC or CDC. [Table 1] original residue exemplary substitution preferred substitution Ala (A) Val; Leu; Ile Val Arg (R) Lys; Gln; Asn Lys Asn (N) Gln; His; Asp, Lys; Gln Asp (D) Glu;Asn Glu Cys (C) Ser; Ser Gln (Q) Asn; Glu Asn Glu (E) Asp; Gln Asp Gly (G) Ala Ala His (H) Asn; Gln; Lys; Arg Arg Ile (I) Leu; Val; Met; Ala; Phe; Norleucine Leu Leu (L) Norleucine; Ile; Val; Met; Ala; Phe Ile Lys (K) Arg; Gln; Asn Arg Met (M) Leu; Phe; Ile Leu Phe (F) Trp; Leu; Val; Tyr Pro (P) Ala Ala Ser (S) Thr Thr Thr (T) Val; Ser Trp (W) Tyr; Tyr Tyr (Y) Trp; Phe; Thr; Phe Val (V) Ile; Leu; Met; Phe; Ala; Leu
[0209] Amino acids can be classified according to common side chain characteristics: (1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile; (2) neutral and hydrophilic: Cys, Ser , Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues affecting chain orientation: Gly, Pro; and (6) aromatic : Trp, Tyr, Phe. Non-conservative substitutions will exchange a member of one of these groups with a member of the other group.
[0210] One class of substitutional variants involves substituting one or more hypervariable region residues of a parent antibody (eg, a humanized or human antibody). In general, the resulting variant selected for further study will have a modification (e.g., improvement) relative to the parental antibody in a particular biological property (e.g., increased affinity, reduced immunogenicity) and / or will have Certain biological properties of the parent antibody are substantially retained. Exemplary substitutional variants are affinity matured antibodies, which can be conveniently produced, for example, using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and variant antibodies are displayed on phage and screened for particular biological activity (eg, binding affinity).
[0211] Alterations (eg, substitutions) can be made in the HVR, eg, to improve antibody affinity. Such modifications can be made in HVR "hot spots", residues encoded by codons that undergo mutations at high frequency during somatic cell maturation (see, e.g., Chowdhury, Methods Mol. Biol. 207:179- 196 (2008), and / or residues that contact the antigen, and test the binding affinity of the obtained variant VH or VL. Affinity maturation by construction and reselection from a second database has been done in, for example, Hoogenboom et al., Methods in Molecular Biology 178:1-37 (O'Brien et al. eds., Human Press, Totowa, NJ, (2001) described. In some embodiments of affinity maturation, by Either (e.g., error-prone PCR, strand shuffling, or oligonucleotide-directed mutagenesis) introduces diversity into the variable genes selected for maturation. A second database is then generated. The database is then screened to identify Any antibody variant with the desired affinity. Another approach to introducing diversity involves an HVR-directed approach, in which several HVR residues are randomized (e.g., 4 to 6 residues at a time). Involved in antigen binding HVR residues can be specifically identified, for example using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 are particularly frequently targeted.
[0212] In some specific embodiments, substitutions, insertions or deletions may occur within one or more HVRs, so long as such modifications do not substantially reduce the ability of the antibody to bind antigen. For example, conservative modifications (eg, conservative substitutions as provided herein) can be made in HVRs that do not substantially reduce binding affinity. Such modifications may, for example, be outside of the antigen contacting residues in the HVR. In certain examples of the variant VH and VL sequences provided above, each HVR is either unmodified, or contains no more than one, two or three amino acid substitutions.
[0213] One method that can be used to identify residues or regions of an antibody that can be targeted for mutagenesis is called "alanine scanning mutagenesis", as in Cunningham and Wells, (1989) Science, 244:1081-1085 mentioned. In this method, a residue or group of residues (e.g., charged residues such as arg, asp, his, lys, and glu) can be identified and neutralized or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether it affects the interaction of the antibody with the antigen. Further substitutions can be introduced at amino acid positions showing functional susceptibility to initial substitution. Alternatively, or additionally, the crystal structure of the antigen-antibody complex can be analyzed to identify contact points between the antibody and antigen. Such contact residues and adjacent residues can be targeted or eliminated as candidates for substitution. Variants can be screened to determine whether they contain the desired property.
[0214] Amino acid sequence inserts include amino- and / or carboxy-terminal fusions ranging in length from one residue to polypeptides comprising 100 or more residues, and single or multiple amino acid residues in-sequence inserts. Examples of terminal inserts include antibodies with an N-terminal methionyl residue. Other insertional variants of the antibody molecule comprise fusions to the N- or C-terminus of the antibody to an enzyme (eg, ADEPT) or polypeptide that increases the serum half-life of the antibody. b. Glycation variants
[0215] In some specific embodiments, the antibodies provided herein are modified to increase or decrease the degree to which the antibody is glycated. The addition or deletion of glycosylation sites to antibodies can be conveniently accomplished by modifying the amino acid sequence so that one or more glycosylation sites are created or removed.
[0216] When the antibody includes an Fc region, the sugar attached thereto can be modified. Native antibodies produced by mammalian cells typically comprise branched, biantennary oligosaccharides attached, typically via an N-linkage, to Asn297 of the CH2 domain of the Fc region, see, e.g., Wright et al., TIBTECH 15:26 -32 (1997). Oligosaccharides may comprise sugars such as mannose, N-acetylglucosamine (GIcNAc), galactose, and sialic acid, as well as fucose attached to the GIcNAc in the "backbone" of the biantennary oligosaccharide structure. In some embodiments, the oligosaccharides in the antibodies of the invention may be modified to produce antibody variants with particular improved properties.
[0217] In one embodiment, antibody variants are provided that have carbohydrate structures that lack fucose attached (directly or indirectly) to the Fc region. For example, the amount of fucose in such antibodies may be from 1% to 80%, from 1% to 65%, from 5% to 65%, or from 20% to 40%. The amount of fucose was calculated by calculating the average amount of fucose at Asn297 within the sugar chain relative to the sum of all glycosyl structures attached to Asn297 as measured by MALDI-TOF mass spectrometry (e.g., complexes, hybrids and high mannose structures) are determined, for example, as described in WO 2008 / 077546. Asn297 refers to the asparagine residue located approximately at position 297 (Eu numbering of Fc region residues) in the Fc region; however, due to minor sequence variations in antibodies, Asn297 can also be located approximately ±3 amine groups from position 297 Acid upstream or downstream, i.e. between positions 294 and 300. Such fucosylated variants may have improved ADCC function, please refer to, for example, US Patent Publication Nos. 2003 / 0157108 (Presta, L.); 2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of publications relating to "defucosylated" or "fucose-deficient" antibody variants include: US 2003 / 0157108; WO 2000 / 61739; WO 2001 / 29246; US 2003 / 0115614; US 2002 / 0164328 ; US 2004 / 0093621; US 2004 / 0132140; US 2004 / 0110704; US 2004 / 0110282; 005 / 035778; WO 2005 / 053742 ; WO 2002 / 031140; Okazaki et al., J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al., Biotech. Bioeng. 87:614 (2004). Examples of cell lines capable of producing defucosylated antibodies include Lecl3 CHO cells deficient in protein fucosylation (Ripka et al., Arch. Biochem. Biophys. 249:533-545 (1986); U.S. Patent Publication No. 2003 / 0157108 A1, Presta, L; and WO 2004 / 056312, Adams et al., especially in Example 11), and knockout cell lines, such as α-1,6-fucosyltransferase genes, FUT8, Knockout CHO cells (see, for example, Yamane-Ohnuki et al., Biotech. Bioeng. 87:614 (2004); Kanda et al., Biotechnol. Bioeng. 94(4):680-688 (2006); and WO2003 / 085107).
[0218] Further provided are antibody variants having bisected oligosaccharides, eg, wherein the biantennary oligosaccharides attached to the Fc region of the antibody are bisected by GIcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described, eg, in WO 2003 / 011878 (Jean-Mairet et al.), US Patent No. 6,602,684 (Umana et al.); and US 2005 / 0123546 (Umana et al.). Antibody variants having at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, eg, in WO 1997 / 30087 (Patel et al); WO 1998 / 58964 (Raju, S); and WO 1999 / 22764 (Raju, S). c. Fc region variants
[0219] In some specific embodiments, one or more amino acid modifications can be introduced into the Fc region of the antibodies provided herein, thereby generating Fc region variants. Fc region variants can include human Fc region sequences (eg, human IgGl, IgG2, IgG3, or IgG4 Fc regions) that include amino acid modifications (eg, substitutions) at one or more amino acid positions.
[0220] In some specific embodiments, the present invention contemplates antibody variants that possess some, but not all, effector functions, making them ideal candidates for applications where the in vivo half-life of the antibody are important, whereas certain effector functions (such as complement and ADCC) are unnecessary or deleterious. In vitro and / or in vivo cytotoxicity assays can be performed to confirm reduction / depletion of CDC and / or ADCC activity. For example, Fc receptor (FcR) binding assays can be performed to ensure that the antibody lacks FcγR binding (and thus likely lacks ADCC activity), but retains FcRn binding ability. The primary cells that regulate ADCC, NK cells, express only FcyRIII, whereas monocytes express FcyRI, FcyRII and FcyRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991). A non-limiting example of an in vitro assay for assessing ADCC activity of a molecule of interest is described in U.S. Pat. No. 5,500,362 (see, e.g., Hellstrom et al., Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986) ) and Hellstrom, I et al., Proc. Nat'l Acad. Sci. USA82:1499-1502 (1985); US Pat. 1987)). Alternatively, nonradioactive assays can be used (see, e.g., ACTI™ Nonradioactive Cytotoxicity Assay for Flow Cytometry (Cell Technology, Inc. Mountain View, CA); and CytoTox 96® Nonradioactive Cytotoxicity Assay (Promega , Madison, WI)). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively, or additionally, the ADCC activity of a molecule of interest can be assessed in vivo, e.g., in an animal model, as in Clynes et al., Proc. Nat'l Acad. Sci. USA 95:652-656 (1998). public. Clq binding assays can also be performed to determine that the antibody is unable to bind Clq and thus lacks CDC activity. Please refer, for example, to Clq and C3c binding ELISAs in WO 2006 / 029879 and WO 2005 / 100402. To assess complement activation, a CDC assay can be performed (see, e.g., Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996); Cragg et al., Blood 101:1045-1052 (2003); and Cragg, Blood 103 :2738-2743 (2004)). FcRn binding and in vivo clearance / half-life assays can also be performed using methods known in the art (see, eg, Petkova et al., Int'l. Immunol. 18(12):1759-1769 (2006)).
[0221] Antibodies with reduced effector function include those having substitutions in one or more of Fc region residues 238, 265, 269, 270, 297, 327, and 329 (US Patent No. 6,737,056). Such Fc mutants include two or more Fc mutants with substitutions in amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" mutants with residues 265 and 297 substituted with alanine. "Fc mutants (US Patent No. 7,332,581).
[0222] Specific antibody variants with improved or reduced binding to FcRs have been described (see, e.g., U.S. Pat. No. 6,737,056; WO 2004 / 056312; and Shields et al., J. Biol. Chem. 9(2): 6591-6604 (2001)).
[0223] In certain embodiments, the antibody variant comprises an Fc region with one or more amino acid substitutions that increase ADCC, e.g., at positions 298, 333 and / or 334 (EU of residues 298, 333, and / or 334) of the Fc region. number) to replace.
[0224] In some embodiments, alterations are made in the Fc region that result in altered (i.e., improved or reduced) Clq binding and / or complement-dependent cytotoxicity (CDC), e.g., as in U.S. Pat. No. 6,194,551, WO 1999 / 51642, and described in Idusogie et al., J. Immunol. 164:4178-4184 (2000).
[0225] Antibodies with increased half-life and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the delivery of maternal IgG to the fetus, are described in US2005 / 0014934 Al (Hinton et al.) (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)). Those antibodies include an Fc region with one or more substitutions therein that improve binding of the Fc region to FcRn. Such Fc variants comprise residues in the Fc region: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, One or more of 413, 424, or 434 have those substituted, eg, of Fc region residue 434 (US Pat. No. 7,371,826). For other examples of Fc region variants, please also refer to Duncan, Nature 322:738-40 (1988); US Patent Nos. US 5,648,260 and US 5,624,821; and WO 1994 / 29351. d) Cysteine engineered antibody variants
[0226] In certain specific embodiments, it is desirable to generate cysteine engineered antibodies, eg, "thioMAbs," in which one or more residues of the antibody are substituted with cysteine residues. In particular embodiments, the substituted residue is present at an antibody accessible position. By substituting those residues with cysteine, a reactive thiol group is placed in an accessible position of the antibody and can be used to conjugate the antibody to other moieties, such as drug moieties or link drug moieties, to create immunoconjugates Linkages, as further described herein. In some specific embodiments, any one or more of the following residues may be substituted by cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 of the Fc region of the heavy chain (EU number). Cysteine engineered antibodies can be produced, eg, as described in US Pat. No. 7,521,541. e) Antibody derivatives
[0227] In certain specific embodiments, the antibodies provided herein can be further modified to include additional non-protein moieties known in the art and readily available. Moieties suitable for derivatization of antibodies include, but are not limited to, water soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol / propylene glycol, carboxymethylcellulose, polydextrose, polyvinyl alcohol, polyvinylpyrrolidone, Poly-1,3-dioxolane, poly-1,3,6-tri (poly-1,3,6-trioxane), ethylene / maleic anhydride copolymer, polyamino acid (homopolymer or random copolymer), and polydextrose or poly(n-vinylpyrrolidone) polyethylene glycol, polypropylene glycol (polypropylene glycol) homopolymer, polypropylene oxide (polypropylene oxide) / ethylene oxide copolymer substances, polyoxyethylated polyols (eg, glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in production due to its stability in water. Polymers can be of any molecular weight and can be branched or unbranched. The number of polymers attached to the antibody can vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and / or type of polymers used for derivatization can be determined according to, including but not limited to, consideration of the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used under defined conditions, Therapy is determined in the middle.
[0228] In another embodiment, a conjugate of an antibody and a non-protein moiety that can be selectively heated by exposure to radiation is provided. In one embodiment, the non-protein moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102:11600-11605 (2005)). The radiation can be of any wavelength, and includes, but is not limited to, wavelengths that do not harm normal cells, but which heat the non-protein moiety to a temperature close to that at which cells of the antibody-non-protein moiety are killed. 8. Mutated Fc region
[0229] In one aspect, the invention provides an isolated polypeptide comprising a variant Fc region having enhanced FcγRIIb binding activity. In some aspects, the polypeptide is an antibody. In some aspects, the polypeptide is an Fc fusion protein. In some specific embodiments, the variant Fc region comprises at least one amino acid residue modification (e.g., ,replace). In some specific embodiments, the inventive variant Fc region has increased binding activity to monkey FcγRIIb compared to the parental Fc region. In some specific embodiments, the monkey FcγRIIb is a rhesus FcγRIIb (SEQ ID NO: 223).
[0230] In some specific embodiments, the ratio of [KD value of parental Fc region to monkey FcγRIIb] / [KD value of variant Fc region to monkey FcγRIIb] may be 2.0 or greater, 3.0 or greater, 4.0 or greater Large, 5.0 or greater, 6.0 or greater, 7.0 or greater, 8.0 or greater, 9.0 or greater, 10 or greater, 15 or greater, 20 or greater, 25 or greater, 30 or greater Large, 40 or larger, or 50 or larger. In yet other embodiments, the variant Fc region has reduced binding activity to monkey FcyRIIIa. In some specific embodiments, the ratio of [KD value of parental Fc region to monkey FcγRIIIa] / [KD value of variant Fc region to monkey FcγRIIIa] may be 0.50 or less, 0.40 or less, 0.30 or less, 0.20 or less, 0.10 or less, 0.09 or less, 0.08 or less, 0.07 or less, 0.06 or less, 0.05 or less, 0.04 or less, 0.03 or less, 0.02 or less, or 0.01 or less. In some specific embodiments, the monkey FcγRIIb has the sequence of SEQ ID NO: 223 (rhesus monkey). In some specific embodiments, monkey FcγRIIIa has the sequence of SEQ ID NO: 224 (rhesus monkey).
[0231] In yet other embodiments, the variant Fc region has enhanced binding activity to human FcyRIIb. In some specific embodiments, the ratio of [KD value of parental Fc region to human FcγRIIb] / [KD value of variant Fc region to human FcγRIIb] may be 2.0 or greater, 3.0 or greater, 4.0 or greater, 5.0 or greater, 6.0 or greater, 7.0 or greater, 8.0 or greater, 9.0 or greater, 10 or greater, 15 or greater, 20 or greater, 25 or greater, 30 or greater, 40 or greater, or 50 or greater. In yet other embodiments, the variant Fc region has reduced binding activity to human FcyRIIIa. In some specific embodiments, the ratio of [KD value of parental Fc region to human FcγRIIIa] / [KD value of variant Fc region to human FcγRIIIa] may be 0.50 or less, 0.40 or less, 0.30 or less, 0.20 or less, 0.10 or less, 0.09 or less, 0.08 or less, 0.07 or less, 0.06 or less, 0.05 or less, 0.04 or less, 0.03 or less, 0.02 or less, or 0.01 or less. In some specific embodiments, the human FcγRIIb has the sequence of SEQ ID NO: 212, 213 or 214. In some specific embodiments, human FcγRIIIa has the sequence of SEQ ID NO: 215, 216, 217 or 218.
[0232] In yet other embodiments, the variant Fc region has lower binding activity to human FcyRIIa (type H) than to human FcyRIIb. In some specific embodiments, the ratio of [the KD value of the parental Fc region to human FcγRIIa (type H)] / [the KD value of the variant Fc region to human FcγRIIa (type H)] may be 5.0 or less, 4.0 or more Small, 3.0 or less, 2.0 or less, 1.0 or less, 0.9 or less, 0.8 or less, 0.7 or less, 0.6 or less, 0.5 or less, 0.4 or less, 0.3 or less Small, 0.2 or less, or 0.1 or less. In yet other embodiments, the variant Fc region has lower binding activity to human FcyRIIa (type R) than to human FcyRIIb. In some specific embodiments, the ratio of [the KD value of the parental Fc region to human FcγRIIa (R type)] / [the KD value of the variant Fc region to human FcγRIIa (R type)] may be 5.0 or less, 4.0 or more Small, 3.0 or less, 2.0 or less, 1.0 or less, 0.9 or less, 0.8 or less, 0.7 or less, 0.6 or less, 0.5 or less, 0.4 or less, 0.3 or less Small, 0.2 or less, or 0.1 or less. In some specific embodiments, human FcγRIIa (type H) has the sequence of SEQ ID NO: 211. In some specific embodiments, human FcγRIIa (type R) has the sequence of SEQ ID NO: 210.
[0233] In some specific embodiments, the ratio of [the KD value of the parental Fc region to monkey FcγRIIa] / [the KD value of the variant Fc region to monkey FcγRIIa] may be 2.0 or greater, 3.0 or greater, 4.0 or greater Large, 5.0 or greater, 6.0 or greater, 7.0 or greater, 8.0 or greater, 9.0 or greater, 10 or greater, 15 or greater, 20 or greater, 25 or greater, 30 or greater Large, 40 or larger, or 50 or larger. In some specific embodiments, monkey FcγRIIa is selected from: monkey FcγRIIa1 (e.g., rhesus FcγRIIa1 (SEQ ID: 220)), monkey FcγRIIa2 (e.g., rhesus FcγRIIa2 (SEQ ID: 221)) and Monkey FcγRIIa3 (eg, rhesus FcγRIIa3 (SEQ ID NO: 222).
[0234] In another embodiment, the KD value of the variant Fc region to monkey FcγRIIb may be 1.0×10-6M or less, 9.0×10-7M or less, 8.0×10-7M or less, 7.0× 10-7M or less, 6.0×10-7M or less, 5.0×10-7M or less, 4.0×10-7M or less, 3.0×10-7M or less, 2.0×10-7M or less Small, or 1.0×10-7M or smaller. In another embodiment, the KD value of the variant Fc region to monkey FcγRIIIa may be 5.0×10-7M or greater, 6.0×10-7M or greater, 7.0×10-7M or greater, 8.0×10-7M or larger, 9.0×10-7M or larger, 1.0×10-6M or larger, 2.0×10-6M or larger, 3.0×10-6M or larger, 4.0×10-6M or larger, 5.0 ×10-6M or greater, 6.0×10-6M or greater, 7.0×10-6M or greater, 8.0×10-6M or greater, 9.0×10-6M or greater, or 1.0×10-5M or larger. In another embodiment, the KD value of the variant Fc region to human FcγRIIb may be 2.0×10-6M or less, 1.0×10-6M or less, 9.0×10-7M or less, 8.0×10-7M or less, 7.0×10-7M or less, 6.0×10-7M or less, 5.0×10-7M or less, 4.0×10-7M or less, 3.0×10-7M or less, 2.0 ×10-7M or less, or 1.0×10-7M or less. In another embodiment, the KD value of the variant Fc region to human FcγRIIIa may be 1.0×10-6M or greater, 2.0×10-6M or greater, 3.0×10-6M or greater, 4.0×10-6M or greater, 5.0×10-6M or greater, 6.0×10-6M or greater, 7.0×10-6M or greater, 8.0×10-6M or greater, 9.0×10-6M or greater, 1.0 ×10-5M or more, 2.0×10-5M or more, 3.0×10-5M or more, 4.0×10-5M or more, or 5.0×10-5M or more. In another embodiment, the KD value of the variant Fc region to human FcγRIIa (type H) may be 1.0×10-7M or greater, 2.0×10-7M or greater, 3.0×10-7M or greater, 4.0 ×10-7M or greater, 5.0×10-7M or greater, 6.0×10-7M or greater, 7.0×10-7M or greater, 8.0×10-7M or greater, 9.0×10-7M or Larger, 1.0×10-6M or larger, 2.0×10-6M or larger, 3.0×10-6M or larger, 4.0×10-6M or larger, or 5.0×10-6M or larger. In another embodiment, the KD value of the variant Fc region to human FcγRIIa (R type) may be 2.0×10-7M or greater, 3.0×10-7M or greater, 4.0×10-7M or greater, 5.0 ×10-7M or greater, 6.0×10-7M or greater, 7.0×10-7M or greater, 8.0×10-7M or greater, 9.0×10-7M or greater, 1.0×10-6M or Larger, 2.0×10-6M or larger, 3.0×10-6M or larger, 4.0×10-6M or larger, or 5.0×10-6M or larger.
[0235] In another embodiment, the KD value of the variant Fc region to monkey FcγRIIa may be 1.0×10-6M or less, 9.0×10-7M or less, 8.0×10-7M or less, 7.0× 10-7M or less, 6.0×10-7M or less, 5.0×10-7M or less, 4.0×10-7M or less, 3.0×10-7M or less, 2.0×10-7M or less Small, or 1.0×10-7M or smaller. In some specific embodiments, monkey FcyRIIa can be selected from any one of monkey FcyRIIa1, monkey FcyRIIa2 and monkey FcyRIIa3.
[0236] When we develop a medicinal product for the treatment of human disease, it is important to evaluate its efficacy and safety in monkeys due to their biological proximity to humans. From this point of view, the pharmaceutical product to be developed is preferably cross-reactive to both humans and monkeys in the target binding activity.
[0237] "Fcγ receptor" (herein referred to as Fcγ receptor, FcγR or FcgR) refers to a receptor that can bind to the Fc region of IgG1, IgG2, IgG3 and IgG4 monoclonal antibodies, and actually represents the Any member of the protein family encoded by the Fcγ receptor gene. In humans, this family includes FcγRI (CD64), which includes the isoforms FcγRIa, FcγRIb, and FcγRIc; FcγRII (CD32), which includes the isoform FcγRIIa (including isoforms H131 (H-type) and R131 (R-type) ), FcγRIIb (including FcγRIIb-1 and FcγRIIb-2) and FcγRIIc; and FcγRIII (CD16), which includes the isoforms FcγRIIIa (including isoforms V158 and F158) and FcγRIIIb (including isoforms FcγRIIIb-NA1 and FcγRIIIb-NA2), And any undiscovered FcγRs, FcγR isoforms or isoforms, but not limited thereto. It has been reported that FcγRIIb1 and FcγRIIb2 are splice variants of human FcγRIIb. Furthermore, a splice variant designated FcyRIIb3 has been reported (J Exp Med, 1989, 170: 1369-1385). In addition to these splice variants, human FcyRIIb includes all splice variants registered with NCBI, which are NP_001002273.1, NP_001002274.1, NP_001002275.1, NP_001177757.1 and NP_003992.3. In addition, human FcγRIIb contains every genetic polymorphism previously reported and FcγRIIb (Arthritis Rheum. 48:3242-3252 (2003); Kono et al., Hum. Mol. Genet. 14:2881-2892 ( 2005); and Kyogoju et al., Arthritis Rheum. 46:1242-1254 (2002)) and each gene allotype to be reported in the future.
[0238] In FcγRIIa, there are two isotypes, one of which is histidine (H type) at amino acid position 131 of FcγRIIa, and the other is substituted by arginine at amino acid position 131 (R type) (Warrmerdam, J. Exp. Med. 172:19-25 (1990)).
[0239] FcyRs include, but are not limited to, human, mouse, rat, rabbit, and monkey-derived FcyRs, and may be derived from any organism. Mouse FcyRs include, but are not limited to, FcyRI (CD64), FcyRII (CD32), FcyRIII (CD16), and FcyRIII-2 (CD16-2) and any mouse FcyR or FcyR isoform. Unless otherwise stated, the term "monkey FcγR" or variants thereof refers to rhesus monkey FcγRIIa1 (SEQ ID NO: 220), FcγRIIa2 (SEQ ID NO: 221), FcγRIIa3 (SEQ ID NO: 222), FcγRIIb (SEQ ID NO: 222) No.: 223) or FcγRIIIaS (SEQ ID NO: 224).
[0240] The polynucleotide sequence of human FcγRI is shown in sequence identification number: 199 (NM_000566.3); the polynucleotide sequence of human FcγRIIa is as sequence identification number: 200 (BC020823.1) or sequence identification number: 201 (NM_001136219 .1) shown; the polynucleotide sequence of human FcγRIIb is shown in sequence identification number: 202 (BC146678.1) or sequence identification number: 203 (NM_004001.3); the polynucleotide sequence of human FcγRIIIa is shown in sequence identification number: 204 (BC033678.1) or sequence identification number: 205 (NM_001127593.1); and the polynucleotide sequence of human FcγRIIIb is shown in sequence identification number: 206 (BC128562.1).
[0241] The amino acid sequence of human FcγRI is shown in sequence identification number: 207 (NP_000557.1); the amino acid sequence of human FcγRIIa is shown in sequence identification number: 208 (AAH20823.1), sequence identification number: 209, sequence Identification number: 210 or sequence identification number: 211; the amino acid sequence of human FcγRIIb is shown in sequence identification number: 212 (AAI46679.1), sequence identification number: 213 or sequence identification number: 214; the amino acid sequence of human FcγRIIIa The amino acid sequence is shown in SEQ ID NO: 215 (AAH33678.1), SEQ ID NO: 216, SEQ ID NO: 217 or SEQ ID NO: 218; and the amino acid sequence of human FcγRIIIb is shown in SEQ ID NO: 219 ( AAI28563.1).
[0242] The amino acid sequence of rhesus monkey FcγRIIa is shown in SEQ ID NO: 220 (FcγRIIa1), SEQ ID NO: 221 (FcγRIIa2) or SEQ ID NO: 222 (FcγRIIa3); the amino acid sequence of rhesus monkey FcγRIIb The sequence is shown in SEQ ID NO: 223; and the amino acid sequence of rhesus monkey FcγRIIIa is shown in SEQ ID NO: 224.
[0243] In one aspect, the invention provides a polypeptide comprising a variant Fc region having enhanced FcyRIIb binding activity as compared to a corresponding reference FcyRIIb binding polypeptide. In yet other aspects, the polypeptides of the invention comprise at least one amino acid modification selected in at least one of: 231, 232, 233, 234, 235, 236, 237, 238, 239, 264, 266, 267, The position of the group consisting of 268, 271, 295, 298, 325, 326, 327, 328, 330, 331, 332, 334 and 396, according to the EU number. In some specific embodiments, FcγRIIb has the sequence of rhesus FcγRIIb (SEQ ID NO: 223). In some specific embodiments, the FcyRIIb has the sequence of a human FcyRIIb (eg, SEQ ID NO: 212, 213, or 214).
[0244] In one aspect, the invention provides a polypeptide comprising a variant Fc region with enhanced FcγRIIb binding activity comprising at least two amino acid modifications, including: (a) an amino acid modification at position 236; and (b) at least one amino acid modification selected from at least one of: 231, 232, 233, 234, 235, 237, 238, 239, 264, 266, 267, 268, 271, 295, 298, 325 , 326, 327, 328, 330, 331, 332, 334 and 396 the position of the group, according to the EU number. In some specific embodiments, FcγRIIb has the sequence of rhesus FcγRIIb (SEQ ID NO: 223). In some specific embodiments, the FcyRIIb has the sequence of a human FcyRIIb (eg, SEQ ID NO: 212, 213, or 214).
[0245] In one aspect, the invention provides a polypeptide comprising a variant Fc region with enhanced FcγRIIb binding activity comprising an amino acid modification at position 236 according to EU numbering.
[0246] In one aspect, the invention provides a polypeptide comprising a variant Fc region with enhanced FcγRIIb binding activity comprising at least two amino acid modifications, including: (a) an amino acid modification at position 236 and (b) at least one amino acid modification at least one position selected from the group consisting of: 231, 232, 235, 239, 268, 295, 298, 326, 330 and 396, according to EU numbering . In yet another embodiment, the variant Fc region comprises an amino acid modification in at least one selected from the group consisting of: 231, 232, 235, 239, 268, 295, 298, 326, 330, and 396 Location, according to EU number. In yet another embodiment, the variant Fc region comprises an amino acid modification at at least one position selected from the group consisting of: 268, 295, 326 and 330, according to EU numbering. In some specific embodiments, FcγRIIb has the sequence of rhesus FcγRIIb (SEQ ID NO: 223). In some specific embodiments, the FcyRIIb has the sequence of a human FcyRIIb (eg, SEQ ID NO: 212, 213, or 214).
[0247] In another aspect, the invention provides a polypeptide comprising a variant Fc region with enhanced FcγRIIb binding activity, which comprises the amino acid modification of any of the following (1)-(37): (1) Position 231 , 236, 239, 268 and 330; (2) positions 231, 236, 239, 268, 295 and 330; (3) positions 231, 236, 268 and 330; (4) positions 231, 236, 268, 295 and 330 ; (5) Positions 232, 236, 239, 268, 295, and 330; (6) Positions 232, 236, 268, 295, and 330; (7) Positions 232, 236, 268, and 330; (8) Positions 235, 236 , 268, 295, 326 and 330; (9) positions 235, 236, 268, 295 and 330; (10) positions 235, 236, 268 and 330; (11) positions 235, 236, 268, 330 and 396; ( 12) Locations 235, 236, 268, and 396; (13) Locations 236, 239, 268, 295, 298, and 330; (14) Locations 236, 239, 268, 295, 326, and 330; (15) Locations 236, 239 , 268, 295 and 330; (16) positions 236, 239, 268, 298 and 330; (17) positions 236, 239, 268, 326 and 330; (18) positions 236, 239, 268 and 330; (19) Locations 236, 239, 268, 330 and 396; (20) Locations 236, 239, 268 and 396; (21) Locations 236 and 268; (22) Locations 236, 268 and 295; (23) Locations 236, 268, 295 , 298 and 330; (24) positions 236, 268, 295, 326 and 330; (25) positions 236, 268, 295, 326, 330 and 396; (26) positions 236, 268, 295 and 330; (27) Locations 236, 268, 295, 330 and 396; (28) Locations 236, 268, 298 and 330; (29) Locations 236, 268, 298 and 396; (30) Locations 236, 268, 326 and 330; (31) Locations 236, 268, 326, 330 and 396; (32) Locations 236, 268 and 330; (33) Locations 236, 268, 330 and 396; (34) Locations 236, 268 and 396; (35) Locations 236 and 295 ; (36) positions 236, 330 and 396; and (37) positions 236 and 396 according to EU numbering. In some specific embodiments, FcγRIIb has the sequence of rhesus FcγRIIb (SEQ ID NO: 223). In some specific embodiments, the FcyRIIb has the sequence of a human FcyRIIb (eg, SEQ ID NO: 212, 213 or 214).
[0248] In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity comprises at least one amino acid selected from: (a) Asp, Glu, Phe, Gly, His, Ile, Lys, Leu , Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr at position 231; (b) Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln , Arg, Ser, Thr, Val, Trp, Tyr at position 232; (c) Asp at position 233; (d) Trp, Tyr at position 234; (e) Trp at position 235; (f) Ala, Asp, Glu , His, Ile, Leu, Met, Asn, Gln, Ser, Thr, Val at position 236; (g) Asp, Tyr at position 237; (h) Glu, Ile, Met, Gln, Tyr at position 238; (i ) Ile, Leu, Asn, Pro, Val at position 239; (j) Ile at position 264; (k) Phe at position 266; (l) Ala, His, Leu at position 267; (m) Asp, Glu at position 268; (n) Asp, Glu, Gly at position 271; (o) Leu at position 295; (p) Leu at position 298; (q) Glu, Phe, Ile, Leu at position 325; (r) Thr at position 326; (s) Ile, Asn at position 327; (t) Thr at position 328; (u) Lys, Arg at position 330; (v) Glu at position 331; (w) Asp at position 332; (x) Asp , Ile, Met, Val, Tyr at position 334; and (y) Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, Group of Tyr at position 39, according to EU numbering. In some specific embodiments, FcγRIIb has the sequence of rhesus FcγRIIb (SEQ ID NO: 223). In some specific embodiments, the FcyRIIb has the sequence of a human FcyRIIb (eg, SEQ ID NO: 212, 213, or 214).
[0249] In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity comprises at least one amino acid modification (eg, substitution) selected from (a) Gly, Thr at position 231; (b) Asp is at position 232; (c) Trp is at position 235; (d) Asn, Thr are at position 236; (e) Val is at position 239; (f) Asp, Glu are at position 268; (g) Leu is at position 295; Groups consisting of h) Leu at position 298; (i) Thr at position 326; (j) Lys, Arg at position 330; and (k) Lys, Met at position 396, according to EU numbering. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity comprises: amino acid modifications (for example, substitutions) of Asn at position 236, Glu at position 268, Lys at position 330, and Met at position 396, according to EU number. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity comprises amino acid modifications (eg, substitutions) of Asn at position 236, Asp at position 268, and Lys at position 330, according to EU numbering. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity comprises: amino acid modification (e.g., substitution) of Asn at position 236, Asp at position 268, Leu at position 295, and Lys at position 330, according to EU number. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity comprises amino acid modifications (eg, substitutions) of Thr at position 236, Asp at position 268, and Lys at position 330, according to EU numbering. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity includes amino acid modifications of Asn at position 236, Asp at position 268, Leu at position 295, Thr at position 326, and Lys at position 330 (e.g. , replacing), according to the EU numbering. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity includes: Trp at position 235, Asn at position 236, Asp at position 268, Leu at position 295, Thr at position 326 and Lys at position 330 Amino acid modification (eg, substitution), according to EU numbering.
[0250] In one aspect, the invention provides a polypeptide comprising an Fc region with enhanced FcγRIIb binding activity comprising an amino acid modification at position 238 according to EU numbering.
[0251] In one aspect, the invention provides a polypeptide comprising an Fc region with enhanced FcγRIIb binding activity comprising at least one amino acid modification selected in at least one of: 234, 238, 250, 264, 267 , 307 and 330 the position of the group, according to the EU number. In yet other embodiments, the polypeptide comprises at least one amino acid modification at at least one position selected from the group consisting of: 234, 250, 264, 267, 307, and 330, according to EU numbering. In some specific embodiments, FcγRIIb has the sequence of rhesus FcγRIIb (SEQ ID NO: 223). In some specific embodiments, the FcyRIIb has the sequence of a human FcyRIIb (eg, SEQ ID NO: 212, 213, or 214).
[0252] In another aspect, the invention provides a polypeptide comprising an Fc region with enhanced FcγRIIb binding activity, which comprises the amino acid modification of any of the following (1)-(9): (1) position 234, 238, 250, 307 and 330; (2) positions 234, 238, 250, 264, 307 and 330; (3) positions 234, 238, 250, 264, 267, 307 and 330; (4) positions 234, 238, 250, 267, 307 and 330; (5) positions 238, 250, 264, 307 and 330; (6) positions 238, 250, 264, 267, 307 and 330; 330; (8) positions 238, 250 and 307; and (9) positions 238, 250, 307 and 330 according to EU numbering. In some specific embodiments, FcγRIIb has the sequence of rhesus FcγRIIb (SEQ ID NO: 223). In some specific embodiments, the FcyRIIb has the sequence of a human FcyRIIb (eg, SEQ ID NO: 212, 213, or 214).
[0253] In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity comprises at least one amino acid modification (eg, substitution) selected from: (a) Tyr at position 234; (b) Asp (c) Val at position 250; (d) Ile at position 264; (e) Ala at position 267; (f) Pro at position 307; and (g) Lys at position 330, According to the EU number. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity comprises: amino acid modification (eg, substitution) of Asp at position 238, according to EU numbering. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity comprises amino acid modifications (eg, substitutions) of Asp at position 238, Val at position 250, and Pro at position 307, according to EU numbering. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity comprises: Amino acid modifications (for example, substitutions) of Asp at position 238, Val at position 250, Pro at position 307, and Lys at position 330, according to EU number. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity includes amino acid modifications of Asp at position 238, Val at position 250, Ile at position 264, Pro at position 307, and Lys at position 330 (e.g. , replacing), according to the EU numbering. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity includes amino acid modifications of Asp at position 238, Val at position 250, Ala at position 267, Pro at position 307, and Lys at position 330 (e.g. , replacing), according to the EU numbering. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity includes amino acid modifications of Tyr at position 234, Asp at position 238, Val at position 250, Pro at position 307, and Lys at position 330 (e.g. , replacing), according to the EU numbering. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity includes: Tyr at position 234, Asp at position 238, Val at position 250, Ala at position 267, Pro at position 307 and Lys at position 330 Amino acid modification (eg, substitution), according to EU numbering. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity includes: Asp at position 238, Val at position 250, Ile at position 264, Ala at position 267, Pro at position 307, and Lys at position 330. Amino acid modification (eg, substitution), according to EU numbering. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity includes: Tyr at position 234, Asp at position 238, Val at position 250, Ile at position 264, Pro at position 307 and Lys at position 330 Amino acid modification (eg, substitution), according to EU numbering. In yet another embodiment, the variant Fc region with enhanced FcγRIIb binding activity includes: Tyr at position 234, Asp at position 238, Val at position 250, Ile at position 264, Ala at position 267, Pro at position 307, and Lys Amino acid modification (eg, substitution) at position 330, according to EU numbering. In some specific embodiments, FcγRIIb has the sequence of rhesus FcγRIIb (SEQ ID NO: 223). In some specific embodiments, FcyRIIb has the sequence of human FcyRIIb (eg, SEQ ID NO: 212, 213 or 214).
[0254] In another aspect, the invention provides an isolated polypeptide comprising a variant Fc region with an increased isoelectric point (pi). In some specific embodiments, the variant Fc region described herein comprises at least two amino acid modifications in the parental Fc region. In some specific embodiments, each amino acid modification increases the isoelectric point of the variant Fc region compared to the isoelectric point of the parental Fc region. They are based on the discovery that modifications of at least two amino acid residues to antibodies with increased pi can enhance the elimination of antigen from plasma, for example when the antibody is administered in vivo.
[0255] In the present invention, the pi may be a theoretical or experimentally determined pi. The value of pi can be determined, for example, by isoelectric focusing, which is known to those of ordinary skill in the art. The theoretical pI value can be calculated, for example, using gene and amino acid sequence analysis software (Genetyx, etc.).
[0256] In one embodiment, the pi value can be increased compared to before modification, for example, at least 0.01, 0.03, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5 or more, at least 0.6, 0.7, 0.8, 0.9 or more, at least 1.0, 1.1, 1.2, 1.3, 1.4, 1.5 or more, or at least 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 3.0 or more.
[0257] In some specific embodiments, the amino acids used to increase the pi may be exposed on the surface of the variant Fc region. In the present invention, the amino acid that can be exposed on the surface generally refers to an amino acid residue located on the surface of the polypeptide constituting the variant Fc region. Amino acid residues located on the surface of a polypeptide refer to amino acid residues whose side chains are accessible to solvent molecules, which are typically and mostly water molecules. However, the side chain does not have to be completely in contact with the solvent molecule, and even when a part of the side chain is in contact with the solvent molecule, the amino acid is defined as "an amino acid residue located on the surface". Amino acid residues of a polypeptide that are on the surface also include amino acid residues that are close to the surface and thus can be influenced by an amino acid residue whose side chain is in contact (even partially) with a solvent molecule. Homology models of polypeptides can be prepared by one of ordinary skill in the art, for example, using commercially available software. Alternatively, methods known to those of ordinary skill in the art, such as X-ray crystallography, may be utilized. The amino acid residues that can be exposed on the surface can be determined, for example, using the coordinates of a three-dimensional model using a computer program such as the InsightII program (Accelrys). The location of the exposed surface can be determined using algorithms known in the art (e.g., Lee and Richards (J. Mol. Biol. 55:379-400 (1971)); Connolly (J. Appl. Cryst. 16:548 -558 (1983)). The position of the exposed surface can be determined using software suitable for protein models and three-dimensional structural information. Software that can be used for this type of use includes, for example, SYBYL Biopolymer Module software (Tripos Associates). When the algorithm requires the user to input size parameters, the "size" of the probe (probe) used for measurement can be set to a radius of about 1.4 Angstroms (Å) or less. In addition, the use of personal computer software to determine the exposure The method of the area of the surface has been described in Pacios (Comput. Chem.18 (4): 377-386 (1994); J. Mol. Model. 1: 46-53 (1995)). Based on the above information, located in Appropriate amino acid residues on the surface of the polypeptide constituting the variant Fc region can be selected.
[0258] In some specific embodiments, the polypeptide comprises a variant Fc region as well as an antigen binding domain. In yet other embodiments, the antigen is a soluble antigen. In one embodiment, the antigen is present in a biological fluid (eg, plasma, interstitial fluid, lymph, ascites, and pleural fluid) of the subject. The antigen may also be a membrane antigen.
[0259] In yet other embodiments, the antigen binding activity of the antigen binding domain is altered according to ion concentration conditions. In one embodiment, the ion concentration is not particularly limited, and refers to hydrogen ion concentration (pH) or metal ion concentration. Herein, metal ions refer to ions of group I elements other than hydrogen, such as alkali metals and copper (copper) group elements, group II elements such as alkaline earth metals and zinc group elements, group III elements other than boron, Group IV elements other than carbon and silicon, group VIII elements such as iron group and platinum group elements, elements belonging to subgroup A of groups V, VI and VII, and metal elements such as antimony, bismuth and polonium. In the present invention, metal ions include, for example, calcium ions, as described in WO 2012 / 073992 and WO 2013 / 125667. In one embodiment, the "ion concentration condition" may be a condition focusing on the difference in biological behavior of the antigen-binding domain between low ion concentration and high ion concentration. In addition, "the antigen-binding activity of the antigen-binding domain is changed according to ion concentration conditions" means that the antigen-binding activity of the antigen-binding domain is changed between low ion concentration and high ion concentration (for example, the antigen-binding domain is referred to as "ion concentration" herein). Concentration-dependent antigen-binding domain"). The antigen-binding activity of an antigen-binding domain may be higher (stronger) or lower (weaker) under conditions of high ion concentration than under conditions of low ion concentration. In one embodiment, the ion concentration-dependent antigen-binding domain (such as pH-dependent antigen-binding domain or calcium ion concentration-dependent antigen-binding domain) can be obtained by conventional methods, for example, such as WO 2009 / 125825, WO 2012 / 073992 and described in WO 2013 / 046722.
[0260] In the present invention, the antigen-binding activity of the antigen-binding domain may be higher under high calcium ion concentration conditions than under low calcium ion concentration conditions. The high calcium ion concentration is not particularly limited, but can be selected from between 100 μM and 10 mM, between 200 μM and 5 mM, between 400 μM and 3 mM, between 200 μM and 2 mM, between 400 μM and 1 mM, or between 500 μM and 2.5 mM It is preferably close to the plasma (blood) concentration of calcium ion in vivo. Meanwhile, the low calcium ion concentration is not particularly limited, but may be selected from between 0.1 μM and 30 μM, between 0.2 μM and 20 μM, between 0.5 μM and 10 μM, between 1 μM and 5 μM, or between 2 μM and 4 μM The concentration is preferably close to the concentration of calcium ions in the early endosome in vivo.
[0261] In one embodiment, the ratio of antibody binding activity under conditions of low calcium ion concentration and high calcium ion concentration is not particularly limited, but the dissociation constant (KD) under low calcium ion concentration conditions is higher than that of high calcium ion concentration The ratio of KD under ion concentration conditions, ie, KD (low calcium ion concentration condition) / KD (high calcium ion concentration condition), is 2 or more, 10 or more, or 40 or more. The upper limit of the ratio may be 400, 1000 or 10000, as long as the antigen-binding domain can be produced by techniques known to those skilled in the art. Alternatively, for example, a dissociation rate constant (kd) can be used instead of KD. In this case, the ratio of kd under the condition of low calcium ion concentration to kd under the condition of high calcium ion concentration, that is, kd(low calcium ion concentration condition) / kd(high calcium ion concentration condition), is 2 or more Large, 5 or greater, 10 or greater, or 30 or greater. The upper limit of the ratio may be 50, 100, or 200 as long as the antigen-binding domain can be produced based on the technical common sense of those having ordinary knowledge in the art.
[0262] In the present invention, the antigen-binding activity of the antigen-binding domain may be higher at a low hydrogen ion concentration (neutral pH) than at a high hydrogen ion concentration (acidic pH). The acidic pH can be, for example, selected from pH 4.0 to pH 6.5, selected from pH 4.5 to pH 6.5, selected from pH 5.0 to pH 6.5, or selected from pH 5.5 to pH 6.5. 5, which is preferably close to the in vivo pH of early endosomes. An acidic pH may also be, for example, pH 5.8 or pH 6.0. In some specific embodiments, the acidic pH is pH 5.8. Meanwhile, the neutral pH can be, for example, selected from pH 6.7 to pH 10.0, selected from pH 6.7 to pH 9.5, selected from pH 7.0 to pH 9.0, or selected from pH 7 .0 to pH 8.0, which is preferably close to the in vivo pH in plasma (blood). Neutral pH can also be, for example, pH 7.4 or pH 7.0. In some specific embodiments, the neutral pH is pH 7.4.
[0263] In one embodiment, the ratio of antibody binding activity under acidic pH conditions to neutral pH conditions is not limited, but the dissociation constant (KD) under acidic pH conditions is higher than the KD under neutral pH conditions The ratio, ie, KD (acidic pH condition) / KD (neutral pH condition), is 2 or greater, 10 or greater, or 40 or greater. The upper limit of the ratio may be 400, 1000 or 10000, as long as the antigen-binding domain can be produced by techniques known to those skilled in the art. Alternatively, for example, a dissociation rate constant (kd) can be used instead of KD. In this case, the ratio of kd at acidic pH to kd at neutral pH, i.e., kd(acidic pH) / kd(neutral pH), is 2 or more, 5 or more , 10 or greater, or 30 or greater. The upper limit of the ratio may be 50, 100, or 200 as long as the antigen-binding domain can be produced based on the technical common sense of those having ordinary knowledge in the art.
[0264] In one embodiment, for example, at least one amino acid residue is substituted with an amino acid residue having a side chain pKa of 4.0-8.0, and / or at least one amine having a side chain pKa of 4.0-8.0 The amino acid is inserted into the antibody binding domain as described in WO 2009 / 125825. Amino acids can be substituted and / or inserted at any position as long as the antigen-binding activity of the antigen-binding domain becomes weaker at acidic pH than at neutral pH compared to before the substitution or insertion. When the antigen binding domain has a variable region or CDR, the position may be within the variable region or CDR. The number of amino acids to be substituted or inserted can be appropriately determined by known methods; and the number can be one or more. Amino acids having a side chain pKa of 4.0-8.0 can be used to alter the antigen-binding activity of the antigen-binding domain, depending on the hydrogen ion concentration conditions. Such amino acids include, for example, neutral amino acids such as His (H) and Glu (E), and non-neutral amino acids such as histidine analogs (US2009 / 0035836), m-NO2-Tyr ( pKa 7.45), 3,5-Br2-Tyr (pKa 7.21) and 3,5-I2-Tyr (pKa 7.38) (Heyl et al., Bioorg. Med. Chem. 11(17):3761-3768 (2003)) . Amino acids having a side chain pKa of 6.0-7.0, including, for example, His(H), may also be used.
[0265] In another embodiment, for the variant Fc region with increased pI, the preferred antigen binding domain has been described and can be obtained by the methods described in Japanese Patent Application Nos. JP2015-021371 and JP2015-185254.
[0266] In some specific embodiments, the variant Fc region with increased pi comprises at least two amino acid modifications at least two selected from: 285, 311, 312, 315, 318, 333, 335, The position of the group consisting of 337, 341, 342, 343, 384, 385, 388, 390, 399, 400, 401, 402, 413, 420, 422 and 431, according to the EU number.
[0267] In yet other embodiments, the variant Fc region with increased pi comprises at least two amino acid modifications at least two selected from: 311, 341, 343, 384, 399, 400, 401, The position of the group formed by 402 and 413, according to the EU number.
[0268] In another aspect, the invention provides a polypeptide comprising a variant Fc region with increased pI comprising the amino acid modification of any of the following (1)-(10): (1) positions 311 and 341 (2) Positions 311 and 343; (3) Positions 311, 343 and 413; (4) Positions 311, 384 and 413; (5) Positions 311 and 399; (6) Positions 311 and 401; (7) Position 311 and 413; (8) positions 400 and 413; (9) positions 401 and 413; and (10) positions 402 and 413, according to EU numbering.
[0269] The pi of a protein can be increased, for example, by reducing the number of amino acids with negatively charged side chains (e.g., aspartic acid and glutamic acid) and / or increasing the number of amine groups with positively charged side chains Acid quantities (eg, arginine, lysine, and histidine) at neutral pH conditions. Amino acids with negatively charged side chains have a negative charge, denoted -1, at pH conditions well above the pKa of their side chains, a theory well known to those of ordinary skill in the art. For example, the theoretical pKa of the side chain of aspartic acid is 3.9, and the side chain has a negative charge represented as -1 at neutral pH conditions (eg, in a solution at pH 7.0). Conversely, amino acids with positively charged side chains have a positive charge, expressed as +1, at pH conditions well below the pKa of their side chains. For example, the theoretical pKa of the side chain of arginine is 12.5, and the side chain has a positive charge denoted +1 at neutral pH conditions (eg, in a solution at pH 7.0). Meanwhile, amino acids with uncharged side chains at neutral pH (for example, in a solution at pH 7.0) are known to contain 15 neutral amino acids, namely, alanine, cysteine, amphetamine, acid, glycine, isoleucine, leucine, methionine, asparagine, proline, glutamine, serine, threonine, valine, tryptophan and tyrosine. Of course, it is understood that the pi increasing amino acid may be a non-neutral amino acid.
[0270] Following the foregoing, methods of increasing the pi of a protein at neutral pH conditions (e.g., in solution at pH 7.0) can confer a charge change of +1 on the protein of interest, e.g., by having side chains uncharged The amino acid substitution of aspartic acid or glutamic acid (whose side chain has a negative charge of -1) in the amino acid sequence of the protein. In addition, a charge change of +1 can be imparted to the protein, for example, by substituting an amino acid with an uncharged side chain with arginine or lysine (whose side chain has a positive charge of +1). Furthermore, it is possible to simultaneously impart +2 to the protein by substituting arginine or lysine (whose side chain has a positive charge of +1) for aspartic acid or glutamic acid (whose side chain has a negative charge of -1). charge changes. Alternatively, in order to increase the pi of the protein, amino acids with uncharged side chains and / or preferably with positively charged side chains can be added or inserted into the amino acid sequence of the protein, or with Amino acids with uncharged side chains and / or preferably with negatively charged side chains can be deleted from the list of amino acids in the protein. It is understood that, for example, the N-terminal and C-terminal amino acid residues of proteins have backbone-derived charges (NH3+ for the amine group at the N-terminus and carboxyl group at the C-terminus) in addition to their side-chain-derived charges. COO-). Therefore, the pi of the protein can also be increased by implementing some addition, deletion, substitution or insertion of functional groups derived from the main chain. Amino acid substitutions to increase pI include, for example, substitution of amino acids with negatively charged side chains with amino acids with uncharged side chains, substitution of side chains with amino acids with positively charged side chains Uncharged amino acids, and substitution of amino acids with positively charged side chains for amino acids with negatively charged side chains in the amino acid sequence of the parental Fc region, can be performed alone or in appropriate combinations.
[0272] Insertion or addition of amino acids to increase pi comprises, for example, insertion or addition of amino acids with uncharged side chains and / or insertion or addition of amino acids with positively charged side chains into the parental Fc region In the amino acid sequence, it can be carried out alone or in an appropriate combination.
[0273] Amino acid deletions to increase pI include, for example, deletion of amino acids with uncharged side chains and / or deletion of amino acids with negatively charged side chains in the amino acid sequence of the parental Fc region, They can be carried out alone or in appropriate combinations.
[0274] In one embodiment, the natural amino acids used to increase pi can be categorized as follows: (a) amino acids with negatively charged side chains can be Glu (E) or Asp (D); (b) Amino acids with uncharged side chains can be Ala (A), Asn (N), Cys (C), Gln (Q), Gly (G), His (H), Ile (I), Leu (L) , Met (M), Phe (F), Pro (P), Ser (S), Thr (T), Trp (W), Tyr (Y) or Val (V); and; (c) has a positively charged side The amino acid of the chain can be His (H), Lys (K) or Arg (R). In one embodiment, the modified amino acid is inserted or substituted with Lys (K) or Arg (R).
[0275] In another aspect, the invention provides an isolated polypeptide comprising a variant Fc region having enhanced FcγRIIb binding activity and increased pi. In some specific embodiments, the variant Fc region described herein comprises at least two amino acid modifications in the parental Fc region.
[0276] In one aspect, the invention provides a polypeptide comprising a variant Fc region with enhanced FcγRIIb binding activity and increased pI comprising at least three amino acid modifications comprising: (a) at least one amino acid modification , at least one selected from: 231, 232, 233, 234, 235, 236, 237, 238, 239, 264, 266, 267, 268, 271, 295, 298, 325, 326, 327, 328, 330 , 331, 332, 334, and 396, according to EU numbering; and (b) at least two amino acid modifications selected from at least two of: 285, 311, 312, 315, The position of the group consisting of 318, 333, 335, 337, 341, 342, 343, 384, 385, 388, 390, 399, 400, 401, 402, 413, 420, 422 and 431, according to the EU number.
[0277] In one aspect, the invention provides a polypeptide comprising a variant Fc region with enhanced FcγRIIb binding activity and increased pI, and comprising at least three amino acid modifications comprising: (a) at least one amino acid Modifications in at least one position selected from the group consisting of: 231, 232, 235, 236, 239, 268, 295, 298, 326, 330 and 396, according to EU numbering; and (b) at least two Amino acid modification at least two positions selected from the group consisting of: 311, 341, 343, 384, 399, 400, 401, 402 and 413, according to EU numbering.
[0278] In another aspect, the invention provides a polypeptide comprising a variant Fc region with enhanced FcγRIIb binding activity and increased pI, which includes the amino acid modification of any of the following (1)-(9):( 1) Locations 235, 236, 268, 295, 311, 326, 330, and 343; (2) Locations 236, 268, 295, 311, 326, 330, and 343; (3) Locations 236, 268, 295, 311, and 330 and 413; (4) positions 236, 268, 311, 330, 396 and 399; (5) positions 236, 268, 311, 330 and 343; (6) positions 236, 268, 311, 330, 343 and 413; ( 7) Positions 236, 268, 311, 330, 384, and 413; (8) Positions 236, 268, 311, 330, and 413; and (9) Positions 236, 268, 330, 396, 400, and 413, according to EU numbering. In some specific embodiments, FcγRIIb has the sequence of rhesus FcγRIIb (SEQ ID NO: 223). In some specific embodiments, FcyRIIb has the sequence of human FcyRIIb (eg, SEQ ID NO: 212, 213 or 214).
[0279] In one aspect, the invention provides a polypeptide comprising a variant Fc region with enhanced FcγRIIb binding activity and increased pI comprising at least three amino acid modifications comprising: (a) at least one amino acid modification , at least one position selected from the group consisting of: 234, 238, 250, 264, 267, 307 and 330, according to EU numbering; and (b) at least two amino acid modifications, which are at least two Choose from: 285, 311, 312, 315, 318, 333, 335, 337, 341, 342, 343, 384, 385, 388, 390, 399, 400, 401, 402, 413, 420, 422 and 431 The position of the formed group, according to the EU number. In yet other embodiments, the polypeptide comprises at least two amino acid modifications at at least two positions selected from the group consisting of: 311, 341, 343, 384, 399, 400, 401, 402, and 413 , according to the EU number. In some specific embodiments, FcγRIIb has the sequence of rhesus FcγRIIb (SEQ ID NO: 223). In some specific embodiments, FcyRIIb has the sequence of human FcyRIIb (eg, SEQ ID NO: 212, 213 or 214).
[0280] In another aspect, the invention provides a polypeptide comprising a variant Fc region with enhanced FcγRIIb binding activity and increased pI, which includes the amino acid modification of any of the following (1)-(16): ( 1) Locations 234, 238, 250, 264, 307, 311, 330, and 343; (2) Locations 234, 238, 250, 264, 307, 311, 330, and 413; (3) Locations 234, 238, 250, and 264 , 267, 307, 311, 330 and 343; (4) positions 234, 238, 250, 264, 267, 307, 311, 330 and 413; (5) positions 234, 238, 250, 267, 307, 311, 330 and 343; (6) positions 234, 238, 250, 267, 307, 311, 330 and 413; (7) positions 234, 238, 250, 307, 311, 330 and 343; (8) positions 234, 238, 250 , 307, 311, 330 and 413; (9) positions 238, 250, 264, 267, 307, 311, 330 and 343; (10) positions 238, 250, 264, 267, 307, 311, 330 and 413; ( 11) Locations 238, 250, 264, 307, 311, 330 and 343; (12) Locations 238, 250, 264, 307, 311, 330 and 413; (13) Locations 238, 250, 267, 307, 311, 330 and 343; (14) positions 238, 250, 267, 307, 311, 330 and 413; (15) positions 238, 250, 307, 311, 330 and 343; and (16) positions 238, 250, 307, 311, 330 and 413, according to the EU number.
[0281] In yet another embodiment, the variant Fc region comprises amino acid modifications selected from any one of a single modification, a combination of single modifications, or a combination of modifications as described in Tables 14-30.
[0282] In some embodiments, the polypeptide comprises a variant Fc region of the invention. In yet another embodiment, the polypeptide is an antibody heavy chain constant region. In yet another embodiment, the polypeptide is an antibody heavy chain. In yet another embodiment, the polypeptide is an antibody. In yet another embodiment, the polypeptide is an Fc fusion protein.
[0283] In yet another embodiment, the invention provides a polypeptide comprising the amino acid sequence of any one of SEQ ID NO: 229-381.
[0284] As used herein, "parental Fc region" refers to the Fc region prior to the introduction of the amino acid modifications described herein. Examples of preferred parental Fc regions include those derived from natural antibodies. Antibodies include, for example, IgA (IgA1, IgA2), IgD, IgE, IgG (IgG1, IgG2, IgG3, IgG4), IgM, and the like. Antibodies can be derived from humans or monkeys (eg, rhesus monkeys, rhesus monkeys, marmosets, chimpanzees, or baboons). Natural antibodies may also contain naturally occurring mutations. Many IgG heterotypic sequences resulting from genetic allotypes have been described in "Sequences of Proteins of Immunological Interest," NIH Publication No. 91-3242, and any of them may be used in the present invention. In particular, for human IgG1, the amino acid sequence at positions 356 to 358 (EU numbering) may be DEL or EEM. Preferred examples of parental Fc regions include those derived from human IgG1 (SEQ ID NO: 195), human IgG2 (SEQ ID NO: 196), human IgG3 (SEQ ID NO: 197) and human IgG4 (SEQ ID NO: 198). Fc region of heavy chain constant region. Another preferred example of the parental Fc region is the Fc region derived from the heavy chain constant region SG1 (SEQ ID NO: 9). In addition, the parental Fc region may be an Fc region manufactured by adding amino acid modifications other than those described herein to an Fc region derived from a natural antibody.
[0285] In addition, amino acid modifications for other purposes may be incorporated in the variant Fc regions described herein. For example, amino acid substitutions that improve FcRn-binding activity can be added (Hinton et al., J. Immunol. 176(1):346-356 (2006); Dall'Acqua et al., J. Biol. Chem.281(33) :23514-23524 (2006); Petkova et al., Intl. Immunol. 18(12):1759-1769 (2006); Zalevsky et al., Nat. Biotechnol.28(2):157-159 (2010); WO 2006 / 019447; WO 2006 / 053301; and WO 2009 / 086320), and amino acid substitutions to improve antibody heterogeneity or stability (WO 2009 / 041613). Alternatively, the polypeptides described in WO 2011 / 122011, WO 2012 / 132067, WO 2013 / 046704 or WO 2013 / 180201 that have the property of enhancing antigen clearance can be combined with the polypeptides described in WO 2013 / 180200 that specifically bind to Polypeptides characteristic of the target tissue, polypeptides that have been described in WO 2009 / 125825, WO 2012 / 073992 or WO 2013 / 047752 and have the characteristic of repeatedly binding to multiple antigen molecules, bind to the variant Fc region described herein. Alternatively, for the purpose of imparting other antigen-binding capabilities, the amino acid modifications disclosed in EP1752471 and EP1772465 can be incorporated into CH3 of the variant Fc region described herein. Alternatively, amino acid modifications that lower the pi of the constant region (WO 2012 / 016227) can be incorporated into the variant Fc region described herein with the aim of increasing plasma retention. Alternatively, for the purpose of improving cellular uptake, amino acid modifications (WO 2014 / 145159) that increase the pi of the constant region can be incorporated into the variant Fc region described herein. Alternatively, amino acid modifications that increase the pi of the constant region (Japanese Patent Application Nos. JP2015-021371 and JP2015-185254) can be incorporated into the variant Fc region described herein for the purpose of enhancing the elimination of target molecules from plasma. In one embodiment, such modification may comprise, for example, a substitution at at least one position selected from the group consisting of 311, 343, 384, 399, 400, and 413, according to EU numbering. In yet another embodiment, such substitutions may be Lys or Arg substitutions for amino acids at each position.
[0286] Amino acid modifications that enhance human FcRn binding activity at acidic pH may also be incorporated in the variant Fc regions described herein. Specifically, such modifications may comprise, for example, substitution of Met at position 428 with Leu and Asn at position 434 with Ser, according to EU numbering (Zalevsky et al., Nat. Biotechnol. 28:157-159 (2010) ); substitution of Asn at position 434 with Ala (Deng et al., Metab. Dispos. 38(4):600-605 (2010)); substitution of Met at position 252 with Tyr, substitution of Ser at position 254 with Thr and Glu at position 256 for Thr (Dall'Acqua et al., J. Biol. Chem. 281:23514-23524 (2006)); Gln for Thr at position 250 and Leu for Met at position 428 (Hinton et al., J. Immunol.176(1):346-356 (2006)); replace Asn at position 434 with His (Zheng et al., Clin. Pharmacol. Ther. 89(2):283-290 (2011) , and WO 2010 / 106180, WO 2010 / 045193, WO 2009 / 058492, WO 2008 / 022152, WO 2006 / 050166, WO 2006 / 053301, WO 2006 / 031370, WO 2005 / 123780, WO 2005 / 047327, WO 2005 / 037867, the modifications described in WO 2004 / 035752 or WO 2002 / 060919. Such modifications may comprise, for example, at least one selected from: substituting Leu for Met at position 428, substituting Ala for Asn at position 434 and Modifications of the group consisting of Thr substitution of Tyr at position 436. Those modifications may further comprise substitution of Arg for Gln at position 438 and / or substitution of Glu for Ser at position 440 (Japanese Patent Application Nos. JP2015-021371 and JP2015- 185254).
[0287] Two or more polypeptides comprising a variant Fc region described herein can be contained in one molecule, wherein the two polypeptides comprising a variant Fc region are associated, much like an antibody. The type of antibody is not limited, and IgA (IgA1, IgA2), IgD, IgE, IgG (IgG1, IgG2, IgG3, IgG4), IgM, and the like can be used.
[0288] The two combined polypeptides comprising a variant Fc region may be a polypeptide comprising a variant Fc region into which the same amino acid modification has been introduced (hereinafter referred to as a homologous variant Fc region), or a polypeptide comprising a variant Fc region into which a different amino acid modification has been introduced. A polypeptide of a variant Fc region, or a polypeptide comprising a variant Fc region into which only one of the amino acid modifications is introduced (hereinafter referred to as a heterologous polypeptide comprising a variant Fc region). One of the preferred amino acid modifications is a modification in the loop configuration from position 233 to 239 (EU numbering) in the CH2 domain of the Fc region, which is involved in binding to FcyRIIb and FcyRIIa. Preferably, the modification is introduced in the loop configuration of the CH2 domain of one of the Fc regions that enhances FcγRIIb binding activity and / or selectivity, while another modification is introduced in the other Fc region that destabilizes it In the ring configuration of the CH2 domain. An example of an amino acid modification that can destabilize the ring structure of the CH2 domain is the substitution of at least one amino acid selected from positions 235, 236, 237, 238 and 239 with other amino acids. Specifically, destabilization can be achieved by, for example, modifying the amino acid at position 235 to Asp, Gln, Glu, or Thr, modifying the amino acid at position 236 to Asn, modifying the amino acid at position 237 to Amended to Phe or Trp, amino acid at position 238 to Glu, Gly or Asn, and amino acid at position 239 to Asp or Glu, according to EU numbering.
[0289] Regarding the binding of heterologous polypeptides comprising variant Fc regions, techniques for inhibiting unintended binding of homologous polypeptides comprising variant Fc regions can be employed by introducing electrostatic repulsion to the CH2 or CH3 domains of the Fc region interface, as described in WO 2006 / 106905.
[0290] For example, the amino acid residues in contact with the interface of the CH2 or CH3 domain of the Fc region include the residue at position 356 (EU numbering) in the CH3 domain, the residue at position 439 (EU numbering), the residue at position The residue at position 357 (EU numbering), the residue at position 370 (EU numbering), the residue at position 399 (EU numbering), and the residue at position 409 (EU numbering).
[0291] More specifically, for example, an Fc region can be produced in which one to three pairs of amino acid residues having the same charge are selected from (1) to (3) as shown below: (1) in the CH3 domain Amino acid residues at positions 356 and 439 (EU numbering); (2) amino acid residues at positions 357 and 370 in the CH3 domain (EU numbering); and (3) amino acid residues at positions 399 and 409 in the CH3 domain Amino acid residues (EU numbering).
[0292] In addition, heterologous polypeptides comprising variant Fc regions can be produced in which one to three pairs of amino acid residues selected from (1) to (3) above have the same charge in the CH3 domain of the first Fc region , the pair of amino acid residues selected from the aforementioned first Fc region also have the same charge in the CH3 domain of the second Fc region, but the charges in the first and second Fc regions are opposite. In the above-mentioned Fc region, for example, negatively charged amino acid residues are preferably selected from glutamic acid (E) and aspartic acid (D), and positively charged amino acid residues are preferably selected from glutamic acid (E) and aspartic acid (D). Selected from Lysine (K), Arginine (R) and Histidine (H).
[0294] Other known techniques may additionally be used for conjugation of heterologous polypeptides comprising variant Fc regions. Specifically, this technique works by replacing the side chains of amino acids present in one of the Fc regions with larger side chains (knobs; which stand for "bumps"), and with smaller ones. Side chains (holes; which represent cavities) replace amino acid side chains present in the Fc region to place the knobs within the holes. This can promote efficient binding between Fc region-containing polypeptides (Fc region-containing polypeptides) having different amino acid sequences from each other (WO 1996 / 027011; Ridgway et al., Prot. Eng. 9:617-621 (1996) ; Merchant et al., Nat. Biotech. 16, 677-681 (1998)).
[0295] In addition, other known techniques may also be used for heterologous conjugation of polypeptides comprising variant Fc regions. Strand-exchange engineered domain CH3 heterodimers (Davis et al., Prot. Eng. Des. & Sel., 23:195-202 (2010)) can be used to efficiently induce peptide binding. This technique can also be used to efficiently induce binding between variant Fc region-containing polypeptides with different amino acid sequences.
[0296] In addition, the heterodimeric antibody production technology utilizing the binding of antibodies CH1 and CL and the binding of VH and VL as described in WO 2011 / 028952 can also be used.
[0297] As described in WO 2008 / 119353 and WO 2011 / 131746, using the method of producing two homodimeric antibodies in advance, culturing the antibodies under reducing conditions to separate them, and allowing them to recombine Polymeric antibody techniques are also possible.
[0298] As in the method described in Strop (J. Mol. Biol. 420:204-219 (2012)), use is made by introducing charged residues such as Lys, Arg, Glu and Asp so that electrostatic repulsion is introduced in Techniques for making heterodimeric antibodies in the CH3 domain are also possible.
[0299] Furthermore, it is also possible to use techniques for making heterodimeric antibodies modified by addition of CH2 and CH3 domains, as described in WO 2012 / 058768.
[0300] When simultaneously expressing two polypeptides including variant Fc regions having different amino acid sequences, in order to produce a polypeptide including heterologous variant Fc regions, a polypeptide including homologous variant Fc regions is usually also produced as an impurity. In this case, polypeptides including heterologous variant Fc regions can be efficiently obtained by isolating and purifying them from polypeptides comprising homologous variant Fc regions using known techniques. A method for efficiently isolating and purifying heterodimeric antibodies from homodimeric antibodies using ion-exchange chromatography has been reported by introducing amino acid modifications in the variable regions of the heavy chains of the two antibodies to create homodimeric antibodies. Differences in isoelectric points between polyantibodies and heterodimeric antibodies (WO 2007 / 114325). Another method for purifying heterodimeric antibodies using Protein A chromatography has been reported, by creating heterodimeric antibodies that include proteins derived from mouse IgG2a that binds Protein A and rat IgG2b that does not bind Protein A (WO 1998 / 050431 and WO 1995 / 033844).
[0301] In addition, protein A chromatography can be used to replace amino acid residues at positions 435 and 436 (EU numbering) with amino acids such as Tyr or His, which are located at the Protein A binding position of the antibody heavy chain, to generate Different protein A binding affinity, and then effectively purify heterodimeric antibodies.
[0302] In the present invention, amino acid modification refers to any one or a combination of substitution, deletion, addition, insertion and modification. In the present invention, amino acid modification can be rewritten as amino acid mutation.
[0303] When substituting amino acid residues, substitutions of different amino acid residues can be carried out, with the aim of changing aspects as described in (a)-(c) below: (a) in sheet or helix Polypeptide backbone structure in structural regions; (b) charge or hydrophobicity at target locations; or (c) size of side chains.
[0304] According to their general side chain properties, amino acid residues are classified into the following groups: (a) hydrophobic: Norleucine, Met, Ala, Val, Leu, and Ile; (b) neutral hydrophilic : Cys, Ser, Thr, Asn and Gln; (c) acidic: Asp and Glu; (d) basic: His, Lys and Arg; (e) residues affecting chain orientation: Gly and Pro; and (f) Aromatic: Trp, Tyr and Phe.
[0305] Amino acid modifications are generated by various methods well known to those of ordinary skill in the art. Such methods include site-directed mutagenesis methods (Hashimoto-Gotoh et al., Gene 152:271-275 (1995); Zoller, Meth. Enzymol. 100:468-500 (1983); Kramer et al., Nucleic Acids Res. 12: 9441- 9456 (1984)); Kramer and Fritz, Methods Enzymol.154: 350-367 (1987); and Kunkel, Proc. Natl. Acad. Sci. USA 82:488-492 (1985)), PCR mutagenesis methods and cassettes mutation method, but not limited thereto.
[0306] The number of amino acid modifications introduced in the Fc region is not limited. In some specific embodiments, it can be 1, 2 or less, 3 or less, 4 or less, 5 or less, 6 or less, 8 or less, 10 or less, 12 or more Fewer, 14 or fewer, 16 or fewer, 18 or fewer, or 20 or fewer.
[0307] Amino acid modifications include post-translational modifications. A specific post-translational modification may be the addition or deletion of sugar chains. For example, the amino acid residue at position 297 (EU numbering) in the IgG1 constant region may be sugar chain modified. The modified sugar chain structure is not limited. For example, sialic acid can be added to sugar chains of the Fc region (MAbs 2010 Sep-Oct, 2(5): 519-527). In general, antibodies expressed in eukaryotic cells include glycosylation in the constant regions. For example, it is known that some types of sugar chains are usually added to antibodies expressed in cells such as naturally occurring antibody-producing mammalian or eukaryotic cells transformed with an expression vector including DNA encoding the antibody of cells.
[0308] Eukaryotic cells referred to herein include yeast and animal cells. For example, CHO cells and HEK293 cells are representative animal cells used for transformation with expression vectors comprising DNA encoding antibodies. On the other hand, constant regions without glycation are also included in the present invention. Antibodies with unglycosylated constant regions can be obtained by expressing the gene encoding the antibody in prokaryotic cells such as Escherichia coli.
[0309] In addition, polypeptides comprising the variant Fc region of the present invention can be chemically modified with various molecules, such as polyethylene glycol (PEG) and cytotoxic substances. Such methods of chemically modifying polypeptides are well established in the art.
[0310] In one aspect, the invention provides an isolated polypeptide comprising a variant Fc region having enhanced FcγRIIb binding activity. In some aspects, the polypeptide is an antibody. In some aspects, the polypeptide is an Fc fusion protein. In some specific embodiments, the antibody is a chimeric antibody or a humanized antibody. The source of the antibody is not particularly limited, but includes, for example, human antibodies, mouse antibodies, rat antibodies, and rabbit antibodies. In some aspects, the polypeptide is an Fc fusion protein.
[0311] The variable regions of antibodies comprising the variant Fc regions provided herein and the protein binding motifs of Fc fusion proteins comprising the variant Fc regions can recognize either antigen. Examples of antigens that can be bound by such antibodies and fusion proteins include, but are not limited to, ligands (cytokines, chemokines, etc.), receptors, cancer antigens MHC antigens, differentiation antigens, immunoglobulins and, in part, immunoglobulins immune complexes.
[0312] Examples of cytokines that can be bound by antibodies or fusion proteins comprising the inventive variant Fc regions and / or recombinantly fused to polypeptides comprising the disclosed variant Fc regions include, but are not limited to, interleukins 1 to 18, colonies Stimulatory factors (G-CSF, M-CSF, GM-CSF, etc.), interferons (IFN-α, IFN-β, IFN-γ, etc.), growth factors (EGF, FGF, IGF, NGF, PDGF, TGF, HGF etc.), tumor necrosis factor (TNF-α and TNF-β), lymphotoxin, erythropoietin, receptor, SCF, TPO, MCAF and BMP.
[0313] Examples of chemokines that can be bound by antibodies or fusion proteins comprising the inventive variant Fc region and / or recombinantly fused to a polypeptide comprising the disclosed variant Fc region include, but are not limited to, CC chemokines such as CCL1 to CCL28, CXC chemokines such as CXCL1 to CXCL17, C chemokines such as XCL1 to XCL2, and CX3C chemokines such as CX3CL1.
[0314] Examples of receptors that can be bound by an antibody or fusion protein comprising the inventive variant Fc region and / or recombinantly fused to a polypeptide comprising the disclosed variant Fc region include, but are not limited to, those belonging to the receptor family, e.g., hematopoietic Growth factor receptor family, cytokine receptor family, tyrosine kinase receptor family, serine / threonine kinase receptor family, TNF receptor family, G protein-coupled receptor family, GPI-anchored receptor family receptor family, tyrosine phosphatase-type receptor family, cohesion factor family and hormone receptor family, receptors. Receptors belonging to these receptor families and their properties have been described in many documents, for example, Cooke ed., New Comprehensive Biochemistry Vol.18B "Hormones and their Actions Part II" pp.1-46 (1988) Elsevier Science Publishers BV ; Patthy (Cell61(1):13-14 (1990)); Ullrich (Cell61(2):203-212 (1990)); Massagué (Cell69(6):1067-1070 (1992)); Miyajima et al. ( Annu. Rev. Immunol.10:295-331 (1992)); Taga et al. (FASEB J.6:3387-3396 (1992)); Fantl et al. (Annu. Rev. Biochem.62:453-481 (1993 )); Smith et al. (Cell76(6):959-962 (1994)); and Flower (Biochim. Biophys. Acta1422(3): 207-234 (1999)).
[0315] Examples of specific receptors belonging to the above receptor families include the human or mouse erythropoietin (EPO) receptor (Jones et al., Blood 76(1):31-35 (1990); D'Andrea et al., Cell 57 (2):277-285 (1989)), human or mouse granule colony stimulating factor (G-CSF) receptor (Fukunaga et al., Proc. Natl. Acad. Sci. USA87(22):8702-8706 (1990 ), mG-CSFR; Fukunaga et al., Cell61(2): 341-350 (1990)), human or mouse thrombopoietin (TPO) receptor (Vigon et al., Proc. Natl. Acad. Sci. USA. 89 (12):5640-5644 (1992); Skoda et al., EMBO J.12(7):2645-2653 (1993)), human or mouse insulin receptor (Ullrich et al., Nature 313(6005):756-761 (1985)), human or mouse Flt-3 ligand receptor (Small et al., Proc. Natl. Acad. Sci. USA.91 (2): 459-463 (1994)), human or mouse platelet-derived growth factor (PDGF) receptors (Gronwald et al., Proc. Natl. Acad. Sci. USA. 85(10):3435-3439 (1988)), human or mouse interferon (IFN)-α and β receptors (Uze et al. Human, Cell60(2):225-234 (1990); Novick et al., Cell77(3):391-400 (1994)), human or mouse leptin receptor, human or mouse growth hormone (GH) receptor , human or mouse interleukin (IL)-10 receptor, human or mouse insulin-like growth factor (IGF)-I receptor, human or mouse leukemia inhibitory factor (LIF) receptor, and human or mouse ciliary neurotrophic factor (CNTF) receptor.
[0316] Cancer antigens are antigens that express cells that become malignant, and they are also called tumor-specific antigens. Abnormal sugar chains that appear on the cell surface or on protein molecules when cells become cancerous are also cancer antigens, and they are also called sugar chain cancer antigens. Examples of cancer antigens that can be bound by an antibody or fusion protein comprising an inventive variant Fc region include, but are not limited to, GPC3, a receptor belonging to the GPI-anchored receptor family described above and also expressed in many cancers, including liver cancer (Midorikawa et al., Int. J. Cancer 103(4):455-465 (2003)), and EpCAM, which is expressed in many cancers, including lung cancer (Linnenbach et al., Proc. Natl. Acad. Sci. USA86(1 ):27-31 (1989)), CA19-9, CA15-3 and sialic acid SSEA-1 (SLX).
[0317] MHC antigens are broadly classified into MHC class I antigens and MHC class II antigens. MHC class I antigens include HLA-A, -B, -C, -E, -F, -G, and -H, while MHC class II antigens include HLA-DR, -DQ, and -DP.
[0318] Examples of differentiation antigens that can be bound by an antibody or fusion protein comprising the inventive variant Fc region and / or recombinantly fused to a polypeptide comprising the disclosed variant Fc region include, but are not limited to, CD1, CD2, CD4, CD5, CD6, CD7, CD8, CD10, CD11a, CD11b, CD11c, CD13, CD14, CD15s, CD16, CD18, CD19, CD20, CD21, CD23, CD25, CD28, CD29, CD30, CD32, CD33, CD34, CD35, CD38, CD40, CD41a, CD41b, CD42a, CD42b, CD43, CD44, CD45, CD45RO, CD48, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD51, CD54, CD55, CD56, CD57, CD58, CD61, CD62E, CD62L, CD62P, CD64, CD69, CD71, CD73, CD95, CD102, CD106, CD122, CD126, and CDwl30.
[0319] Immunoglobulins include IgA, IgM, IgD, IgG and IgE. Immunological compounds comprise at least any immunoglobulin component.
[0320] Other examples of antigens that can be bound by an antibody or fusion protein comprising the inventive variant Fc region and / or recombinantly fused to a polypeptide comprising the disclosed variant Fc region include, but are not limited to, 17-IA, 4-1BB, 4Dc, 6-keto-PGF1a, 8-iso-PGF2a, 8-oxo-dG, A1 adenosine receptor, A33, ACE, ACE-2, Activin, Activin A, Activin AB, Activin B , Activin C, Activin RIA, Activin RIA ALK-2, Activin RIB ALK-4, Activin RIIA, Activin RIIB, ADAM, ADAM10, ADAM12, ADAM15, ADAM17 / TACE, ADAM8, ADAM9, ADAMTS, ADAMTS4 , ADAMTS5, addressin, aFGF, ALCAM, ALK, ALK-1, ALK-7, α-1-antitrypsin, α-V / β-1 antagonist, ANG, Ang, APAF-1, APE, APJ, APP, APRIL, AR, ARC, ART, artesunate (artemin), anti-Id, ASPARTIC, atrial natriuretic peptide, av / b3 integrin, Axl, b2M, B7-1, B7-2, B7-H, B-lymphocyte stimulating factor (BlyS), BACE, BACE-1, Bad, BAFF, BAFF-R, Bag-1, BAK, Bax, BCA-1, BCAM, Bcl, BCMA, BDNF, b- ECGF, bFGF, BID, Bik, BIM, BLC, BL-CAM, BLK, BMP, BMP-2 BMP-2a, BMP-3 Osteogenin, BMP-4, BMP-2b, BMP-5, BMP-6 Vgr-1 , BMP-7 (OP-1), BMP-8 (BMP-8a, OP-2), BMPR, BMPR-IA (ALK-3), BMPR-IB (ALK-6), BRK-2, RPK-1 , BMPR-II (BRK-3), BMP, b-NGF, BOK, bombesin, bone-derived trophic factor, BPDE, BPDE-DNA, BTC, complement factor 3 (C3), C3a, C4, C5, C5a, C10, CA125, CAD-8, calcistatin, cAMP, carcinoembryonic antigen (CEA), cancer-associated antigen, cytolytic enzyme A, cytolytic enzyme B, cytolytic enzyme C / DPPI, cell Autolytic enzyme D, cellular autolytic enzyme E, cellular autolytic enzyme H, cellular autolytic enzyme L, cellular autolytic enzyme O, cellular autolytic enzyme S, cellular autolytic enzyme V, cellular autolytic enzyme X / Z / P , CBL, CCI, CCK2, CCL, CCL1, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3 , CCL4, CCL5, CCL6, CCL7, CCL8, CCL9 / 10, CCR, CCR1, CCR10, CCR11, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CD1, CD2, CD3, CD3E, CD4, CD5 , CD6, CD7, CD8, CD10, CD11a, CD11b, CD11c, CD13, CD14, CD15, CD16, CD18, CD19, CD20, CD21, CD22, CD23, CD25, CD27L, CD28, CD29, CD30, CD30L, CD32, CD33 (p67 protein), CD34, CD38, CD40, CD40L, CD44, CD45, CD46, CD49a, CD52, CD54, CD55, CD56, CD61, CD64, CD66e, CD74, CD80 (B7-1), CD89, CD95, CD123, CD137, CD138, CD140a, CD146, CD147, CD148, CD152, CD164, CEACAM5, CFTR, cGMP, CINC, Botulinum toxin, Clostridium perfringens, CKb8-1, CLC, CMV, CMV UL, CNTF, CNTN-1, COX, C-Ret, CRG-2, CT-1, CTACK, CTGF, CTLA-4, CX3CL1, CX3CR1, CXCL, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCR, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, cytokeratin tumor-associated antigen, DAN, DCC, DcR3, DC-SIGN, complement regulator (decay acceleration factor), go(1-3)-IGF-I (brain IGF-1), Dhh, digoxin (digoxin), DNAM-1, DNase, Dpp, DPPIV / CD26, Dtk, ECAD, EDA, EDA- A1, EDA-A2, EDAR, EGF, EGFR (ErbB-1), EMA, EMMPRIN, ENA, endothelin receptor, enkephalinase, eNOS, Eot, eotaxin 1, EpCAM, liver Ephrin B2 / EphB4, EPO, ERCC, E-selectin, ET-1, Factor IIa, Factor VII, Factor VIIIc, Factor IX, Fibroblast Activation Protein (FAP), Fas, FcR1, FEN- 1. Ferritin, FGF, FGF-19, FGF-2, FGF3, FGF-8, FGFR, FGFR-3, fibrin, FL, FLIP, Flt-3, Flt-4, follicle stimulating hormone, irregular Fractalkine, FZD1, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD9, FZD10, G250, Gas6, GCP-2, GCSF, GD2, GD3, GDF, GDF-1, GDF-3 (Vgr -2), GDF-5 (BMP-14, CDMP-1), GDF-6 (BMP-13, CDMP-2), GDF-7 (BMP-12, CDMP-3), GDF8 (myostatin), GDF-9, GDF-15 (MIC-1), GDNF, GFAP, GFRa-1, GFR-α1, GFR-α2, GFR-α3, GITR, Glucagon, Glut4, Glycoprotein IIb / IIIa (GPIIb / IIIa ), GM-CSF, gp130, gp72, GRO, growth hormone releasing hormone, hapten (NP-cap or NIP-cap), HB-EGF, HCC, HCMV gB envelope glycoprotein, HCMV gH envelope glycoprotein, HCMV UL, Hematopoietic growth factor (HGF), Hep B gp120, heparanase, Her2, Her2 / neu (ErbB-2), Her3 (ErbB-3), Her4 (ErbB-4), herpes simplex virus (HSV), gB glycoprotein, HSV gD glycoprotein, HGFA, high molecular weight melanoma-associated antigen (HMW-MAA), HIV gp120, HIV IIIB gp 120 V3 loop, HLA, HLA-DR, HM1.24. HMFG PEM, HRG, Hrk, human cardiac myosin, human cytomegalovirus (HCMV), human growth hormone (HGH), HVEM, I-309, IAP, ICAM, ICAM-1, ICAM-3, ICE, ICOS, IFNg, Ig, IgA receptor, IgE, IGF, IGF binding protein, IGF-1R, IGFBP, IGF-I, IGF-II, IL, IL-1, IL-1R, IL-2, IL-2R, IL-4, IL-4R, IL-5, IL-5R, IL-6, IL-6R, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL- 18. IL-18R, IL-23, interferon (IFN)-α, IFN-β, IFN-γ, inhibin, iNOS, insulin A chain, insulin B chain, insulin-like growth factor 1, integrin α2, integrin Integrin α3, Integrin α4, Integrin α4 / β1, Integrin α4 / β7, Integrin α5 (α V), Integrin α5 / β1, Integrin α5 / β3, Integrin α6, Integrin β1, Integrin β2 , interferon gamma, IP-10, I-TAC, JE, kallikrein 2, kallikrein 5, kallikrein 6, kallikrein 11, kallikrein 12, kinin Kallikrein 14, Kallikrein 15, Kallikrein L1, Kallikrein L2, Kallikrein L3, Kallikrein L4, KC, KDR, Keratinocyte Growth Factor (KGF), Malemenin 5 , LAMP, LAP, LAP (TGF-1), latent TGF-1, latent TGF-1 bp1, LBP, LDGF, LECT2, lefty, Lewis-Y antigen, Lewis-Y related antigen, LFA-1, LFA- 3. Lfo, LIF, LIGHT, lipoprotein, LIX, LKN, Lptn, L-selection protein, LT-a, LT-b, LTB4, LTBP-1, lung surface, luteinizing hormone, lymphotoxin beta receptor, Mac-1, MAdCAM, MAG, MAP2, MARC, MCAM, MCK-2, MCP, M-CSF, MDC, Mer, METALLOPROTEASES, MGDF receptor, MGMT, MHC (HLA-DR), MIF, MIG, MIP, MIP -1-α, MK, MMAC1, MMP, MMP-1, MMP-10, MMP-11, MMP-12, MMP-13, MMP-14, MMP-15, MMP-2, MMP-24, MMP-3 , MMP-7, MMP-8, MMP-9, MPIF, Mpo, MSK, MSP, mucin (Muc1), MUC18, Mullerian inhibitory substance, Mug, MuSK, NAIP, NAP, NCAD, N-calcium Anenin, NCA 90, NCAM, neprilysin, neurotrophin-3, -4 or -6, neurturin, nerve growth factor (NGF), NGFR, NGF-β, nNOS, NO, NOS, Npn, NRG- 3. NT, NTN, OB, OGG1, OPG, OPN, OSM, OX40L, OX40R, p150, p95, PADPr, parathyroid hormone, PARC, PARP, PBR, PBSF, PCAD, P-cadherin, PCNA, PDGF, PDK-1, PECAM, PEM, PF4, PGE, PGF, PGI2, PGJ2, PIN, PLA2, placental alkaline phosphatase (PLAP), PIGF, PLP, PP14, proinsulin, prodilatin, protein C, PS, PSA , PSCA, prostate-specific membrane antigen (PSMA), PTEN, PTHrp, Ptk, PTN, R51, RANK, RANKL, RANTES, relaxin A chain, relaxin B chain, nephrin, respiratory fusion virus (RSV) F, RSV Fgp, Ret, Rheumatoid Factor, RLIP76, RPA2, RSK, S100, SCF / KL, SDF-1, Serine, Serum Albumin, sFRP-3, Shh, SIGIRR, SK-1, SLAM, SLPI, SMAC, SMDF, SMOH, SOD, SPARC, Stat, STEAP, STEAP-II, TACE, TACI, TAG-72 (tumor-associated glycoprotein-72), TARC, TCA-3, T-cell receptor (e.g., T- Cell receptor α / β), TdT, TECK, TEM1, TEM5, TEM7, TEM8, TERT, testicular PLAP alkaline phosphatase, TfR, TGF, TGF-α, TGF-β, TGF-β Pan-specific, TGF -βRI (ALK-5), TGF-βRII, TGF-βRIIb, TGF-βRIII, TGF-β1, TGF-β2, TGF-β3, TGF-β4, TGF-β5, Thrombin protease, Thymus Ck-1, Thyroid stimulation Hormone, Tie, TIMP, TIQ, Tissue Factor, TMEFF2, Tmpo, TMPRSS2, TNF, TNF-α, TNF-αβ, TNF-β2, TNFc, TNF-RI, TNF-RII, TNFRSF10A (TRAIL R1 Apo-2, DR4 ), TNFRSF10B (TRAIL R2 DR5, KILLER, TRICK-2A, TRICK-B), TNFRSF10C (TRAIL R3 DcR1, LIT, TRID), TNFRSF10D (TRAIL R4 DcR2, TRUNDD), TNFRSF11A (RANK ODF R, TRANCE R), TNFRSF11B (OPG OCIF, TR1), TNFRSF12 (TWEAK R FN14), TNFRSF13B (TACI), TNFRSF13C (BAFF R), TNFRSF14 (HVEM ATAR, HveA, LIGHT R, TR2), TNFRSF16 (NGFR p75NTR), TNFRSF17 (BCMA), TNFRSF18 (GITR AITR), TNFRSF19 (TROY TAJ, TRADE), TNFRSF19L (RELT), TNFRSF1A (TNF RI CD120a, p55-60), TNFRSF1B (TNF RII CD120b, p75-80), TNFRSF26 (TNFRH3), TNFRSF3 (LTbR TNF RIII , TNFC R), TNFRSF4 (OX40 ACT35, TXGP1 R), TNFRSF5 (CD40 p50), TNFRSF6 (Fas Apo-1, APT1, CD95), TNFRSF6B (DcR3 M68, TR6), TNFRSF7 (CD27), TNFRSF8 (CD30), TNFRSF9 (4-1BB CD137, ILA), TNFRSF21 (DR6), TNFRSF22 (DcTRAIL R2 TNFRH2), TNFRST23 (DcTRAIL R1 TNFRH1), TNFRSF25 (DR3 Apo-3, LARD, TR-3, TRAMP, WSL-1), TNFSF10 (TRAIL Apo-2 ligand, TL2), TNFSF11 (TRANCE / RANK ligand ODF, OPG ligand), TNFSF12 (TWEAK Apo-3 ligand, DR3 ligand), TNFSF13 (APRIL TALL2), TNFSF13B (BAFF BLYS, TALL1, THANK, TNFSF20), TNFSF14 (LIGHT HVEM ligand, LTg), TNFSF15 (TL1A / VEGI), TNFSF18 (GITR ligand AITR ligand, TL6), TNFSF1A (TNF-a Conectin, DIF, TNFSF2), TNFSF1B ( TNF-b LTa, TNFSF1), TNFSF3 (LTb TNFC, p33), TNFSF4 (OX4 ligand, gp34, TXGP1), TNFSF5 (CD40 ligand CD154, gp39, HIGM1, IMD3, TRAP), TNFSF6 (Fas ligand Apo- 1 ligand, APT1 ligand), TNFSF7 (CD27 ligand CD70), TNFSF8 (CD30 ligand CD153), TNFSF9 (4-1BB ligand CD137 ligand), TP-1, t-PA, Tpo, TRAIL, TRAIL R, TRAIL-R1, TRAIL-R2, TRANCE, transferrin receptor, TRF, Trk, TROP-2, TSG, TSLP, tumor-associated antigen CA125, tumor-associated antigen expression Lewis-Y-related carbohydrates, TWEAK, TXB2, Ung, uPAR, uPAR-1, urokinase, VCAM, VCAM-1, VECAD, VE-cadherin, VE-cadherin-2, VEFGR-1 (flt-1), VEGF, VEGFR, VEGFR-3 ( flt-4), VEGI, VIM, virus antigen, VLA, VLA-1, VLA-4, VNR integrin, von Willebrand factor, WIF-1, WNT1, WNT2, WNT2B / 13, WNT3 Aβ , CD81, CD97, CD98, DDR1, DKK1, EREG, Hsp90, IL-17 / IL-17R, IL-20 / IL-20R, oxidized LDL, PCSK9, prekallikrein, RON, TMEM16F, SOD1 , stained granulin A, stained granulin B, tau, VAP1, high molecular weight kininogen, IL-31, IL-31R, Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1 .6, Nav1.7, Nav1.8, Nav1.9, EPCR, C1, C1q, C1r, C1s, C2, C2a, C2b, C3, C3a, C3b, C4, C4a, C4b, C5, C5a, C5b, C6 , C7, C8, C9, factor B, factor D, factor H, properdin, sclerostin, fibrinogen, fibrin, procoagulation protease, coagulation protease, tissue factor, factor V , Factor Va, Factor VII, Factor VIIa, Factor VIII, Factor VIIIa, Factor IX, Factor IXa, Factor X, Factor Xa, Factor XI, Factor XIa, Factor XII, Factor XIIa, Factor XIII, Factor XIIIa, TFPI, anticoagulation Serum protease III, EPCR, thrombomodulin, TAPI, tPA, plasminogen (plasminogen), plasmin (plasmin), PAI-1, PAI-2, GPC3, Syndecan )-1, syndecan-2, syndecan-3, syndecan-4, LPA, and S1P; and receptors for hormones and growth factors. .
[0321] As discussed herein, modification of one or more amino acid residues in the amino acid sequence comprising the variable region is permissible so long as their antigen binding activity is maintained. When modifying the amino acid sequence of the variable region, the modified position and the number of modified amino acids are not particularly limited. For example, amino acids occurring in CDRs and / or FRs may be modified as appropriate. When the modified amino acid is in the variable region, the binding activity is preferably maintained and is not particularly limited; for example, the binding activity may be 50% or more, 80% or more, and 100% compared to before modification or larger. In addition, binding activity can be increased by amino acid modification. For example, the binding activity can be 2, 5, 10 times higher than before modification, etc. Amino acid sequence modification may be at least any of amino acid residue substitution, addition, deletion and modification.
[0322] For example, modification of the N-terminal glutamine of a variable region to pyroglutamic acid by pyroglutamylation is a modification well known to those of ordinary skill in the art. Thus, when the N-terminus of the heavy chain is glutamine, the antibodies described herein may include variable regions in which glutamine is modified to pyroglutamate.
[0323] The antibody variable regions described herein may have any sequence, and they may be antibody variable regions of any origin, such as mouse antibodies, rat antibodies, rabbit antibodies, goat antibodies, camel antibodies, by Humanizing these non-human antibodies produces humanized antibodies as well as human antibodies. In addition, these antibodies can have various amino acid substitutions introduced into their variable regions to improve their antigen binding, pharmacokinetics, stability and immunogenicity. Due to their pH dependence in antigen binding, variable regions may be capable of repeatedly binding antigen (WO 2009 / 125825).
[0324] A kappa chain and a lambda chain are present in the antibody light chain constant region, and either is acceptable. Furthermore, they may have some amino acid modifications such as substitutions, deletions, additions and / or insertions.
[0325] In addition, the polypeptides including variant Fc regions described herein can be linked to other proteins, such as physiologically active peptides, to become Fc fusion proteins. Such fusion proteins may be multimers of at least two polypeptides comprising variant Fc regions. Examples of other proteins include, but are not limited to, receptors, adhesion molecules, ligands, and enzymes. Examples of Fc fusion proteins include proteins fused with the Fc region to receptors that bind to target molecules, including TNFR-Fc fusion proteins, IL1R-Fc fusion proteins, VEGFR-Fc fusion proteins, and CTLA4-Fc fusion proteins (Economides et al., Nat. Med. 9(1):47-52 (2003); Dumont et al., BioDrugs. 20(3):151-60 (2006)). In addition, the fused protein can be other molecules with target binding activity, for example, scFvs (WO 2005 / 037989), single domain antibodies (WO 2004 / 058821; WO 2003 / 002609), antibody-like molecules (Davinder, Curr. Op. . Biotech. 17:653-658 (2006); Current Opinion in Biotechnology 18:1-10 (2007); Nygren et al., Curr. Op. Struct. Biol. 7:463-469 (1997); and Hoss. Protein Science 15 :14-27 (2006)) such as DARPins (WO 2002 / 020565), Affibodies (WO 1995 / 001937), Avimers (WO 2004 / 044011; WO 2005 / 040229) and Adnectins (WO 2002 / 032925). Furthermore, antibodies and Fc fusion proteins can be multispecific and can bind to multiple types of target molecules or epitopes. B. Recombinant Methods and Compositions
[0327] Antibodies can be produced using recombinant methods and compositions, eg, as described in US 4,816,567. In one embodiment, an isolated nucleic acid encoding an anti-myostatin antibody described herein is provided. In another embodiment, an isolated nucleic acid encoding a polypeptide comprising a variant Fc region or a parental Fc region described herein is provided. Such nucleic acids can encode amino acid sequences comprising the VL and / or amino acid sequences comprising the VH of the antibody (eg, the light and / or heavy chains of the antibody). In yet another embodiment, one or more vectors (eg, expression vectors) comprising such nucleic acids are provided. In yet another embodiment, host cells comprising such nucleic acids are provided. In one embodiment, the host cell comprises (eg, has been transformed with): (1) a vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) A first vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody, and a second vector comprising a nucleic acid encoding an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is a eukaryote, eg, Chinese Hamster Ovary (CHO) cells or lymphocytes (eg, Y0, NS0 and Sp20 cells). In one embodiment, there is provided a method of producing an anti-myostatin antibody, wherein the method comprises culturing a host cell as provided above comprising a nucleic acid encoding the antibody under conditions suitable for expression of the antibody, and optionally extracting the antibody from the host The cells (or host cell culture medium) recover the antibody. In another embodiment, there is provided a method of producing a polypeptide comprising a variant Fc region or a parental Fc region, wherein said method comprises culturing a host cell comprising a nucleic acid encoding a polypeptide as described above under conditions suitable for expression of the polypeptide The antibody, Fc region or variant Fc region provided, and optionally the polypeptide recovered from the host cell (or host cell culture medium).
[0328] For recombinant production of anti-myostatin antibodies, eg, nucleic acid encoding the antibody as described above, is isolated and inserted into one or more vectors for further cloning and / or expression in host cells. For recombinant production of the Fc region, nucleic acid encoding the Fc region is isolated and inserted into one or more vectors for further cloning and / or expression in host cells. Such nucleic acids are readily isolated and sequenced using conventional procedures (eg, using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).
[0329] Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be produced in bacteria, especially when glycation and Fc effector functions are not required. For expression of antibody fragments and polypeptides in bacteria see, eg, US 5,648,237, US 5,789,199 and US 5,840,523. (Please also refer to Charlton, Methods in Molecular Biology, Vol. 248 (Edited by B.K.C. Lo, Humana Press, Totowa, NJ, 2003), pp. 245-254, which describes the expression of antibody fragments in E. coli). After expression, antibodies can be isolated from the soluble fraction of the bacterial cell paste and can be further purified.
[0330] In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are suitable selection or expression hosts for antibody-encoding vectors, including fungal and yeast strains whose saccharification pathway has been "humanized" resulting in Generation of antibodies with partial or full human glycation patterns. See Gerngross, Nat. Biotech. 22:1409-1414 (2004) and Li et al., Nat. Biotech. 24:210-215 (2006).
[0331] Suitable host cells for the expression of glycated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells....
Claims
1. Use of an antibody or antibody fragment that binds to latent myostatin for the preparation of a medicament for treating muscular dystrophy, wherein the antibody or antibody fragment binds to latent myostatin, blocks the spontaneous release of mature myostatin, inhibits the activation of myostatin, blocks the protein hydrolysis release of mature myostatin, and does not bind to mature myostatin or GDF11, wherein the antibody or antibody fragment binds to an antigenic determinant located within a fragment consisting of amino acids 81-100 of the myostatin propeptide of sequence identification number 78, and wherein the antibody or antibody fragment binds to the same antigenic determinant as an antibody including the VH sequence of sequence identification number 12 and the VL sequence of sequence identification number 14.
2. As claimed in claim 1, wherein the antibody binds to latent myostatin and has a higher affinity at neutral pH than at acidic pH.
3. As requested in item 1, wherein the antibody is a monoclonal antibody.
4. As requested in claim 1, wherein the antibody is a human, humanized, or chimeric antibody.
5. As requested in claim 1, wherein the antibody or antibody fragment is an antibody fragment that binds to myosin.
6. As requested in claim 1, wherein the antibody is a full-length IgG antibody.
Citation Information
Patent Citations
Myostatin binding proteins
WO2010070094A1
Compositions and methods for modulating cell signaling
WO2014074532A2
Anti-pro / latent-myostatin antibodies and uses thereof
WO2016073853A1
